Mallinckrodt (MNKTQ) 10-Q 8 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 04, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Mallinckrodt plc
Entity Central Index Key	1,567,892
Trading Symbol	MNK
Current Fiscal Year End Date	--12-29
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Amendment Flag	false
Ordinary Shares Outstanding		97,178,768

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Net sales	$ 824.5	$ 866.6	$ 1,635.4	$ 1,682.4
Cost of sales	408.4	377.8	800.7	768.5
Gross profit	416.1	488.8	834.7	913.9
Selling, general and administrative expenses	232.1	224.9	540.2	434.2
Research and development expenses	69.2	74.8	131.4	132.9
Restructuring charges, net	0.6	14	17.8	22.4
Non-restructuring impairment charges	0	0	0	16.9
Losses (gains) on divestiture and license	2.1	0	(57)	0
Operating income	112.1	175.1	202.3	307.5
Interest expense	(92.2)	(95.6)	(186.4)	(192.8)
Interest income	0.6	0.4	1.5	0.6
Other income (expense), net	10	(1.3)	2.5	(2)
Income from continuing operations before income taxes	30.5	78.6	19.9	113.3
Income tax benefit	(40.1)	(98.1)	(79.6)	(161.9)
Income from continuing operations	70.6	176.7	99.5	275.2
(Loss) income from discontinued operations, net of income taxes	(7.8)	22.6	362.5	42.4
Net income	$ 62.8	$ 199.3	$ 462	$ 317.6
Basic earnings per share (Note 7):
Income from continuing operations, per share	$ 0.72	$ 1.63	$ 0.99	$ 2.50
(Loss) income from discontinued operations, per share	(0.08)	0.21	3.59	0.39
Net income, per share	$ 0.64	$ 1.84	$ 4.58	$ 2.89
Basic weighted-averaged shares outstanding (in shares)	98.5	108.6	100.9	109.9
Diluted earnings per share (Note 7):
Income from continuing operations, per share	$ 0.72	$ 1.62	$ 0.98	$ 2.48
(Loss) income from discontinued operations, per share	(0.08)	0.21	3.58	0.38
Net income, per share	$ 0.64	$ 1.82	$ 4.57	$ 2.87
Diluted weighted-average shares outstanding (in shares)	98.7	109.4	101.2	110.8

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Net income	$ 62.8	$ 199.3	$ 462	$ 317.6
Other comprehensive income (loss), net of tax:
Currency translation adjustments	5	(1.2)	7.4	7.6
Unrecognized gain on derivatives, net of ($0.2), $-, ($0.2) and $- tax	0.4	0.2	0.6	0.4
Unrecognized (loss) gain on benefit plans, net of $-, ($0.3), ($31.4) and $5.1 tax	(0.7)	0.4	45.9	(8.4)
Unrecognized (loss) gain on investments, net of $-, $-, $- and $- tax	(2.8)	0	10.6	0
Total other comprehensive income (loss), net of tax	1.9	(0.6)	64.5	(0.4)
Comprehensive Income	$ 64.7	$ 198.7	$ 526.5	$ 317.2

Condensed Consolidated Stateme4

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Unrecognized gain derivatives, tax	$ (0.2)	$ 0	$ (0.2)	$ 0
Unrecognized (loss) gain on benefit plans, tax	0	(0.3)	(31.4)	5.1
Unrecognized (loss) gain on investments, tax	$ 0	$ 0	$ 0	$ 0

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2017	Dec. 30, 2016
Current Assets:
Cash and cash equivalents	$ 330.2	$ 342
Accounts receivable, less allowance for doubtful accounts of $4.0 and $4.0	482.1	431
Inventories	339.4	350.7
Prepaid expenses and other current assets	134	131.9
Notes receivable	154	0
Current assets held for sale	0	310.9
Total current assets	1,439.7	1,566.5
Property, plant and equipment, net	940.7	881.5
Goodwill	3,446.2	3,498.1
Intangible assets, net	8,604.7	9,000.5
Other assets	189.9	259.7
Total Assets	14,621.2	15,206.3
Current Liabilities:
Current maturities of long-term debt	519.4	271.2
Accounts payable	113.9	112.1
Accrued payroll and payroll-related costs	92.8	76.1
Accrued interest	54.1	68.7
Income taxes payable	122	101.7
Accrued and other current liabilities	460.2	557.1
Current liabilities held for sale	0	120.3
Total current liabilities	1,362.4	1,307.2
Long-term debt	5,338.5	5,880.8
Pension and postretirement benefits	67.7	136.4
Environmental liabilities	73.6	73
Deferred income taxes	2,254.4	2,398.1
Other income tax liabilities	67.5	70.4
Other liabilities	361.1	356.1
Total liabilities	(9,525.2)	(10,222)
Shareholders' Equity:
Preferred shares	0	0
Ordinary shares	23.7	23.6
Ordinary shares held in treasury at cost	(1,296.9)	(919.8)
Additional paid-in capital	5,459.7	5,424
Retained earnings	917.5	529
Accumulated other comprehensive loss	(8)	(72.5)
Total Shareholders' Equity	5,096	4,984.3
Total Liabilities and Shareholders' Equity	14,621.2	15,206.3
Ordinary A
Shareholders' Equity:
Ordinary A shares	$ 0	$ 0

Condensed Consolidated Balance6

Condensed Consolidated Balance Sheets (Parenthetical) $ in Millions	Jun. 30, 2017USD ($)$ / sharesshares	Jun. 30, 2017€ / shares	Dec. 30, 2016USD ($)$ / sharesshares	Dec. 30, 2016€ / shares
Allowance for doubtful accounts | $	$ 4		$ 4
Preferred shares, par value (in usd per share) | $ / shares	$ 0.20		$ 0.20
Preferred shares, shares authorized (in shares)	500,000,000		500,000,000
Preferred shares, shares issued (in shares)	0		0
Preferred shares, shares outstanding (in shares)	0		0
Ordinary shares, par value (in usd per share) | $ / shares	$ 0.20		$ 0.20
Ordinary shares, shares authorized (in shares)	500,000,000		500,000,000
Ordinary shares, shares issued (in shares)	118,646,325		118,182,944
Ordinary shares, shares outstanding (in shares)	97,138,549		104,667,545
Ordinary shares held in treasury at cost (in shares)	21,507,776		13,515,399
Ordinary A
Ordinary shares, par value (in usd per share) | € / shares		€ 1		€ 1
Ordinary shares, shares authorized (in shares)	40,000		40,000
Ordinary shares, shares issued (in shares)	0		0
Ordinary A shares, shares outstanding (in shares)	0		0

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016
Cash Flows From Operating Activities:
Net income	$ 462	$ 317.6
Adjustments to reconcile net cash from operating activities:
Depreciation and amortization	406	419
Share-based compensation	31.8	22.1
Deferred income taxes	(157.6)	(215.4)
Non-cash impairment charges	0	16.9
Gain on divestitures	(419.1)	(2.1)
Other non-cash items	32.4	18.6
Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable, net	(52.6)	(17.2)
Inventories	(8.5)	8
Accounts payable	(10.7)	4.4
Income taxes	12.5	58.4
Other	(73.7)	52.7
Net cash from operating activities	222.5	683
Cash Flows From Investing Activities:
Capital expenditures	(101.6)	(84.5)
Acquisitions and intangibles, net of cash acquired	0	(169.5)
Proceeds from divestitures, net of cash	576.9	3
Other	(9.9)	4.6
Net cash from investing activities	465.4	(246.4)
Cash Flows From Financing Activities:
Issuance of external debt	40	36.3
Repayment of external debt and capital leases	(332.8)	(177.5)
Debt financing costs	(13)	0
Proceeds from exercise of share options	3.9	4.9
Repurchase of shares	(380.8)	(326.6)
Other	(19.5)	(23)
Net cash from financing activities	(702.2)	(485.9)
Effect of currency rate changes on cash	1.6	2.1
Net change in cash, cash equivalents and restricted cash	(12.7)	(47.2)
Cash and Cash Equivalents and Restricted Cash	361.1	588.4
Cash and cash equivalents	330.2	521.9
Restricted Cash and Investments, Current	0	0.3
Restricted Cash and Investments, Noncurrent	$ 18.2	$ 19

Condensed Consolidated Stateme8

Condensed Consolidated Statement of Changes in Shareholders' Equity Statement - 6 months ended Jun. 30, 2017 - USD ($) $ in Millions	Total	Ordinary Shares	Treasury Shares	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss
Beginning balance, ordinary shares (in shares) at Dec. 30, 2016	118,182,944	118,200,000
Beginning balance, treasury shares (in shares) at Dec. 30, 2016	13,515,399		13,500,000
Beginning balance at Dec. 30, 2016	$ 4,984.3	$ 23.6	$ (919.8)	$ 5,424	$ 529	$ (72.5)
Impact of accounting standard adoptions	(72.1)				(72.1)
Net income	462				462
Currency translation adjustments	7.4					7.4
Change in derivatives, net of tax	0.6					0.6
Unrecognized gain on benefit plans	45.9					45.9
Unrecognized gain on investments	10.6					10.6
Share options exercised (in shares)		100,000
Share options exercised (in usd)	3.9	$ 0		3.9
Vesting of restricted shares (in shares)		300,000
Vesting of restricted shares (in usd)	(4.4)	$ 0.1	(4.5)	0
Share-based compensation	31.8			31.8
Reissuance of treasury shares	2.3		$ 3.7		(1.4)
Repurchase of shares (in shares)			8,000,000
Repurchase of shares (in usd)	$ 376.3		$ (376.3)
Ending balance, ordinary shares (in shares) at Jun. 30, 2017	118,646,325	118,600,000
Ending balance, treasury shares (in shares) at Jun. 30, 2017	21,507,776		21,500,000
Ending balance at Jun. 30, 2017	$ 5,096	$ 23.7	$ (1,296.9)	$ 5,459.7	$ 917.5	$ (8)

Background and Basis of Present

Background and Basis of Presentation	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Basis of Presentation	1. Background and Basis of Presentation Background Mallinckrodt plc and its subsidiaries (collectively, "Mallinckrodt" or "the Company"), is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The Company operates in two reportable segments, which are further described below: • Specialty Brands includes branded medicines; and • Specialty Generics includes specialty generic drugs, active pharmaceutical ingredients ("API") and external manufacturing. The Company owns or has rights to use the trademarks and trade names that are used in conjunction with the operation of its business. One of the more important trademarks that the Company owns or has rights to use that appears in this Quarterly Report on Form 10-Q is "Mallinckrodt," which is a registered trademark or the subject of pending trademark applications in the United States ("U.S.") and other jurisdictions. Solely for convenience, the Company only uses the ™ or ® symbols the first time any trademark or trade name is mentioned in the following notes. Such references are not intended to indicate in any way that the Company will not assert, to the fullest extent permitted under applicable law, its rights to its trademarks and trade names. Each trademark or trade name of any other company appearing in the following notes is, to the Company's knowledge, owned by such other company. Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in U.S. Dollars and in accordance with accounting principles generally accepted in the U.S. ("GAAP"). The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of net sales and expenses. Actual results may differ from those estimates. The unaudited condensed consolidated financial statements include the accounts of Mallinckrodt plc, its wholly-owned subsidiaries and entities in which they own or control more than fifty percent of the voting shares, or have the ability to control through similar rights. The results of entities disposed of are included in the unaudited condensed consolidated financial statements up to the date of disposal and, where appropriate, these operations have been reflected as discontinued operations. Divestitures of product lines and businesses that did not qualify as discontinued operations have been reflected in operating income. All intercompany balances and transactions have been eliminated in consolidation and, in the opinion of management, all normal recurring adjustments necessary for a fair presentation have been included in the interim results reported. The December 30, 2016 balance sheet data was derived from the unaudited condensed consolidated financial statements, but does not include all of the annual disclosures required by GAAP; accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited annual consolidated and combined financial statements included in its Annual Report on Form 10-K for the period ended September 30, 2016, filed with the U.S. Securities and Exchange Commission ("SEC") on November 29, 2016. The Company completed the sale of its Nuclear Imaging business on January 27, 2017. As a result, prior year balances have been recast to present the financial results of this business as a discontinued operation. Fiscal Year The Company historically reported its results based on a "52-53 week" year ending on the last Friday of September. On May 17, 2016, the Board of Directors of the Company approved a change in the Company’s fiscal year end to the last Friday in December from the last Friday in September. The change in fiscal year became effective for the Company’s 2017 fiscal year, which began on December 31, 2016 and will end on December 29, 2017. As a result of the change in fiscal year end, the Company filed a Transition Report on Form 10-Q on February 7, 2017 covering the period from October 1, 2016 through December 30, 2016. Unless otherwise indicated, the three and six months ended June 30, 2017 refers to the thirteen and twenty-six week period ended June 30, 2017 and the three and six months ended June 24, 2016 refers to the thirteen and twenty-six week period ended June 24, 2016 .

Recently Issued Accounting Stan

Recently Issued Accounting Standards	6 Months Ended
	Jun. 30, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recently Issued Accounting Standards	2. Recently Issued Accounting Standards Adopted The Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2017-04, "Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment," in January 2017. This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The Company early adopted this standard in fiscal 2017, which did not have a material impact to the unaudited condensed consolidated financial statements. The Company will apply this standard to prospective goodwill impairment tests. The FASB issued ASU 2016-16, "Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory," in October 2016. This update simplifies the practice of how income tax consequences of an intra-entity transfer of an asset other than inventory should be recognized. Upon adoption, the entity must recognize such income tax consequences when the intra-entity transfer occurs rather than waiting until such time as the asset has been sold to an outside party. The Company early adopted this standard in fiscal 2017, which resulted in a $75.0 million decrease to beginning retained earnings with an offsetting decrease of $67.2 million to other assets and a $7.8 million decrease to prepaid expenses on its unaudited condensed consolidated balance sheet. The prior periods were not restated. The FASB issued ASU 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments," in August 2016 and ASU 2016-18 "Statement of Cash Flows (Topic 230): Restricted Cash," in November 2016. These updates provide guidance for nine targeted clarifications with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. The Company early adopted these standards in fiscal 2017 and revised the prior year statement of cash flow. The adoption of ASU 2016-18, regarding presentation of restricted cash, increased the net cash used in investing activities during the six months ended June 24, 2016 by $47.2 million . The adoption of ASU 2016-15, regarding the other targeted clarifications, did not result in any material changes to the unaudited condensed consolidated financial statements. The FASB issued ASU 2016-09, "Stock Compensation," in March 2016. This update simplifies several aspects of the accounting for share-based payment award transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification of certain tax effects within the statement of cash flows. The Company adopted this guidance in fiscal 2017, which resulted in a $2.9 million increase to beginning retained earnings to recognize net operating loss carryforwards, net of a valuation allowance, attributable to excess tax benefits on stock compensation that had not been previously recognized in additional paid-in capital. The FASB issued ASU 2015-16, "Simplifying the Accounting for Measurement-Period Adjustments," in September 2015. This update requires an acquirer to recognize adjustments to the provisional amounts that are identified during the measurement period in the reporting period in which the adjusting amounts are determined. The amendments in this update require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. The Company adopted this standard in fiscal 2017, which did not have any impact on historical acquisitions. The FASB issued ASU 2015-11, "Simplifying the Measurement of Inventory," in July 2015. The issuance of this update is part of the FASB's initiative to more closely align the measurement of inventory between GAAP and International Financial Reporting Standards ("IFRS"). Under the new guidance, inventory must be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company adopted this standard in fiscal 2017, which did not have a material impact to the unaudited condensed consolidated financial statements. Not Yet Adopted The FASB issued ASU 2017-09, "Compensation - Stock Compensation: Scope of Modification Accounting," in May 2017. Under the new guidance, the effects of a modification should be accounted for unless all of the following are met: (1) the fair value or calculated intrinsic value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. This guidance is effective for the Company in the first quarter of fiscal 2018. The Company is assessing the timing of adoption and the impact of future modifications to the unaudited condensed consolidated financial statements. The FASB issued ASU 2017-07, "Compensation - Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Post Retirement Benefit Cost," in March 2017. This update requires that the service cost component be disaggregated from the other components of net benefit cost. Service cost should be reported in the same line item or items as other compensation costs arising from services rendered by pertinent employees during the period. The other components of net benefit cost should be presented in the income statement separately from the service cost component and outside a subtotal of income from operations, if one is presented. This guidance is effective for the Company in the first quarter of fiscal 2018. The Company expects the impact of this guidance to be immaterial to the unaudited condensed consolidated financial statements upon adoption. The FASB issued ASU 2017-01, "Business Combinations (Topic 805): Clarifying the Definition of a Business," in January 2017. This update provides a screen to determine whether or not a set of assets is a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set of assets is not a business. If the screen is not met, the amendments in this update (1) require that to be considered a business, a set of assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. This guidance is effective for the Company in the first quarter of fiscal 2018. Early adoption is permitted for transactions not previously reported in the Company's consolidated financial statements. The Company is assessing the timing of adoption and impact of this guidance on future transactions. The FASB issued ASU 2014-09, "Revenue from Contracts with Customers," in May 2014. The issuance of ASU 2014-09 and IFRS 15, "Revenue from Contracts with Customers," completes the joint effort by the FASB and the International Accounting Standards Board to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and IFRS. Under the new guidance, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services, applying the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract(s); (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract(s); and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance is effective for the Company in the first quarter of fiscal year 2018. The FASB subsequently issued additional ASUs to clarify the guidance in ASU 2014-09. The ASUs issued include ASU 2016-08, "Revenue from Contracts with Customers;" ASU 2016-10 "Revenue from Contracts with Customers, Identifying Performance Obligations and Licensing;" and ASU 2016-12, "Narrow-Scope Improvements and Practical Expedients." The Company has completed its assessment of certain customer arrangements and has preliminarily assessed certain other customer arrangements based on the nature of its business; and as of this time, the Company does not anticipate a significant impact upon adoption. However, the assessment is ongoing and a more detailed analysis of contracts subject to the preliminary assessment or review of additional contracts may identify a more significant impact. The Company currently expects, in part due to the limited anticipated impact, that it will utilize the modified retrospective transition approach of adopting the ASU. The Company's status of various ASUs are further described within the notes to the financial statements included within the Company's Annual Report filed on Form 10-K for the fiscal year ended September 30, 2016.

Discontinued Operations and Div

Discontinued Operations and Divestitures	6 Months Ended
	Jun. 30, 2017
Discontinued Operations [Abstract]
Discontinued Operations and Divestitures	3. Discontinued Operations and Divestitures Discontinued Operations Nuclear Imaging: On January 27, 2017, the Company completed the sale of its Nuclear Imaging business to IBA Molecular ("IBAM") for approximately $690.0 million before tax impacts, including up-front consideration of approximately $574.0 million , up to $77.0 million of contingent consideration and the assumption of certain liabilities. The Company recorded a pre-tax gain on the sale of the Nuclear Imaging business of $363.4 million during the six months ended June 30, 2017, which excluded any potential proceeds from the contingent consideration and reflects a charge of $5.9 million during the three months ended June 30, 2017 primarily as a result of ongoing working capital adjustments associated with the purchase agreement. The following table summarizes the financial results of the Nuclear Imaging business presented in the unaudited condensed consolidated statements of income: Three Months Ended Six Months Ended Major line items constituting income from discontinued operations June 30, 2017 June 24, 2016 June 30, 2017 June 24, 2016 Net sales $ — $ 104.0 $ 31.6 $ 206.2 Cost of sales — 51.5 15.6 99.2 Selling, general and administrative expenses — 23.5 7.8 45.4 Restructuring charges, net — 0.1 — 0.4 Other — 1.1 (0.2 ) 1.4 Income from discontinued operations — 27.8 8.4 59.8 (Loss) gain on divestiture of discontinued operations (5.9 ) — 363.4 — (Loss) income from discontinued operations, before income taxes (5.9 ) 27.8 371.8 59.8 Income tax (benefit) expense (0.1 ) 8.8 5.3 19.0 (Loss) income from discontinued operations, net of income taxes $ (5.8 ) $ 19.0 $ 366.5 $ 40.8 During the three months ended June 30, 2017 there was income tax benefit of $0.1 million associated with the $5.9 million loss recognized on divestiture. During the six months ended June 30, 2017, there was income tax expense of $1.0 million associated with the $363.4 million gain on divestiture and a $4.3 million income tax expense associated with the $8.4 million income from discontinued operations. The tax impact of the gain recognized on divestiture was favorably impacted by a benefit from permanently deductible items. The following table summarizes the assets and liabilities of the Nuclear Imaging business that are classified as held for sale on the unaudited condensed consolidated balance sheets: June 30, 2017 December 30, 2016 Carrying amounts of major classes of assets included as part of discontinued operations Accounts receivable $ — $ 49.6 Inventories — 20.0 Property, plant and equipment, net — 188.7 Other current and non-current assets — 52.6 Total assets classified as held for sale in the balance sheet $ — $ 310.9 Carrying amounts of major classes of liabilities included as part of discontinued operations Accounts payable $ — $ 19.7 Other current and non-current liabilities — 100.6 Total liabilities classified as held for sale in the balance sheet $ — $ 120.3 The following table summarizes significant cash and non-cash transactions of the Nuclear Imaging business that are included within the unaudited condensed consolidated statements of cash flows for the respective periods: Three Months Ended Six Months Ended June 30, 2017 June 24, 2016 June 30, 2017 June 24, 2016 Depreciation $ — $ 5.0 $ — $ 9.8 Capital expenditures — 1.2 0.3 3.8 All other notes to the unaudited condensed consolidated financial statements that were impacted by this discontinued operation have been reclassified accordingly. CMDS: On November 27, 2015, the Company completed the sale of its contrast media and delivery systems ("CMDS") business to Guerbet S.A. ("Guerbet") for cash consideration of approximately $270.0 million , subject to net working capital adjustments. During the three months ended June 24, 2016 , the Company had $0.7 million of net sales and a gain on the sale of business of $1.7 million , with no related income tax effect. During the six months ended June 24, 2016 , the Company had $1.8 million of net sales, a $0.2 million income tax benefit and no income (loss), net of tax. All activity related to the CMDS business has been reported in discontinued operations. Divestitures On January 30, 2017, the Company announced that it had entered into a definitive agreement to sell its Intrathecal Therapy business to Piramal Enterprises Limited's subsidiary in the United Kingdom ("U.K."), Piramal Critical Care ("Piramal"), for approximately $203.0 million , including fixed consideration of $171.0 million and contingent consideration of up to $32.0 million . The $171.0 million of fixed consideration consisted of $17.0 million received at closing and a $154.0 million note receivable that is due one year from the transaction closing date. The transaction was completed on March 17, 2017. The Company recorded a pre-tax gain on the sale of the business of $57.0 million during the six months ended June 30, 2017, which excluded any potential proceeds from the contingent consideration and reflects a post-sale adjustment of $2.1 million during the three months ended June 30, 2017. The financial results of the Intrathecal Therapy business are presented within continuing operations as this divestiture did not meet the criteria for discontinued operations classification. As part of the divestiture and calculation of the gain, the Company wrote off intangible assets of $48.7 million and goodwill of $49.8 million , from the Specialty Brands segment, ascribed to the Intrathecal Therapy business. The Company is committed to reimburse up to $7.3 million of product development expenses incurred by Piramal. The remaining items included in the gain calculation are attributable to inventory transferred and transaction costs incurred by the Company.

Acquisitions, License Agreement

Acquisitions, License Agreements and Other Investments	6 Months Ended
	Jun. 30, 2017
Acquisitions [Abstract]
Acquisitions, License Agreements and Other Investments	4. Acquisitions, License Agreements and Other Investments The Company did not have any acquisitions during the six months ended June 30, 2017 . The Company had acquisitions in prior periods that may affect the comparability of the unaudited condensed consolidated statements of income in this Quarterly Report on Form 10-Q. During the three months ended June 30, 2017 and June 24, 2016 , the Company recognized $2.9 million and $2.6 million , respectively, of expense primarily associated with fair value adjustments of acquired inventory. During the six months ended June 30, 2017 and June 24, 2016 , the Company recognized $5.9 million and $4.7 million , respectively, of expense primarily associated with fair value adjustments of acquired inventory. The amount of acquisition-related costs included within operating income for the three and six months ended June 30, 2017 was $1.1 million . The amount of acquisition-related costs included within operating income for the three and six months ended June 24, 2016 was $0.1 million and $2.0 million , respectively. The Company's acquisitions and license agreements are described further within the notes to the financial statements included within the Company's Annual Report filed on Form 10-K for the fiscal year ended September 30, 2016. Hemostasis Products On February 1, 2016, the Company acquired three commercial stage topical hemostasis drugs from The Medicines Company ("the Hemostasis Acquisition") - RECOTHROM® Thrombin topical (Recombinant) ("Recothrom"), PreveLeak TM Surgical Sealant ("PreveLeak"), and RAPLIXA TM (Fibrin Sealant (Human)) ("Raplixa") - for upfront consideration of $173.5 million , inclusive of existing inventory, and contingent sales-based milestone payments that could result in up to $395.0 million of additional consideration. The fair value of the contingent consideration and acquired contingent liabilities associated with the transaction were $52.0 million and $10.6 million , respectively, at February 1, 2016. The Hemostasis Acquisition was funded with cash on hand. Licenses and Other Investments In January 2017, $21.5 million of consideration was remitted to Mesoblast Limited ("Mesoblast") in exchange for equity shares and rights to a nine month exclusivity period related to any potential commercial and development agreements the Company may enter into for Mesoblast's therapy products used to treat acute graft versus host disease and/or chronic low back pain. As a result of this transaction the Company recorded an available for sale investment of $19.7 million included within prepaid and other current assets and an intangible asset of $1.8 million , which is being amortized over the nine month exclusivity period, in the unaudited condensed consolidated balance sheet.

Restructuring and Related Charg

Restructuring and Related Charges	6 Months Ended
	Jun. 30, 2017
Restructuring and Related Activities [Abstract]
Restructuring and Related Charges	5. Restructuring and Related Charges In July 2016, the Company's Board of Directors approved a $100.0 million to $125.0 million restructuring program ("the 2016 Mallinckrodt Program") designed to further improve the Company's cost structure as it continues to transform the business. The 2016 Mallinckrodt Program is expected to include actions across both the Specialty Brands and Specialty Generics segments, as well as within corporate functions. There is no specified time period associated with the 2016 Mallinckrodt Program. In addition to the 2016 Mallinckrodt Program, the Company takes certain restructuring actions to generate synergies from its acquisitions. Net restructuring and related charges by segment are as follows: Three Months Ended Six Months Ended June 30, June 24, June 30, June 24, Specialty Brands $ 0.3 $ 8.8 $ 9.5 $ 16.8 Specialty Generics 0.5 1.0 7.9 1.6 Corporate 0.7 5.4 2.8 6.9 Restructuring and related charges, net 1.5 15.2 20.2 25.3 Less: accelerated depreciation (0.9 ) (1.2 ) (2.4 ) (2.9 ) Restructuring charges, net $ 0.6 $ 14.0 $ 17.8 $ 22.4 Net restructuring and related charges by program are comprised of the following: Three Months Ended Six Months Ended June 30, June 24, June 30, June 24, 2016 Mallinckrodt Program $ 1.5 $ — $ 20.2 $ — 2013 Mallinckrodt Program — 14.3 — 22.4 Acquisitions — 0.9 — 2.9 Total 1.5 15.2 20.2 25.3 Less: non-cash charges, including accelerated share-based compensation expense (0.9 ) (1.2 ) (2.4 ) (2.9 ) Total charges expected to be settled in cash $ 0.6 $ 14.0 $ 17.8 $ 22.4 The following table summarizes cash activity for restructuring reserves, substantially all of which are related to employee severance and benefits: 2016 Mallinckrodt Program 2013 Mallinckrodt Program Acquisitions Total Balance at December 30, 2016 $ 9.5 $ 5.1 $ 0.2 $ 14.8 Charges 18.5 — — 18.5 Changes in estimate (0.7 ) — — (0.7 ) Cash payments (14.4 ) (3.6 ) (0.2 ) (18.2 ) Reclassifications (0.3 ) 0.3 — — Balance at June 30, 2017 $ 12.6 $ 1.8 $ — $ 14.4 Net restructuring and related charges, including associated asset impairments, incurred cumulative-to-date related to the 2016 Mallinckrodt Program was as follows: 2016 Mallinckrodt Program Specialty Brands $ 16.7 Specialty Generics 9.2 Corporate 7.8 $ 33.7 Substantially all of the restructuring reserves were included in accrued and other current liabilities on the Company's unaudited condensed consolidated balance sheets.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes The Company recognized an income tax benefit of $40.1 million on income from continuing operations before income taxes of $30.5 million for the three months ended June 30, 2017 and an income tax benefit of $98.1 million on income from continuing operations before income taxes of $78.6 million for the three months ended June 24, 2016. This resulted in effective tax rates of negative 131.5% and negative 124.8% for the three months ended June 30, 2017 and June 24, 2016, respectively. The income tax benefit for the three months ended June 30, 2017 is comprised of $44.7 million of current tax expense and $84.8 million of deferred tax benefit which is predominantly related to acquired intangible assets. The income tax benefit for the three months ended June 24, 2016 is comprised of $1.8 million of current tax expense and $99.9 million of deferred tax benefit which is predominantly related to acquired intangible assets. The Company recognized an income tax benefit of $79.6 million on income from continuing operations before income taxes of $19.9 million for the six months ended June 30, 2017 and an income tax benefit of $161.9 million on income from continuing operations before income taxes of $113.3 million for the six months ended June 24, 2016. This resulted in effective tax rates of negative 400.0% and negative 142.9% for the six months ended June 30, 2017 and June 24, 2016, respectively. The income tax benefit for the six months ended June 30, 2017 is comprised of $80.6 million of current tax expense and $160.2 million of deferred tax benefit. The net deferred tax benefit of $160.2 million includes $187.4 million of deferred tax benefit which is predominantly related to acquired intangible assets offset by $27.2 million of deferred tax expense related to utilization of tax attributes. The income tax benefit for the six months ended June 24, 2016 is comprised of $48.0 million of current tax expense and $209.9 million of deferred tax benefit which is predominantly related to acquired intangible assets. The effective tax rate for the three months ended June 30, 2017, as compared with the three months ended June 24, 2016 decreased by 6.7 percentage points. Included within this net decrease was a 33.1 percentage point decrease primarily attributable to diminutive income from continuing operations before taxes for the three months ended June 30, 2017 as compared with the three months ended June 24, 2016. Also within this decrease was an 8.5 percentage point decrease attributable to changes in operating income which resulted in more income in lower tax rate jurisdictions and less income in the higher tax rate U.S. jurisdiction. The remaining 34.9 percentage point increase was related to the tax benefit of a U.K. tax credit on a dividend between affiliates, which occurred within the three months ended June 24, 2016. The effective tax rate for the six months ended June 30, 2017, as compared with the six months ended June 24, 2016 decreased by 257.1 percentage points. Included within this net decrease was a 274.0 percentage point decrease primarily attributable to diminutive income from continuing operations before taxes for the six months ended June 30, 2017 as compared with the six months ended June 24, 2016. Also within this decrease was a 15.3 percentage point decrease attributable to changes in operating income which resulted in more income in lower tax rate jurisdictions and less income in the higher tax rate U.S. jurisdiction. Of the remaining 32.2 percentage point increase, a 24.2 percentage point increase is related to the tax benefit of a U.K. tax credit on a dividend between affiliates, which occurred within the three months ended June 24, 2016, and an 8.0 percentage point increase is related to the divestiture of the Intrathecal Therapy Business, which occurred during the three months ended March 31, 2017. During the three and six months ended June 30, 2017, the Company recognized an income tax benefit of $0.1 million and income tax expense of $5.3 million , respectively associated with the Nuclear Imaging business, as discussed in Note 3, in discontinued operations within the unaudited condensed consolidated statement of income. The Company early adopted ASU 2016-16 in the first quarter of 2017 utilizing the modified retrospective basis adoption method, with a cumulative-effect adjustment directly to retained earnings as of the beginning of the period for $75.0 million with an offsetting decrease of $67.2 million to other assets and a $7.8 million decrease to prepaid expenses on its unaudited condensed consolidated balance sheets. The prior periods were not restated. The Company adopted ASU 2016-09 in the first quarter of 2017 and recorded an adjustment to retained earnings of $2.9 million to recognize net operating loss carryforwards, net of a valuation allowance, attributable to excess tax benefits on stock compensation that had not been previously recognized to additional paid-in capital. The Company refined its acquisition accounting estimate associated with the measurement of its acquired Stratatech net deferred tax liabilities in the first quarter of 2017, resulting in a decrease to the acquired net deferred tax liabilities from $24.3 million to $22.1 million . The divestiture of the Intrathecal Therapy Business was completed on March 17, 2017. This divestiture resulted in a net deferred tax liability increase of $40.3 million . Significant components of this increase include an increase of $56.5 million of deferred tax liability associated with future consideration, a decrease of $4.3 million of deferred tax asset associated with net operating losses, a decrease of $17.9 million of deferred tax liability associated with intangibles, and an increase of $2.6 million of deferred tax asset associated with committed product development. The Company's unrecognized tax benefits, excluding interest, totaled $119.1 million at June 30, 2017 and $118.7 million at December 30, 2016 . The net increase of $0.4 million primarily resulted from a net increase to current year positions of $4.1 million , net decreases from prior period tax positions of $2.0 million , and net decreases from lapse of statute of limitations of $1.7 million . If favorably settled, $117.3 million of unrecognized tax benefits at June 30, 2017 would favorably impact the effective tax rate. The total amount of accrued interest related to these obligations was $5.9 million at June 30, 2017 and $7.1 million at December 30, 2016 . It is reasonably possible that within the next twelve months, as a result of the resolution of various U.K. and non-U.K. examinations, appeals and litigation and the expiration of various statutes of limitation, that the unrecognized tax benefits will decrease by up to $18.2 million and the amount of related interest and penalties will decrease by up to $3.8 million .

Earnings per Share

Earnings per Share	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Earnings per Share	7. Earnings per Share Basic earnings per share is computed by dividing net income by the number of weighted-average shares outstanding during the period. Diluted earnings per share is computed using the weighted-average shares outstanding and, if dilutive, potential ordinary shares outstanding during the period. Potential ordinary shares represent the incremental ordinary shares issuable for restricted share units and share option exercises. The Company calculates the dilutive effect of outstanding restricted share units and share options on earnings per share by application of the treasury stock method. The weighted-average number of shares outstanding used in the computations of basic and diluted earnings per share were as follows ( in millions ): Three Months Ended Six Months Ended June 30, 2017 June 24, 2016 June 30, 2017 June 24, 2016 Basic 98.5 108.6 100.9 109.9 Dilutive impact of restricted share units and share options 0.2 0.8 0.3 0.9 Diluted 98.7 109.4 101.2 110.8 The computation of diluted weighted-average shares outstanding for the three and six months ended June 30, 2017 excludes approximately 4.0 million and 3.6 million shares of equity awards, respectively, because the effect would have been anti-dilutive. The computation of diluted weighted-average shares outstanding for the three and six months ended June 24, 2016 excludes approximately 1.5 million and 1.4 million shares of equity awards, respectively, because the effect would have been anti-dilutive.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2017
Inventory, Net [Abstract]
Inventories	8. Inventories Inventories were comprised of the following at the end of each period: June 30, December 30, Raw materials and supplies $ 72.5 $ 72.6 Work in process 170.6 178.4 Finished goods 96.3 99.7 $ 339.4 $ 350.7

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment
Property, Plant and Equipment Disclosure	9. Property, Plant and Equipment The gross carrying amount and accumulated depreciation of property, plant and equipment at the end of each period was as follows: June 30, December 30, 2016 Property, plant and equipment, gross $ 1,786.6 $ 1,679.4 Less: accumulated depreciation (845.9 ) (797.9 ) Property, plant and equipment, net $ 940.7 $ 881.5 Depreciation expense for property, plant and equipment was as follows: Three Months Ended Six Months Ended June 30, 2017 June 24, 2016 June 30, 2017 June 24, 2016 Depreciation expense $ 27.4 $ 28.3 $ 56.2 $ 60.3

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	10. Goodwill and Intangible Assets The gross carrying amount and accumulated impairment of goodwill by segment at the end of each period were as follows: June 30, 2017 December 30, 2016 Gross Carrying Amount Accumulated Impairment Gross Carrying Amount Accumulated Impairment Specialty Brands $ 3,446.2 $ — $ 3,498.1 $ — Specialty Generics 207.0 (207.0 ) 207.0 (207.0 ) Total $ 3,653.2 $ (207.0 ) $ 3,705.1 $ (207.0 ) During the six months ended June 30, 2017 , the gross carrying value of goodwill within the Specialty Brands segment decreased by $51.9 million . The decrease was primarily attributable to the sale of the Intrathecal Therapy business to Piramal. The Company ascribed $49.8 million of goodwill to that business and it was factored into the gain on sale of the business. The remainder of the decrease was related to a purchase accounting adjustment for the Stratatech acquisition primarily attributable to changes in deferred tax balances. The gross carrying amount and accumulated amortization of intangible assets at the end of each period were as follows: June 30, 2017 December 30, 2016 Gross Carrying Amount Accumulated Impairment Gross Carrying Amount Accumulated Impairment Amortizable: Completed technology $ 9,955.6 $ 1,932.1 $ 10,028.7 $ 1,617.1 Licenses 177.1 118.4 177.1 112.7 Customer relationships 28.7 10.4 27.6 8.4 Trademarks 82.0 12.6 82.1 10.9 Other 8.6 7.9 6.7 6.7 Total $ 10,252.0 $ 2,081.4 $ 10,322.2 $ 1,755.8 Non-Amortizable: Trademarks $ 35.0 $ 35.0 In-process research and development 399.1 399.1 Total $ 434.1 $ 434.1 Intangible asset amortization expense was as follows: Three Months Ended Six Months Ended June 30, 2017 June 24, 2016 June 30, 2017 June 24, 2016 Amortization expense $ 174.7 $ 175.8 $ 349.8 $ 350.8 The estimated aggregate amortization expense on intangible assets owned by the Company is expected to be as follows: Remainder of Fiscal 2017 $ 344.9 Fiscal 2018 686.5 Fiscal 2019 686.2 Fiscal 2020 685.9 Fiscal 2021 685.7

Debt

Debt	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Debt	11. Debt Debt was comprised of the following at the end of each period: June 30, 2017 December 30, 2016 Principal Unamortized Discount and Debt Issuance Costs Principal Unamortized Discount and Debt Issuance Costs Current maturities of long-term debt: Variable-rate receivable securitization $ 200.0 $ 0.1 $ 250.0 $ 0.3 3.50% notes due April 2018 300.0 0.5 — — Term loan due March 2021 — — 20.0 0.3 4.00% term loan due February 2022 1.1 — 1.0 — Term loan due September 2024 18.7 0.3 — — Capital lease obligation and vendor financing agreements 0.5 — 0.8 — Total current debt 520.3 0.9 271.8 0.6 Long-term debt: 3.50% notes due April 2018 — — 300.0 0.9 4.875% notes due April 2020 700.0 7.0 700.0 8.2 Term loan due March 2021 — — 1,928.5 33.4 4.00% term loan due February 2022 5.2 — 5.5 — 9.50% debentures due May 2022 10.4 — 10.4 — 5.75% notes due August 2022 884.0 10.5 884.0 11.6 8.00% debentures due March 2023 4.4 — 4.4 — 4.75% notes due April 2023 541.5 5.1 600.0 6.1 5.625% notes due October 2023 738.0 10.5 738.0 11.4 Term loan due September 2024 1,841.7 29.4 — — 5.50% notes due April 2025 692.1 9.6 695.0 10.2 Revolving credit facility — 6.7 100.0 3.2 Total long-term debt 5,417.3 78.8 5,965.8 85.0 Total debt $ 5,937.6 $ 79.7 $ 6,237.6 $ 85.6 The Company's debt instruments are further described within the notes to the financial statements included within the Company's Annual Report filed on Form 10-K for the fiscal year ended September 30, 2016. On February 28, 2017, Mallinckrodt International Finance, S.A. ("MIFSA") and Mallinckrodt CB LLC ("MCB") refinanced the March 2014 and August 2014 term loans, both of which were due in March 2021 ("the Existing Term Loans"). The refinanced term loans had an initial aggregate principal amount of $1,865.0 million , are due in September 2024 and bear interest at LIBOR plus 2.75% ("the 2017 Term Loan"). The 2017 Term Loan requires quarterly principal amortization payments in an amount equal to 0.25% of the original principal balance of the 2017 Term Loan payable on the last day of each calendar quarter, which will commence on June 30, 2017, with the remaining balance due on September 24, 2024. The Company accounted for the term loan refinancing as a debt modification. In conjunction with the term loan refinancing, MIFSA and MCB replaced the existing revolving credit facility of $500.0 million due in March 2019 with a $900.0 million facility that matures on February 28, 2022 ("the 2017 Revolving Credit Facility"). The 2017 Revolving Credit Facility bears interest at LIBOR plus 2.25% . The 2017 Revolving Credit Facility reduced the letter of credit provision from $150.0 million to $50.0 million . Unused commitments under the 2017 Revolving Credit Facility are subject to an annual commitment fee of 0.275% . Fees applied to outstanding letters of credit is based on the interest rate applied to borrowings. The 2017 Revolving Credit Facility added certain wholly-owned subsidiaries of the Company as borrowers, in addition to Mallinckrodt plc, MIFSA and MCB. The 2017 Term Loan and 2017 Revolving Credit Facility (collectively "the 2017 Facilities") are fully and unconditionally guaranteed by Mallinckrodt plc, certain of its direct or indirect wholly-owned U.S. subsidiaries and each of its direct or indirect wholly-owned subsidiaries that owns directly or indirectly any such wholly-owned U.S. subsidiaries and certain of its other subsidiaries (collectively, "the Guarantors"). The 2017 Facilities are secured by a security interest in certain assets of MIFSA, MCB and the Guarantors. The 2017 Facilities contain customary affirmative and negative covenants, which include, among other things, restrictions on the Company's ability to declare or pay dividends, create liens, incur additional indebtedness, enter into sale and lease-back transactions, make investments, dispose of assets and merge or consolidate with any other person. As a result of the 2017 Facilities financing transaction and the write-off of certain deferred financing costs associated with an $83.5 million payment on the Existing Term Loans, the Company recorded a $10.0 million charge included within the other expense line in the unaudited condensed consolidated statement of income. As of June 30, 2017 , the applicable interest rate on outstanding borrowings under the Company's revolving credit facility was approximately 3.55% , and there were no outstanding borrowings. As of June 30, 2017 , the applicable interest rate on outstanding borrowings under the variable-rate receivable securitization was 2.02% , and outstanding borrowings totaled $200.0 million . At June 30, 2017 , the applicable interest rate for the term loan due September 2024 was 4.05% , and outstanding borrowings totaled $1,860.4 million . As of June 30, 2017 , the Company continues to be in full compliance with the provisions and covenants associated with its debt agreements.

Retirement Plans

Retirement Plans	6 Months Ended
	Jun. 30, 2017
Compensation and Retirement Disclosure [Abstract]
Retirement Plans	12. Retirement Plans The net periodic benefit cost for the Company's defined benefit pension plans was as follows: Three Months Ended Six Months Ended June 30, June 24, June 30, June 24, Service cost $ 0.2 $ 0.4 $ 1.5 $ 0.8 Interest cost 0.4 3.5 2.1 7.0 Expected return on plan assets — (4.2 ) (1.3 ) (8.4 ) Amortization of net actuarial loss 0.4 2.6 2.6 5.2 Amortization of prior service cost 0.1 — 0.2 — Plan settlements 0.5 3.3 69.7 7.0 Net periodic benefit cost $ 1.6 $ 5.6 $ 74.8 $ 11.6 The net periodic benefit credit for the Company's postretirement benefit plans was approximately zero for the three months ended June 30, 2017 and June 24, 2016 , and for the six months ended June 30, 2017 and June 24, 2016 was approximately zero and $0.1 million , respectively. Net periodic benefit cost for the Company's defined benefit pension plans and postretirement benefit plans was included within cost of sales; research and development; and selling, general and administrative ("SG&A") expenses on the unaudited condensed consolidated statements of income. Pension Plan Termination During the six months ended June 30, 2017, the Company completed the third-party settlement of remaining obligations of six defined benefit pension plans that were terminated during fiscal 2016. In conjunction with this final settlement, the Company made a $61.3 million cash contribution to the terminated plans and recognized a $69.7 million charge, included within SG&A expenses.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	6 Months Ended
	Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income	13. Accumulated Other Comprehensive Income The following summarizes the change in accumulated other comprehensive income for the six months ended June 30, 2017 and June 24, 2016: Currency Translation Unrecognized Gain (Loss) on Derivatives Unrecognized Gain (Loss) on Benefit Plans Unrecognized Gain on Equity Securities Accumulated Other Comprehensive Income (Loss) Balance at December 30, 2016 $ (19.5 ) $ (5.7 ) $ (47.3 ) $ — $ (72.5 ) Other comprehensive income before reclassifications 12.1 — 5.5 10.6 28.2 Amounts reclassified from accumulated other comprehensive income (4.7 ) 0.6 40.4 — 36.3 Net current period other comprehensive income 7.4 0.6 45.9 10.6 64.5 Balance at June 30, 2017 $ (12.1 ) $ (5.1 ) $ (1.4 ) $ 10.6 $ (8.0 ) Currency Translation Unrecognized Gain (Loss) on Derivatives Unrecognized Gain (Loss) on Benefit Plans Unrecognized Gain on Equity Securities Accumulated Other Comprehensive Income (Loss) Balance at December 25, 2015 $ (7.9 ) $ (6.3 ) $ (51.1 ) $ — $ (65.3 ) Other comprehensive income (loss) before reclassifications 8.3 — (15.5 ) — (7.2 ) Amounts reclassified from accumulated other comprehensive income (0.7 ) 0.4 7.1 — 6.8 Net current period other comprehensive income (loss) 7.6 0.4 (8.4 ) — (0.4 ) Balance at June 24, 2016 $ (0.3 ) $ (5.9 ) $ (59.5 ) $ — $ (65.7 ) The following summarizes reclassifications from accumulated other comprehensive income for the six months ended June 30, 2017 and June 24, 2016: Amount Reclassified from Accumulated Other Comprehensive Income Six Months Ended June 30, June 24, Line Item in the Unaudited Condensed Consolidated Statement of Income Amortization and other of unrealized loss on derivatives $ 0.8 $ 0.4 Interest expense Income tax provision (0.2 ) — Income tax benefit Net of income taxes 0.6 0.4 Amortization of pension and post-retirement benefit plans: Net actuarial loss 2.6 5.3 (1) Prior service credit (1.1 ) (1.4 ) (1) Divestiture of discontinued operations (3.1 ) — Income from discontinued operations, net of income taxes Plan settlements 69.7 7.0 (1) Selling, general and administrative expenses Total before tax 68.1 10.9 Income tax provision (27.7 ) (3.8 ) Income tax benefit Net of income taxes 40.4 7.1 Currency translation (4.7 ) (0.7 ) Income from discontinued operations, net of income taxes Total reclassifications for the period $ 36.3 $ 6.8 (1) These accumulated other comprehensive income components are included in the computation of net periodic benefit cost. See Note 12 for additional details .

Equity

Equity	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Equity	14. Equity Share Repurchases On November 19, 2015, the Company's Board of Directors authorized a $500.0 million share repurchase program (the "November 2015 Program"), which was completed in the three months ended December 30, 2016. On March 16, 2016, the Company's Board of Directors authorized an additional $350.0 million share repurchase program (the "March 2016 Program"), which was completed during the three months ended March 31, 2017. On March 1, 2017, the Company's Board of Directors authorized an additional $1.0 billion share repurchase program (the "March 2017 Program"), which commenced upon the completion of the March 2016 Program. The March 2017 Program has no time limit or expiration date, and the Company currently expects to fully utilize the program. March 2017 Repurchase Program March 2016 Repurchase Program November 2015 Repurchase Program Number of Shares Amount Number of Shares Amount Number of Shares Amount Authorized repurchase amount $ 1,000.0 $ 350.0 $ 500.0 Repurchases: Fiscal 2016 (1) — — — — 6,510,824 425.6 Transition Period 2016 — — 1,501,676 84.0 1,063,337 74.4 Fiscal 2017 2,594,703 110.3 5,366,741 266.0 — — Remaining amount available $ 889.7 $ — $ — (1) Represents the Company's historical fiscal year ending on the last Friday in September. The Company also repurchases shares from employees in order to satisfy employee tax withholding requirements in connection with the vesting of restricted shares and share option exercises.

Guarantees

Guarantees	6 Months Ended
	Jun. 30, 2017
Guarantees [Abstract]
Guarantees	15. Guarantees In disposing of assets or businesses, the Company has historically provided representations, warranties and indemnities to cover various risks and liabilities, including unknown damage to the assets, environmental risks involved in the sale of real estate, liability to investigate and remediate environmental contamination at waste disposal sites and manufacturing facilities, and unidentified tax liabilities related to periods prior to disposition. The Company assesses the probability of potential liabilities related to such representations, warranties and indemnities and adjusts potential liabilities as a result of changes in facts and circumstances. The Company believes, given the information currently available, that their ultimate resolutions will not have a material adverse effect on its financial condition, results of operations and cash flows. In connection with the sale of the Specialty Chemicals business (formerly known as Mallinckrodt Baker) in fiscal 2010, the Company agreed to indemnify the purchaser with respect to various matters, including certain environmental, health, safety, tax and other matters. The indemnification obligations relating to certain environmental, health and safety matters have a term of 17 years from the sale, while some of the other indemnification obligations have an indefinite term. The amount of the liability relating to all of these indemnification obligations included in other liabilities on the Company's unaudited condensed consolidated balance sheets as of June 30, 2017 and December 30, 2016 was $15.0 million and $15.1 million , respectively, of which $12.3 million and $12.4 million , respectively, related to environmental, health and safety matters. The value of the environmental, health and safety indemnity was measured based on the probability-weighted present value of the costs expected to be incurred to address environmental, health and safety claims made under the indemnity. The aggregate fair value of these indemnification obligations did not differ significantly from their aggregate carrying value at June 30, 2017 and December 30, 2016. As of June 30, 2017 , the maximum future payments the Company could be required to make under these indemnification obligations were $70.2 million . The Company was required to pay $30.0 million into an escrow account as collateral to the purchaser, of which $18.2 million and $19.0 million remained in restricted cash, included in long-term other assets on the unaudited condensed consolidated balance sheets at June 30, 2017 and December 30, 2016 , respectively. The Company has recorded liabilities for known indemnification obligations included as part of environmental liabilities, which are discussed in Note 16. The Company is also liable for product performance; however, the Company believes, given the information currently available, that their ultimate resolutions will not have a material adverse effect on its financial condition, results of operations and cash flows. The Company was previously required to provide the U.S. Nuclear Regulatory Commission financial assurance demonstrating its ability to fund the decommissioning of its Maryland Heights, Missouri, radiopharmaceuticals production facility upon closure. Following the sale of the Nuclear Imaging business, the surety bond was canceled in April 2017 and the Company is no longer required to provide financial assurance to the U.S. Nuclear Regulatory Commission for that facility. As of June 30, 2017 , the Company had various other letters of credit, guarantees and surety bonds totaling $28.7 million . In addition, as part of the Company's legal separation, the Company entered into a separation and distribution agreement with Covidien plc ("Covidien"), which was subsequently acquired by Medtronic plc, and such agreement provides for cross-indemnities principally designed to place financial responsibility of the obligations and liabilities of the Company's business with the Company and financial responsibility for the obligations and liabilities of Covidien's remaining business with Covidien, among other indemnities.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies The Company is subject to various legal proceedings and claims, including patent infringement claims, product liability matters, environmental matters, employment disputes, contractual disputes and other commercial disputes, including those described below. The Company believes that these legal proceedings and claims likely will be resolved over an extended period of time. Although it is not feasible to predict the outcome of these matters, the Company believes, unless indicated below, given the information currently available, that their ultimate resolutions will not have a material adverse effect on its financial condition, results of operations and cash flows. Governmental Proceedings Multnomah County Lawsuit. On August 3, 2017, the County of Multnomah filed a lawsuit in Multnomah County Circuit Court in Oregon against certain prescription opioid manufacturers, including the Company, as well as distributors and healthcare providers. The lawsuit alleges the creation of a public nuisance arising from defendants’ manufacturing, distribution, marketing and promotion of opioids and alleges other common law claims. Plaintiff seeks economic damages and costs. The Company intends to vigorously defend itself in this matter. Department of Justice Subpoena. On July 26, 2017, the Company received a subpoena from the Department of Justice for documents related to the marketing and sale of the Company’s opioid products. Staubus, et al. v. Purdue Pharma, L.P., et al . On June 13, 2017, the District Attorneys General of Tennessee’s First, Second and Third Judicial Districts and Baby Doe jointly filed a lawsuit in Sullivan County Circuit Court in Kingsport, Tennessee against certain prescription opioid manufacturers, including the Company. The lawsuit alleges violations of Tennessee’s Drug Dealer Liability Act and public nuisance laws arising out of defendants’ alleged opioid sales and marketing practices. Plaintiffs seek restitution, damages, injunctive relief and attorneys’ fees and costs. The Company intends to vigorously defend itself in this matter. SEC Subpoena. In January 2017, the Company received a subpoena from the SEC for documents related to the Company’s public statements, filings and other disclosures regarding Acthar sales, profits, revenue, promotion and pricing. Boston Subpoena. In December 2016, the Company received a subpoena from the United States Attorney’s Office ("USAO") for the District of Massachusetts for documents related to the Company’s provision of financial and other support to patients, including through charitable foundations, and related matters. Texas Pricing Investigation. In November 2014, the Company received a Civil Investigative Demand ("CID") from the Civil Medicaid Fraud Division of the Texas Attorney General's Office. According to the CID, the Attorney General's office is investigating the possibility of false reporting of information by the Company regarding the prices of certain of its drugs used by Texas Medicaid to establish reimbursement rates for pharmacies that dispensed the Company's drugs to Texas Medicaid recipients. Mallinckrodt Inc. v. U.S. Food and Drug Administration and United States of America. The Company filed a Complaint for Declaratory and Injunctive Relief ("the Complaint") in the U.S. District Court for the District of Maryland Greenbelt Division against the FDA and the United States of America in November 2014 for judicial review of what the Company believes is the FDA's inappropriate and unlawful reclassification of the Company's Methylphenidate HCl Extended-Release tablets USP (CII) ("Methylphenidate ER") in the Orange Book: Approved Drug Products with Therapeutic Equivalence ("Orange Book") on November 13, 2014. In its Complaint, the Company asked the court to: issue an injunction to (a) set aside the FDA's reclassification of the Company's Methylphenidate ER products from freely substitutable at the pharmacy level (class AB) to presumed to be therapeutically inequivalent (class BX) in the Orange Book and (b) prohibit the FDA from reclassifying the Company's Methylphenidate ER products in the future without following applicable legal requirements; and issue a declaratory judgment that the FDA's action reclassifying the Company's Methylphenidate ER products in the Orange Book is unlawful. The Company concurrently filed a motion with the same court requesting an expedited hearing to issue a temporary restraining order ("TRO") directing the FDA to reinstate the Orange Book AB rating for the Company's Methylphenidate ER products on a temporary basis. The court denied the Company's motion for a TRO. In December 2014, the FDA filed a motion to dismiss the Complaint with the district court. The Company filed its opposition to the motion to dismiss in January 2015, and concurrently filed a motion for summary judgment. In July 2015, the court granted the FDA’s motion to dismiss with respect to three of the five counts in the Complaint and granted summary judgment in favor of the FDA with respect to the two remaining counts. The Company appealed the court’s decision to the U.S. Court of Appeals for the Fourth Circuit. On October 18, 2016, the FDA initiated proceedings, proposing to withdraw approval of the Company's Abbreviated New Drug Application ("ANDA") for Methylphenidate ER. On October 21, 2016, the United States Court of Appeals for the Fourth Circuit issued an order removing the Company’s pending litigation with the FDA from the Court’s oral argument calendar and placing that litigation in abeyance pending the outcome of the withdrawal proceedings. The Company concurrently submitted to the FDA requests for a hearing in the withdrawal proceeding and for a 90-day extension of the deadline for submitting documentation supporting the necessity of a hearing. The FDA granted the Company’s initial request to extend the deadline to March 20, 2017, and on February 21, 2017, the FDA suspended the deadline in order to give the Center for Drug Evaluation and Research ("CDER") an opportunity to complete its production of documents. CDER shared an initial set of documents with the Company in June 2017 and is in the process of finalizing a second set of documents to share with the Company. The Company is preparing the supporting documentation for its submission and plans to vigorously set forth its position in the withdrawal proceedings. Therakos Investigation. In March 2014, the USAO for the Eastern District of Pennsylvania requested the production of documents related to an investigation of the U.S. promotion of Therakos’ immunotherapy drug/device system UVADEX/UVAR XTS and UVADEX/CELLEX (collectively, the "Therakos System"), for indications not approved by the FDA, including treatment of patients with graft versus host disease ("GvHD") and solid organ transplant patients, including pediatric patients. The investigation also includes Therakos’ efforts to secure FDA approval for additional uses of, and alleged quality issues relating to, UVADEX/UVAR. In August 2015, the USAO for the Eastern District of Pennsylvania sent Therakos a subsequent request for documents related to the investigation and has since made certain related requests. We are in the process of responding to those requests. FTC Investigation. In June 2014, Questcor Inc. ("Questcor") received a subpoena and CID from the FTC seeking documentary materials and information regarding the FTC's investigation into whether Questcor's acquisition of certain rights to develop, market, manufacture, distribute, sell and commercialize MNK-1411 (the product formerly described as Synacthen Depot®) from Novartis AG and Novartis Pharma AG (collectively, "Novartis") violates antitrust laws. Subsequently, California, Maryland, Texas, Washington, New York and Alaska (collectively, "the Investigating States") commenced similar investigations focused on whether the transaction violates state antitrust laws. On January 17, 2017, the FTC, all Investigating States (except California) ("the Settling States") and the Company entered into an agreement to resolve this matter for a one-time cash payment of $102.0 million and an agreement to license MNK-1411 to a third party designated by the FTC for possible development in Infantile Spasms ("IS") and Nephrotic Syndrome ("NS") in the U.S. To facilitate that settlement, a complaint was filed on January 18, 2017, in the U.S. District Court for the District of Columbia. The settlement was approved by the court on January 30, 2017. On July 16, 2017, the Company announced the completion of the U.S. license of both the Synacthen trademark and certain intellectual property associated with MNK-1411 to West Pharmaceuticals to develop and pursue possible FDA approval of the product in IS and NS. The Company retains the right to develop MNK-1411 for all other indications in the U.S. and retains rights to the Synacthen trademark outside the U.S. Questcor DOJ Investigation. In September 2012, Questcor received a subpoena from the USAO for the Eastern District of Pennsylvania for information relating to its promotional practices related to Acthar. Questcor has also been informed by the USAO for the Eastern District of Pennsylvania that the USAO for the Southern District of New York and the SEC are participating in the investigation to review Questcor's promotional practices and related matters related to Acthar. On March 9, 2015, the Company received a "No Action" letter from the SEC regarding its review of the Company's promotional practices related to Acthar. DEA Investigation. In November 2011 and October 2012, the Company received subpoenas from the U.S. Drug Enforcement Administration requesting production of documents relating to its suspicious order monitoring program for controlled substances. The USAO for the Eastern District of Michigan is investigating the possibility that the Company failed to report suspicious orders of controlled substances during the period 2006-2011 in violation of the Controlled Substances Act and its related regulations. The USAO for the Northern District of New York and Office of Chief Counsel for the U.S. Drug Enforcement Administration ("DEA") are investigating the possibility that the Company failed to maintain appropriate records and security measures with respect to manufacturing of certain controlled substances at its Hobart facility during the period 2012-2013. On July 11, 2017, the Company entered into a final settlement with the DEA and the USAOs for the Eastern District of Michigan and the Northern District of New York to settle these investigations. As part of the agreement, the Company paid $35.0 million to resolve all potential claims. We have responded to or are in the process of responding to each of the unresolved subpoenas and CIDs and we intend to cooperate fully in each such investigation. Patent/Antitrust Litigation Putative Class Action Litigation . On April 6, 2017, a putative class action lawsuit was filed against the Company and United BioSource Corporation ("UBC") in the U.S. District Court for the Northern District of Illinois. The case is captioned City of Rockford v. Mallinckrodt ARD, Inc., et al. The complaint purports to be brought on behalf of all self-funded entities in the U.S. and its Territories that paid for Acthar from August 2007 to the present. The lawsuit alleges that the Company engaged in anticompetitive, unfair, and deceptive acts to artificially raise and maintain the price of Acthar. To this end, the suit alleges that the Company unlawfully maintained a monopoly in a purported ACTH product market by acquiring the U.S. rights to Synacthen Depot; conspired with UBC and violated anti-racketeering laws by selling Acthar through an exclusive distributor; and committed a fraud on consumers by failing to correctly identify Acthar’s active ingredient on package inserts. The Company intends to vigorously defend itself in this matter. Inomax Patent Litigation: Praxair Distribution, Inc. and Praxair, Inc. (collectively "Praxair"). In February 2015, INO Therapeutics LLC and Ikaria, Inc., subsidiaries of the Company, filed suit in the U.S. District Court for the District of Delaware against Praxair following receipt of a January 2015 notice from Praxair concerning its submission of an ANDA containing a Paragraph IV patent certification with the FDA for a generic version of Inomax. In July 2016, the Company filed a second suit against Praxair in the U.S. District Court for the District of Delaware following receipt of a Paragraph IV notice concerning three additional patents recently added to the FDA Orange Book that was submitted by Praxair regarding its ANDA for a generic version of Inomax. The infringement claims in the second suit have been added to the original suit. In September 2016, the Company filed a third suit against Praxair in the U.S. District Court for the District of Delaware following receipt of a Paragraph IV notice concerning a fourth patent recently added to the FDA Orange Book that was submitted by Praxair regarding its ANDA for a generic version of Inomax. The Company intends to vigorously enforce its intellectual property rights relating to Inomax in both the Inter Partes Review ("IPR") and Praxair litigation proceedings to prevent the marketing of infringing generic products prior to the expiration of the patents covering Inomax. Trial of the suit filed in February 2015 was held in March 2017 and a decision is not expected until later in 2017. An adverse outcome in the Praxair litigation ultimately could result in the launch of a generic version of Inomax before the expiration of the last of the listed patents on February 19, 2034 (August 19, 2034 including pediatric exclusivity), which could adversely affect the Company's ability to successfully maximize the value of Inomax and have an adverse effect on its financial condition, results of operations and cash flows. Inomax Patents: IPR Proceedings. In February 2015 and March 2015, the U.S. Patent and Trademark Office ("USPTO") issued Notices of Filing Dates Accorded to Petitions for IPR petitions filed by Praxair Distribution, Inc. concerning ten patents covering Inomax (i.e., five patents expiring in 2029 and five patents expiring in 2031). In July 2015, the USPTO Patent Trial and Appeal Board ("PTAB") issued rulings denying the institution of four of the five IPR petitions challenging the five patents expiring in 2029. The PTAB also issued a ruling in July 2015 that instituted the IPR proceeding in the fifth of this group of patents and the PTAB ruled in July 2016 that one claim of this patent survived review and is valid while the remaining claims were unpatentable. The Company believes the valid claim describes and encompasses the manner in which Inomax is distributed in conjunction with its approved labeling and that Praxair infringes that claim. Praxair filed an appeal and the Company filed a cross-appeal of this decision to the Court of Appeals for the Federal Circuit. In March 2016, Praxair Distribution, Inc. submitted additional IPR petitions for the five patents expiring in 2029. The PTAB issued non-appealable rulings in August and September 2016 denying institution of all five of these additional IPR petitions. In September 2015, the USPTO PTAB issued rulings that instituted the IPR proceedings in each of the second set of five patents that expire in 2031. In September 2016, the PTAB ruled that all claims in the five patents expiring in 2031 are patentable. Ofirmev Patent Litigation: B. Braun Medical Inc. In April 2017, Mallinckrodt Hospital Products Inc. and Mallinckrodt IP, subsidiaries of the Company, and Pharmatop, the owner of the two U.S. patents licensed exclusively by the Company, filed suit in the U.S. District Court for the District of Delaware against B. Braun Medical Inc. ("B. Braun") alleging that B. Braun infringed U.S. Patent Nos. 6,992,218 ("the ‘218 patent") and 9,399,012 ("the ‘012 patent") following receipt of a February 2017 notice from B. Braun concerning its submission of a New Drug Application ("NDA"), containing a Paragraph IV patent certification with the FDA for a competing version of Ofirmev. Following receipt of a second Paragraph IV notice letter from B. Braun on April 24, 2017 directed to the ‘012 patent, Mallinckrodt Hospital Products Inc. and Mallinckrodt IP filed suit in June 2017 in the U.S. District Court for the District of Delaware against B. Braun alleging that B. Braun infringed the ‘012 patent and U.S. 9,610,265 (“the ‘265 patent”). In both instances, a protective suit was filed in the U.S. District Court for the Eastern District of Pennsylvania to protect the 30-month stay against any venue challenge in Delaware. In July 2017, B. Braun filed motions to dismiss both actions in Delaware due to improper venue based on the recent U.S. Supreme Court TC Heartland decision on venue in patent cases, and also filed a separate motion to dismiss in the original action in Pennsylvania. Following receipt of a third Paragraph IV notice letter from B. Braun on July 13, 2017 that included a certification to the ‘265 patent, amended complaints were filed in July 2017 in the U.S. District Courts for the Districts of Delaware and Eastern District of Pennsylvania by Mallinckrodt Hospital Products Inc., Mallinckrodt IP and Pharmatop. Also in July 2017, Mallinckrodt Hospital Products Inc., Mallinckrodt IP and Pharmatop filed a motion to stay the action in the Eastern District of Pennsylvania. Ofirmev Patent Litigation: Agila Specialties Private Limited, Inc. (now Mylan Laboratories Ltd.) and Agila Specialties Inc. (a Mylan Inc. Company), (collectively “Agila”). In December 2014, Cadence and Mallinckrodt IP, subsidiaries of the Company, and Pharmatop, the owner of the two U.S. patents licensed exclusively by the Company, filed suit in the U.S. District Court for the District of Delaware against Agila alleging that Agila infringed U.S. Patent No. 6,028,222 ("the '222 patent") and the '218 patent following receipt of a November 2014 notice from Agila concerning its submission of a NDA containing a Paragraph IV patent certification with the FDA for a competing version of Ofirmev. Separately, on December 1, 2016 Mallinckrodt IP filed suit in the U.S. District Court for the District of Delaware against Agila alleging that Agila infringed the ‘012 patent. On December 31, 2016, the parties entered into settlement agreements on both suits under which Agila was granted the non-exclusive right to market a competing intravenous acetaminophen product in the U.S. under its NDA on or after December 6, 2020, or earlier under certain circumstances. Ofirmev Patent Litigation: InnoPharma Licensing LLC and InnoPharma, Inc. In September 2014, Cadence and Mallinckrodt IP, subsidiaries of the Company, and Pharmatop, the owner of the two U.S. patents licensed exclusively by the Company, filed suit in the U.S. District Court for the District of Delaware against InnoPharma Licensing LLC and InnoPharma, Inc. (both are subsidiaries of Pfizer and collectively "InnoPharma") alleging that InnoPharma infringed U.S. Patent No. 6,028,222 ("the '222 patent") and the '218 patent following receipt of an August 2014 notice from InnoPharma concerning its submission of a New Drug Application ("NDA"), containing a Paragraph IV patent certification with the FDA for a competing version of Ofirmev. Separately, on December 1, 2016 Mallinckrodt IP filed suit in the U.S. District Court for the District of Delaware against InnoPharma alleging that InnoPharma infringed the ‘012 patent. On May 4, 2017, the parties entered into settlement agreements on both suits under which InnoPharma was granted the non-exclusive right to market a competing intravenous acetaminophen product in the U.S. under its NDA on or after December 6, 2020, or earlier under certain circumstances. The Company has successfully asserted the ‘222 and ‘218 patents and maintained their validity in both litigation and proceedings at the USPTO. The Company will continue to vigorously enforce its intellectual property rights relating to Ofirmev to prevent the marketing of infringing generic or competing products prior to December 6, 2020, which, if unsuccessful, could adversely affect the Company's ability to successfully maximize the value of Ofirmev and have an adverse effect on its financial condition, results of operations and cash flows. Tyco Healthcare Group LP, et al. v. Mutual Pharmaceutical Company, Inc. In March 2007, the Company filed a patent infringement suit in the U.S. District Court for the District of New Jersey against Mutual Pharmaceutical Co., Inc., et al. (collectively, "Mutual") after Mutual submitted an ANDA to the FDA seeking to sell a generic version of the Company's 7.5 mg RESTORIL™ sleep aid product. Mutual also filed antitrust and unfair competition counterclaims. The patents at issue have since expired or been found invalid. The trial court issued an opinion and order granting the Company's motion for summary judgment regarding Mutual's antitrust and unfair competition counterclaims. Mutual appealed this decision to the U.S. Court of Appeals for the Federal Circuit and the Federal Circuit issued a split decision, affirming the trial court in part and remanding to the trial court certain counterclaims for further proceedings. The Company filed a motion for summary judgment with the U.S. District Court regarding the remanded issues. In May 2015, the trial court issued an opinion granting-in-part and denying-in-part the Company’s motion for summary judgment. In March 2017, the parties entered into a settlement agreement and the case was dismissed. Commercial and Securities Litigation Employee Stock Purchase Plan Securities Litigation. On July 20, 2017, a purported purchaser of Mallinckrodt stock through Mallinckrodt’s Employee Stock Purchase Plans (“ESPPs”), filed a derivative lawsuit in the Federal District Court in the Eastern District of Missouri, captioned Solomon v. Mallinckrodt plc, et al. , against the Company, its Chief Executive Officer Mark C. Trudeau ("CEO") , its Chief Financial Officer Matthew K. Harbaugh ("CFO"), its Controller Kathleen A. Schaefer, and current and former directors of the Company. The complaint purports to be brought on behalf of all persons who purchased or otherwise acquired Mallinckrodt stock between November 25, 2014, and January 18, 2017, in the ESPPs. In the alternative, the plaintiff alleges a class action for those same purchasers/acquirers of stock in the ESPPs during the same period. The complaint asserts claims under Section 11 of the Securities Act, and for breach of fiduciary duty, misrepresentation, non-disclosure, mismanagement of the ESPPs’ assets and breach of contract arising from substantially similar allegations as those contained in the putative class action securities litigation described in the following paragraph. The Company intends to vigorously defend itself in this matter. Putative Class Action Securities Litigation. On January 23, 2017, a putative class action lawsuit was filed against the Company and its CEO in the U.S. District Court for the District of Columbia, captioned Patricia A. Shenk v. Mallinckrodt plc, et al . The complaint purports to be brought on behalf of all persons who purchased Mallinckrodt’s publicly traded securities on a domestic exchange between November 25, 2014 and January 18, 2017. The lawsuit generally alleges that the Company made false or misleading statements related to Acthar and Synacthen to artificially inflate the price of the Company’s stock. In particular, the complaint alleges a failure by the Company to provide accurate disclosures concerning the long-term sustainability of Acthar revenues, and the exposure of Acthar to Medicare and Medicaid reimbursement rates. On January 26, 2017, a second putative class action lawsuit, captioned Jyotindra Patel v. Mallinckrodt plc, et al. was filed against the same defendants named in the Shenk lawsuit in the U.S. District Court for the District of Columbia. The Patel complaint purports to be brought on behalf of shareholders during the same period of time as that set forth in the Shenk lawsuit and asserts claims similar to those set forth in the Shenk lawsuit. On March 13, 2017, a third putative class action lawsuit, captioned Amy T. Schwartz, et al., v. Mallinckrodt plc, et al., was filed against the same defendants named in the Shenk lawsuit in the U.S. District Court for the District of Columbia. The Schwartz complaint purports to be brought on behalf of shareholders who purchased shares of the Company between July 14, 2014 and January 18, 2017 and asserts claims similar to those set forth in the Shenk lawsuit. On March 23, 2017, a fourth putative class action lawsuit, captioned Fulton County Employees’ Retirement System v. Mallinckrodt plc, et al., was filed against the Company and its CEO and CFO in the U.S. District Court for the District of Columbia. The Fulton County complaint purports to be brought on behalf of shareholders during the same period of time as that set forth in the Schwartz lawsuit and asserts claims similar to those set forth in the Shenk lawsuit. On March 27, 2017, four separate plaintiff groups moved to consolidate the pending cases and to be appointed as lead plaintiffs in the consolidated case. Since that time, two of the plaintiff groups have withdrawn their motions. The Company intends to vigorously defend itself in this matter. Retrophin Litigation. In January 2014, Retrophin, Inc. ("Retrophin") filed a lawsuit against Questcor in the U.S. District Court for the Central District of California, alleging a variety of federal and state antitrust violations based on Questcor's acquisition from Novartis of certain rights to develop, market, manufacture, distribute, sell and commercialize Synacthen. In June 2015, the parties entered into a binding settlement agreement, under the terms of which Retrophin agreed to dismiss the litigation with prejudice and Questcor agreed to make a one-time cash payment to Retrophin in the amount of $15.5 million . Putative Class Action Securities Litigation. In September 2012, a putative class action lawsuit was filed against Questcor and certain of its officers and directors in the U.S. District Court for the Central District of California, captioned John K. Norton v. Questcor Pharmaceuticals, et al . The complaint purported to be brought on behalf of shareholders who purchased Questcor common stock between April 26, 2011 and September 21, 2012. The complaint generally alleged that Questcor and certain of its officers and directors engaged in various acts to artificially inflate the price of Questcor stock and enable insiders to profit through stock sales. The complaint asserted that Questcor and certain of its officers and directors violated sections l0(b) and/or 20(a) of the Securities Exchange Act of 1934, as amended ("the Exchange Act"), by making allegedly false and/or misleading statements concerning the clinical evidence to support the use of Acthar for indications other than infantile spasms, the promotion of the sale and use of Acthar in the treatment of multiple sclerosis and nephrotic syndrome, reimbursement for Acthar from third-party insurers, and Questcor's outlook and potential market growth for Acthar. The complaint sought damages in an unspecified amount and equitable relief against the defendants. This lawsuit was consolidated with four subsequently-filed actions asserting similar claims under the caption: In re Questcor Securities Litigation . In October 2013, the District Court granted in part and denied in part Questcor's motion to dismiss the consolidated amended complaint. In October 2013, Questcor filed an answer to the consolidated amended complaint and fact discovery was concluded in January 2015. In April 2015, the parties executed a long-form settlement agreement, under the terms of which Questcor agreed to pay $38.0 million to resolve the plaintiff's claims, inclusive of all fees and costs. Questcor and the individual defendants maintain that the plaintiffs' claims are without merit, and entered into the settlement to eliminate the uncertainties, burden and expense of further protracted litigation. During fiscal 2015, the Company established a $38.0 million reserve for this settlement, which was subsequently paid to a settlement fund. The court issued its final approval of the settlement on September 18, 2015. Glenridge Litigation. In June 2011, Glenridge Pharmaceuticals, LLC ("Glenridge"), filed a lawsuit against Questcor in the Superior Court of California, Santa Clara County, alleging that Questcor had underpaid royalties to Glenridge under a royalty agreement related to net sales of Acthar. In August 2012, Questcor filed a separate lawsuit against the three principals of Glenridge, as well as Glenridge, challenging the enforceability of the royalty agreement. In August 2013, the lawsuits were consolidated into one case in the Superior Court of California, Santa Clara County. In October 2014, the parties entered into a binding term sheet settling the lawsuit. Under the terms of the settlement, the royalty rate payable by Questcor was reduced, royalties were capped instead of being payable for so long as Acthar was sold and Questcor agreed to pay Glenridge a reduced amount in satisfaction of royalties Questcor had previously accrued but not paid during the course of the lawsuit. In February 2015, the settlement agreement was finalized, with terms consistent with the October 2014 term sheet. Pricing Litigation State of Utah v. Apotex Corp., et al. The Company, along with several other pharmaceutical companies, was a defendant in this matter which was filed in May 2008, in the Third Judicial Circuit of Salt Lake County, Utah. The State of Utah alleges, generally, that the defendants reported false pricing information in connection with certain drugs that are reimbursable under Utah Medicaid, resulting in overpayment by Utah Medicaid for those drugs, and is seeking monetary damages and attorneys' fees. The Company believes that it has meritorious defenses to these claims and vigorously defended against them. In December 2015, the parties entered into a binding settlement agreement, under the terms of which the State of Utah agreed to dismiss the litigation with prejudice and the Company agreed to make a one-time cash payment to the State of Utah within the reserve established for this matter. Environmental Remediation and Litigation Proceedings The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites, including those described below. The ultimate cost of site cleanup and timing of future cash outlays is difficult to predict, given the uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations and alternative cleanup methods. The Company concluded that, as of June 30, 2017 , it was probable that it would incur remedial costs in the range of $38.0 million to $116.1 million . The Company also concluded that, as of June 30, 2017 , the best estimate within this range was $75.9 million , of which $2.3 million was included in accrued and other current liabilities and the remainder was included in environmental liabilities on the unaudited condensed consolidated balance sheet at June 30, 2017 . While it is not possible at this time to determine with certainty the ultimate outcome of these matters, the Company believes, given the information currently available, that the final resolution of all known claims, after taking into account amounts already accrued, will not have a material adverse effect on its financial condition, results of operations and cash flows. Coldwater Creek, Saint Louis County, Missouri. The Company is named as a defendant in numerous tort complaints with numerous plaintiffs pending in the U.S. District Court for the Eastern District of Missouri that were filed in or after February 2012. These cases allege personal injury for alleged exposure to radiological substances, including in Coldwater Creek in Missouri, and in the air. Plaintiffs allegedly lived and/or worked in various locations in Saint Louis County, Missouri, near Coldwater Creek. Radiological residues which may have been present in the creek have previously been remediated by the U.S. Army Corps of Engineers ("USACE"). The USACE continues to study and remediate the creek and surrounding areas. The Company believes that it has meritorious defenses to these complaints and is vigorously defending against them. The Company is unable to estimate a range of rea

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measurements	17. Financial Instruments and Fair Value Measurements Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level fair value hierarchy, which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy are as follows: Level 1— observable inputs such as quoted prices in active markets for identical assets or liabilities; Level 2— significant other observable inputs that are observable either directly or indirectly; and Level 3— significant unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period: June 30, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Debt and equity securities held in rabbi trusts $ 32.6 $ 21.5 $ 11.1 $ — Equity securities 31.9 31.9 — — Foreign exchange forward and option contracts 0.6 0.6 — — $ 65.1 $ 54.0 $ 11.1 $ — Liabilities: Deferred compensation liabilities $ 35.1 $ — $ 35.1 $ — Contingent consideration and acquired contingent liabilities 228.4 — — 228.4 Foreign exchange forward and option contracts 0.3 0.3 — — $ 263.8 $ 0.3 $ 35.1 $ 228.4 December 30, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Debt and equity securities held in rabbi trusts $ 33.6 $ 22.8 $ 10.8 $ — Foreign exchange forward and option contracts 0.7 0.7 — — $ 34.3 $ 23.5 $ 10.8 $ — Liabilities: Deferred compensation liabilities $ 32.5 $ — $ 32.5 $ — Contingent consideration and acquired contingent liabilities 250.5 — — 250.5 Foreign exchange forward and option contracts 3.4 3.4 — — $ 286.4 $ 3.4 $ 32.5 $ 250.5 Debt and equity securities held in rabbi trusts. Debt securities held in rabbi trusts primarily consist of U.S. government and agency securities and corporate bonds. When quoted prices are available in an active market, the investments are classified as level 1. When quoted market prices for a security are not available in an active market, they are classified as level 2. Equity securities held in rabbi trusts primarily consist of U.S. common stocks, which are valued using quoted market prices reported on nationally recognized securities exchanges. Equity securities . Equity securities consist of shares in Mesoblast, for which quoted prices are available in an active market; therefore, the investment is classified as level 1 and is valued based on quoted market prices reported on a nationally recognized securities exchange. Foreign exchange forward and option contracts. Foreign currency option and forward contracts are used to economically manage the foreign exchange exposures of operations outside the U.S. Quoted prices are available in an active market; as such, these derivatives are classified as level 1. Deferred compensation liabilities. The Company maintains a non-qualified deferred compensation plan in the U.S., which permits eligible employees of the Company to defer a portion of their compensation. A recordkeeping account is set up for each participant and the participant chooses from a variety of funds for the deemed investment of their accounts. The recordkeeping accounts generally correspond to the funds offered in the Company's U.S. tax-qualified defined contribution retirement plan and the account balance fluctuates with the investment returns on those funds. Contingent consideration and acquired contingent liabilities. The Company maintains various contingent consideration and acquired contingent liabilities associated with the acquisitions of Questcor, Hemostasis products and Stratatech. During the six months ended June 30, 2017, the Company paid the required annual payment of $25.0 million related to the license of developmental product MNK-1411 from Novartis. The fair value of the remaining contingent payments was measured based on the net present value of a probability-weighted assessment. At June 30, 2017, the total remaining payments under the license agreement shall not exceed $140.0 million . At June 30, 2017 and December 30, 2016, the fair value of the MNK-1411 contingent liability was $103.2 million and $124.7 million , respectively. As part of the Hemostasis Acquisition, the Company provided contingent consideration to The Medicines Company in the form of sales-based milestones associated with Raplixa and PreveLeak, and acquired contingent liabilities associated with The Medicines Company's prior acquisitions of the aforementioned products. The Company determined the fair value of the contingent consideration and acquired contingent liabilities based on an option pricing model to be $60.5 million and $11.4 million , respectively, at June 30, 2017 . The fair value of the contingent consideration and acquired contingent liabilities based on an option pricing model were $58.9 million and $11.2 million , respectively, as of December 30, 2016. As part of the Stratatech acquisition, the Company provided contingent consideration to the Stratatech Corporation, primarily in the form of regulatory filing and approval milestones associated with the deep partial thickness and full thickness indications associated with the StrataGraft product. The Company assesses the likelihood of and timing of making such payments. The fair value of the contingent payments was measured based on the net present value of a probability-weighted assessment. The Company determined the fair value of the contingent consideration associated with the Stratatech acquisition to be $53.3 million and $55.7 million at June 30, 2017 and December 30, 2016, respectively. The following table provides a summary of the changes in the Company's contingent consideration and acquired contingent liabilities: Balance at December 30, 2016 $ 250.5 Payments (25.0 ) Accretion expense 2.7 Fair value adjustment 0.2 Balance at June 30, 2017 $ 228.4 Financial Instruments Not Measured at Fair Value The following methods and assumptions were used by the Company in estimating fair values for financial instruments not measured at fair value as of June 30, 2017 and December 30, 2016: • The carrying amounts of cash and cash equivalents, accounts receivable, notes receivable, accounts payable and the majority of other current assets and liabilities approximate fair value because of their short-term nature. The Company classifies cash on hand and deposits in banks, including commercial paper, money market accounts and other investments it may hold from time to time, with an original maturity of three months or less, as cash and cash equivalents (level 1). The fair value of restricted cash was equivalent to its carrying value of $18.2 million and $19.1 million as of June 30, 2017 and December 30, 2016 , (level 1), respectively, which was included in prepaid expenses and other current assets and other assets on the unaudited condensed consolidated balance sheets. • The Company received a portion of consideration for the sale of the Intrathecal business in the form of a note receivable. The fair value of the note receivable was equivalent to its carrying value of $154.0 million as of June 30, 2017 (level 1). • The Company entered into short-term investment certificates during the three months ended December 30, 2016. These certificates are carried at cost, which approximates fair value, of $5.0 million and $11.1 million at June 30, 2017 and December 30, 2016 , respectively (level 2). These certificates are included in prepaid expenses and other current assets on the unaudited condensed consolidated balance sheets. • The Company's life insurance contracts are carried at cash surrender value, which is based on the present value of future cash flows under the terms of the contracts (level 3). Significant assumptions used in determining the cash surrender value include the amount and timing of future cash flows, interest rates and mortality charges. The fair value of these contracts approximates the carrying value of $66.9 million and $67.6 million at June 30, 2017 and December 30, 2016 , respectively. These contracts are included in other assets on the unaudited condensed consolidated balance sheets. • The carrying value of the Company's revolving credit facility and variable-rate receivable securitization approximates fair value due to the short-term nature of these instruments. The carrying value of the 4.00% term loan approximates the fair value of the instrument, as calculated using the discounted exit price, which is therefore classified as level 3. Since the quoted market prices for the Company's term loans and 8.00% and 9.50% debentures are not available in an active market, they are classified as level 2 for purposes of developing an estimate of fair value. The Company's 3.50% , 4.75% , 4.875% , 5.50% , 5.625% and 5.75% notes are classified as level 1, as quoted prices are available in an active market for these notes. The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period: June 30, 2017 December 30, 2016 Carrying Value Fair Value Carrying Value Fair Value Variable-rate receivable securitization $ 200.0 $ 200.0 $ 250.0 $ 250.0 3.50% notes due April 2018 300.0 300.0 300.0 298.7 4.875% notes due April 2020 700.0 681.9 700.0 699.5 Term loans due March 2021 — — 1,948.5 1,953.2 4.00% term loan due February 2022 6.3 6.3 6.5 6.5 9.50% debentures due May 2022 10.4 11.5 10.4 12.0 5.75% notes due August 2022 884.0 830.8 884.0 850.3 8.00% debentures due March 2023 4.4 4.7 4.4 4.9 4.75% notes due April 2023 541.5 461.8 600.0 520.9 5.625% notes due October 2023 738.0 674.6 738.0 682.4 Term loan due September 2024 1,860.4 1,855.4 — — 5.50% notes due April 2025 692.1 604.0 695.0 615.7 Revolving credit facility — — 100.0 100.0 Concentration of Credit and Other Risks Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of accounts receivable. The Company does not typically require collateral from customers. A portion of the Company's accounts receivable outside the U.S. includes sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries' national economies. The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales: Three Months Ended Six Months Ended June 30, June 24, June 30, June 24, CuraScript, Inc. 43 % 38 % 39 % 36 % McKesson Corporation 8 % 7 % 9 % 10 % The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period: June 30, December 30, McKesson Corporation 26 % 28 % Amerisource Bergen Corporation 15 % 15 % CuraScript, Inc. 18 % 15 % Cardinal Health, Inc. 9 % 10 % The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales: Three Months Ended Six Months Ended June 30, June 24, June 30, June 24, Acthar 39 % 34 % 36 % 33 % Inomax 15 % 14 % 16 % 14 %

Segment Data

Segment Data	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment Data	18. Segment Data The two reportable segments are further described below: • Specialty Brands includes branded medicines; and • Specialty Generics includes specialty generic drugs, API and external manufacturing. Selected information by reportable segment was as follows: Three Months Ended Six Months Ended June 30, June 24, June 30, June 24, Net sales: Specialty Brands $ 594.5 $ 589.3 $ 1,151.7 $ 1,124.3 Specialty Generics 216.0 263.4 454.6 527.8 Net sales of reportable segments 810.5 852.7 1,606.3 1,652.1 Other (1) 14.0 13.9 29.1 30.3 Net sales $ 824.5 $ 866.6 $ 1,635.4 $ 1,682.4 Operating income: Specialty Brands $ 274.1 $ 302.1 $ 549.1 $ 563.0 Specialty Generics 63.3 98.1 139.5 197.0 Segment operating income 337.4 400.2 688.6 760.0 Unallocated amounts: Corporate and unallocated expenses (2) (49.1 ) (34.1 ) (116.3 ) (59.5 ) Intangible asset amortization (174.7 ) (175.8 ) (349.8 ) (350.8 ) Restructuring and related charges, net (3) (1.5 ) (15.2 ) (20.2 ) (25.3 ) Non-restructuring impairment charges — — — (16.9 ) Operating income $ 112.1 $ 175.1 $ 202.3 $ 307.5 (1) Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business. (2) Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments. (3) Includes restructuring-related accelerated depreciation. Net sales by product family within the Company's reportable segments are as follows: Three Months Ended Six Months Ended June 30, June 24, June 30, June 24, Acthar $ 319.4 $ 298.3 $ 591.2 $ 546.7 Inomax 125.5 121.1 253.9 236.6 Ofirmev 75.7 70.7 149.1 141.8 Therakos immunotherapy 51.2 52.5 102.4 102.7 Hemostasis products 13.5 13.9 26.6 25.3 Other 9.2 32.8 28.5 71.2 Specialty Brands 594.5 589.3 1,151.7 1,124.3 Hydrocodone (API) and hydrocodone-containing tablets 23.0 38.2 53.3 79.0 Oxycodone (API) and oxycodone-containing tablets 25.1 30.6 47.2 68.5 Methylphenidate ER 20.2 24.3 43.9 48.9 Other controlled substances 107.7 124.7 215.1 246.6 Other products 40.0 45.6 95.1 84.8 Specialty Generics 216.0 263.4 454.6 527.8 Other (1) 14.0 13.9 29.1 30.3 Net sales $ 824.5 $ 866.6 $ 1,635.4 $ 1,682.4 (1) Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business.

Condensed Consolidating Financi

Condensed Consolidating Financial Statements	6 Months Ended
	Jun. 30, 2017
Condensed Consolidating Financial Statements [Abstract]
Condensed Consolidating Financial Statements	19. Condensed Consolidating Financial Statements MIFSA, an indirectly 100% -owned subsidiary of Mallinckrodt plc, is the borrower under the 3.50% notes due April 2018 and the 4.75% notes due April 2023 (collectively, "the Notes"), which are fully and unconditionally guaranteed by Mallinckrodt plc. The following information provides the composition of the Company's comprehensive income, assets, liabilities, equity and cash flows by relevant group within the Company: Mallinckrodt plc as guarantor of the Notes, MIFSA as issuer of the Notes and the other subsidiaries. There are no subsidiary guarantees related to the Notes. Set forth on the following pages are the condensed consolidating financial statements for the three and six months ended June 30, 2017 and June 24, 2016 , and as of June 30, 2017 and December 30, 2016 . Eliminations represent adjustments to eliminate investments in subsidiaries and intercompany balances and transactions between or among Mallinckrodt plc, MIFSA and other subsidiaries. Condensed consolidating financial information for Mallinckrodt plc and MIFSA, on a standalone basis, has been presented using the equity method of accounting for subsidiaries. MALLINCKRODT PLC CONDENSED CONSOLIDATING BALANCE SHEET As of June 30, 2017 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Assets Current Assets: Cash and cash equivalents $ 0.9 $ 149.9 $ 179.4 $ — $ 330.2 Accounts receivable, net — — 482.1 — 482.1 Inventories — — 339.4 — 339.4 Prepaid expenses and other current assets 0.4 0.4 133.2 — 134.0 Notes receivable — — 154.0 — 154.0 Current assets held for sale — — — — — Intercompany receivables 95.7 19.7 1,135.7 (1,251.1 ) — Total current assets 97.0 170.0 2,423.8 (1,251.1 ) 1,439.7 Property, plant and equipment, net — — 940.7 — 940.7 Goodwill — — 3,446.2 — 3,446.2 Intangible assets, net — — 8,604.7 — 8,604.7 Investment in subsidiaries 4,846.2 21,498.0 10,484.6 (36,828.8 ) — Intercompany loans receivable 805.2 — 4,203.7 (5,008.9 ) — Other assets — — 189.9 — 189.9 Total Assets $ 5,748.4 $ 21,668.0 $ 30,293.6 $ (43,088.8 ) $ 14,621.2 Liabilities and Shareholders' Equity Current Liabilities: Current maturities of long-term debt $ — $ 317.8 $ 201.6 $ — $ 519.4 Accounts payable 0.1 0.9 112.9 — 113.9 Accrued payroll and payroll-related costs — — 92.8 — 92.8 Accrued interest — 53.0 1.1 — 54.1 Income taxes payable — — 122.0 — 122.0 Accrued and other current liabilities 0.5 0.4 459.3 — 460.2 Current liabilities held for sale — — — — — Intercompany payables 651.8 476.3 123.0 (1,251.1 ) — Total current liabilities 652.4 848.4 1,112.7 (1,251.1 ) 1,362.4 Long-term debt — 5,318.6 19.9 — 5,338.5 Pension and postretirement benefits — — 67.7 — 67.7 Environmental liabilities — — 73.6 — 73.6 Deferred income taxes — — 2,254.4 — 2,254.4 Other income tax liabilities — — 67.5 — 67.5 Intercompany loans payable — 5,008.9 — (5,008.9 ) — Other liabilities — 7.5 353.6 — 361.1 Total Liabilities 652.4 11,183.4 3,949.4 (6,260.0 ) 9,525.2 Shareholders' Equity 5,096.0 10,484.6 26,344.2 (36,828.8 ) 5,096.0 Total Liabilities and Shareholders' Equity $ 5,748.4 $ 21,668.0 $ 30,293.6 $ (43,088.8 ) $ 14,621.2 MALLINCKRODT PLC CONDENSED CONSOLIDATING BALANCE SHEET As of December 30, 2016 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Assets Current Assets: Cash and cash equivalents $ 0.5 $ 44.5 $ 297.0 $ — $ 342.0 Accounts receivable, net — — 431.0 — 431.0 Inventories — — 350.7 — 350.7 Prepaid expenses and other current assets 1.0 — 130.9 — 131.9 Notes receivable — — — — — Current assets held for sale — — 310.9 — 310.9 Intercompany receivables 59.7 65.1 1,081.3 (1,206.1 ) — Total current assets 61.2 109.6 2,601.8 (1,206.1 ) 1,566.5 Property, plant and equipment, net — — 881.5 — 881.5 Goodwill — — 3,498.1 — 3,498.1 Intangible assets, net — — 9,000.5 — 9,000.5 Investment in subsidiaries 5,534.1 20,624.1 10,988.5 (37,146.7 ) — Intercompany loans receivable 3.5 — 3,325.9 (3,329.4 ) — Other assets — — 259.7 — 259.7 Total Assets $ 5,598.8 $ 20,733.7 $ 30,556.0 $ (41,682.2 ) $ 15,206.3 Liabilities and Shareholders' Equity Current Liabilities: Current maturities of long-term debt $ — $ 19.7 $ 251.5 $ — $ 271.2 Accounts payable 0.1 0.1 111.9 — 112.1 Accrued payroll and payroll-related costs — — 76.1 — 76.1 Accrued interest — 53.9 14.8 — 68.7 Income taxes payable — — 101.7 — 101.7 Accrued and other current liabilities 1.9 7.5 547.7 — 557.1 Current liabilities held for sale — — 120.3 — 120.3 Intercompany payables 612.5 467.1 126.5 (1,206.1 ) — Total current liabilities 614.5 548.3 1,350.5 (1,206.1 ) 1,307.2 Long-term debt — 5,860.6 20.2 — 5,880.8 Pension and postretirement benefits — — 136.4 — 136.4 Environmental liabilities — — 73.0 — 73.0 Deferred income taxes — — 2,398.1 — 2,398.1 Other income tax liabilities — — 70.4 — 70.4 Intercompany loans payable — 3,329.4 — (3,329.4 ) — Other liabilities — 7.0 349.1 — 356.1 Total Liabilities 614.5 9,745.3 4,397.7 (4,535.5 ) 10,222.0 Shareholders' Equity 4,984.3 10,988.4 26,158.3 (37,146.7 ) 4,984.3 Total Liabilities and Shareholders' Equity $ 5,598.8 $ 20,733.7 $ 30,556.0 $ (41,682.2 ) $ 15,206.3 MALLINCKRODT PLC CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME For the three months ended June 30, 2017 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Net sales $ — $ — $ 824.5 $ — $ 824.5 Cost of sales 0.9 — 407.5 — 408.4 Gross profit (0.9 ) — 417.0 — 416.1 Selling, general and administrative expenses 15.1 0.2 216.8 — 232.1 Research and development expenses 1.8 — 67.4 — 69.2 Restructuring charges, net — — 0.6 — 0.6 Non-restructuring impairment charges — — — — — Losses on divestiture and license — — 2.1 — 2.1 Operating income (17.8 ) (0.2 ) 130.1 — 112.1 Interest expense (3.4 ) (88.7 ) (18.7 ) 18.6 (92.2 ) Interest income 2.0 0.3 16.9 (18.6 ) 0.6 Other income, net 2.2 6.6 1.2 — 10.0 Intercompany fees (3.5 ) — 3.5 — — Equity in net income of subsidiaries 81.0 254.7 172.9 (508.6 ) — Income from continuing operations before income taxes 60.5 172.7 305.9 (508.6 ) 30.5 Income tax benefit (1.3 ) (0.2 ) (38.6 ) — (40.1 ) Income from continuing operations 61.8 172.9 344.5 (508.6 ) 70.6 Income (loss) from discontinued operations, net of income taxes 1.0 — (8.8 ) — (7.8 ) Net income 62.8 172.9 335.7 (508.6 ) 62.8 Other comprehensive income, net of tax 1.9 1.9 3.4 (5.3 ) 1.9 Comprehensive income $ 64.7 $ 174.8 $ 339.1 $ (513.9 ) $ 64.7 MALLINCKRODT PLC CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME For the three months ended June 24, 2016 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Net sales $ — $ — $ 866.6 $ — $ 866.6 Cost of sales — — 377.8 — 377.8 Gross profit — — 488.8 — 488.8 Selling, general and administrative expenses 12.3 0.2 212.4 — 224.9 Research and development expenses — — 74.8 — 74.8 Restructuring charges, net — — 14.0 — 14.0 Non-restructuring impairment charge — — — — — Losses on divestiture and license — — — — — Operating income (12.3 ) (0.2 ) 187.6 — 175.1 Interest expense (56.3 ) (81.6 ) (20.3 ) 62.6 (95.6 ) Interest income — 0.1 62.9 (62.6 ) 0.4 Other income (expense), net 2.6 0.1 (4.0 ) — (1.3 ) Intercompany fees (4.5 ) — 4.5 — — Equity in net income of subsidiaries 260.2 380.5 308.9 (949.6 ) — Income from continuing operations before income taxes 189.7 298.9 539.6 (949.6 ) 78.6 Income tax benefit (9.6 ) (10.2 ) (78.3 ) — (98.1 ) Income from continuing operations 199.3 309.1 617.9 (949.6 ) 176.7 (Loss) income from discontinued operations, net of income taxes — (0.2 ) 22.8 — 22.6 Net income 199.3 308.9 640.7 (949.6 ) 199.3 Other comprehensive loss, net of tax (0.6 ) (0.6 ) (1.4 ) 2.0 (0.6 ) Comprehensive income $ 198.7 $ 308.3 $ 639.3 $ (947.6 ) $ 198.7 MALLINCKRODT PLC CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME For the six months ended June 30, 2017 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Net sales $ — $ — $ 1,635.4 $ — $ 1,635.4 Cost of sales 0.9 — 799.8 — 800.7 Gross profit (0.9 ) — 835.6 — 834.7 Selling, general and administrative expenses 33.3 0.4 506.5 — 540.2 Research and development expenses 1.8 — 129.6 — 131.4 Restructuring charges, net — — 17.8 — 17.8 Non-restructuring impairment charge — — — — — Gains on divestiture and license — — (57.0 ) — (57.0 ) Operating income (36.0 ) (0.4 ) 238.7 — 202.3 Interest expense (6.7 ) (174.0 ) (38.9 ) 33.2 (186.4 ) Interest income 3.1 0.6 31.0 (33.2 ) 1.5 Other income (expense), net 17.6 (3.3 ) (11.8 ) — 2.5 Intercompany fees (9.0 ) — 9.0 — — Equity in net income of subsidiaries 489.7 851.7 673.4 (2,014.8 ) — Income from continuing operations before income taxes 458.7 674.6 901.4 (2,014.8 ) 19.9 Income tax benefit (3.3 ) (0.5 ) (75.8 ) — (79.6 ) Income from continuing operations 462.0 675.1 977.2 (2,014.8 ) 99.5 (Loss) income from discontinued operations, net of income taxes — (1.7 ) 364.2 — 362.5 Net income 462.0 673.4 1,341.4 (2,014.8 ) 462.0 Other comprehensive income, net of tax 64.5 64.5 128.4 (192.9 ) 64.5 Comprehensive income $ 526.5 $ 737.9 $ 1,469.8 $ (2,207.7 ) $ 526.5 MALLINCKRODT PLC CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME For the six months ended June 24, 2016 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Net sales $ — $ — $ 1,682.4 $ — $ 1,682.4 Cost of sales — — 768.5 — 768.5 Gross profit — — 913.9 — 913.9 Selling, general and administrative expenses 26.2 0.4 407.6 — 434.2 Research and development expenses — — 132.9 — 132.9 Restructuring charges, net — — 22.4 — 22.4 Non-restructuring impairment charge — — 16.9 — 16.9 Gains on divestiture and license — — — — — Operating income (26.2 ) (0.4 ) 334.1 — 307.5 Interest expense (126.2 ) (163.1 ) (42.0 ) 138.5 (192.8 ) Interest income — 0.3 138.8 (138.5 ) 0.6 Other income (expense), net 14.9 — (16.9 ) — (2.0 ) Intercompany fees (7.3 ) 0.1 7.2 — — Equity in net income of subsidiaries 452.7 712.5 561.7 (1,726.9 ) — Income from continuing operations before income taxes 307.9 549.4 982.9 (1,726.9 ) 113.3 Income tax benefit (9.7 ) (14.0 ) (138.2 ) — (161.9 ) Income from continuing operations 317.6 563.4 1,121.1 (1,726.9 ) 275.2 (Loss) income from discontinued operations, net of income taxes — (1.7 ) 44.1 — 42.4 Net income 317.6 561.7 1,165.2 (1,726.9 ) 317.6 Other comprehensive loss, net of tax (0.4 ) (0.4 ) (1.2 ) 1.6 (0.4 ) Comprehensive income $ 317.2 $ 561.3 $ 1,164.0 $ (1,725.3 ) $ 317.2 MALLINCKRODT PLC CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the six months ended June 30, 2017 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Cash Flows From Operating Activities: Net cash from operating activities $ 1,177.0 $ 175.8 $ 1,487.0 $ (2,617.3 ) $ 222.5 Cash Flows From Investing Activities: Capital expenditures — — (101.6 ) — (101.6 ) Acquisitions and intangibles, net of cash acquired — — — — — Proceeds from divestiture of discontinued operations, net of cash — — 576.9 — 576.9 Intercompany loan investment, net (801.7 ) — (860.4 ) 1,662.1 — Investment in subsidiary — (307.9 ) — 307.9 — Other — — (9.9 ) — (9.9 ) Net cash from investing activities (801.7 ) (307.9 ) (395.0 ) 1,970.0 465.4 Cash Flows From Financing Activities: Issuance of external debt — — 40.0 — 40.0 Repayment of external debt and capital leases — (242.1 ) (90.7 ) — (332.8 ) Debt financing costs — (12.5 ) (0.5 ) — (13.0 ) Proceeds from exercise of share options 3.9 — — — 3.9 Repurchase of shares (380.8 ) — — — (380.8 ) Intercompany loan borrowings, net — 1,662.1 — (1,662.1 ) — Intercompany dividends — (1,170.0 ) (1,447.3 ) 2,617.3 — Capital contribution — — 307.9 (307.9 ) — Other 2.0 — (21.5 ) — (19.5 ) Net cash from financing activities (374.9 ) 237.5 (1,212.1 ) 647.3 (702.2 ) Effect of currency rate changes on cash — — 1.6 — 1.6 Net change in cash, cash equivalents and restricted cash 0.4 105.4 (118.5 ) — (12.7 ) Cash, cash equivalents and restricted cash at beginning of period 0.5 44.5 316.1 — 361.1 Cash, cash equivalents and restricted cash at end of period $ 0.9 $ 149.9 $ 197.6 $ — $ 348.4 Cash and cash equivalents at end of period $ 0.9 $ 149.9 $ 179.4 $ — $ 330.2 Restricted Cash, Current at end of period — — — — — Restricted Cash, Noncurrent at end of period — — 18.2 — 18.2 Cash, cash equivalents and restricted cash at end of period $ 0.9 $ 149.9 $ 197.6 $ — $ 348.4 MALLINCKRODT PLC CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the six months ended June 24, 2016 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Cash Flows From Operating Activities: Net cash from operating activities $ (4.3 ) $ (72.9 ) $ 760.2 $ — $ 683.0 Cash Flows From Investing Activities: Capital expenditures — — (84.5 ) — (84.5 ) Acquisitions and intangibles, net of cash acquired — — (169.5 ) — (169.5 ) Proceeds from divestiture of discontinued operations, net of cash — (1.4 ) 4.4 — 3.0 Intercompany loan investment, net — 105.8 (952.4 ) 846.6 — Investment in subsidiary — (461.7 ) — 461.7 — Other — — 4.6 — 4.6 Net cash from investing activities — (357.3 ) (1,197.4 ) 1,308.3 (246.4 ) Cash Flows From Financing Activities: Issuance of external debt — — 36.3 — 36.3 Repayment of external debt and capital leases — (160.3 ) (17.2 ) — (177.5 ) Debt financing costs — — — — — Proceeds from exercise of share options 4.9 — — — 4.9 Repurchase of shares (326.6 ) — — — (326.6 ) Intercompany loan borrowings, net 325.8 520.8 — (846.6 ) — Capital contribution — — 461.7 (461.7 ) — Other — — (23.0 ) — (23.0 ) Net cash from financing activities 4.1 360.5 457.8 (1,308.3 ) (485.9 ) Effect of currency rate changes on cash — — 2.1 — 2.1 Net change in cash, cash equivalents and restricted cash (0.2 ) (69.7 ) 22.7 — (47.2 ) Cash, cash equivalents and restricted cash at beginning of period 0.3 158.5 429.6 — 588.4 Cash, cash equivalents and restricted cash at end of period $ 0.1 $ 88.8 $ 452.3 $ — $ 541.2 Cash and cash equivalents at end of period $ 0.1 $ 88.8 $ 433.0 $ — $ 521.9 Restricted Cash, Current at end of period — — 0.3 — 0.3 Restricted Cash, Noncurrent at end of period — — 19.0 — 19.0 Cash, cash equivalents and restricted cash at end of period $ 0.1 $ 88.8 $ 452.3 $ — $ 541.2

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	20. Subsequent Events Commitments and Contingencies Multnomah County Lawsuit. On August 3, 2017, the County of Multnomah filed a lawsuit in Multnomah County Circuit Court in Oregon against certain prescription opioid manufacturers, including the Company, as well as distributors and healthcare providers. The lawsuit alleges the creation of a public nuisance arising from defendants’ manufacturing, distribution, marketing and promotion of opioids and alleges other common law claims. Plaintiff seeks economic damages and costs. The Company intends to vigorously defend itself in this matter. Department of Justice Subpoena. On July 26, 2017, the Company received a subpoena from the Department of Justice for documents related to the marketing and sale of the Company’s opioid products. Employee Stock Purchase Plan Securities Litigation. On July 20, 2017, a purported purchaser of Mallinckrodt stock through Mallinckrodt’s ESPPs, filed a derivative lawsuit in the Federal District Court in the Eastern District of Missouri, captioned Solomon v. Mallinckrodt plc, et al. , against the Company, its CEO, its CFO, its Controller, and current and former directors of the Company. The complaint purports to be brought on behalf of all persons who purchased or otherwise acquired Mallinckrodt stock between November 25, 2014 and January 18, 2017 in the ESPPs. In the alternative, the plaintiff alleges a class action for those same purchasers/acquirers of stock in the ESPPs during the same period. The complaint asserts claims under Section 11 of the Securities Act, and for breach of fiduciary duty, misrepresentation, non-disclosure, mismanagement of the ESPPs’ assets and breach of contract arising from substantially similar allegations as those contained in the Putative Class Action Securities Litigation filed in January 2017. The Company intends to vigorously defend itself in this matter. FTC Investigation. On July 16, 2017, in connection with the settlement with the FTC and the Settling States, the Company announced the completion of the license of both the Synacthen trademark and certain intellectual property associated with MNK-1411 to West Pharmaceuticals to develop and pursue possible FDA approval of the product in IS and NS. The Company retains the right to develop MNK-1411 for all other indications in the U.S. and retains rights to the Synacthen trademark outside the U.S. DEA Investigation. On July 11, 2017, the Company entered into a final settlement with the DEA and the USAOs for the Eastern District of Michigan and the Northern District of New York, respectively, to settle these investigations. As part of the agreement, the Company paid $35.0 million in July 2017 to resolve all potential claims. See further discussion of the aforementioned matters in Note 16 of the notes to the unaudited condensed consolidated financial statements. Accounts Receivable Securitization On July 28, 2017, Mallinckrodt Securitization S.à r.l. ("Mallinckrodt Securitization"), a wholly owned special purpose subsidiary of the Company, entered into a $250.0 million accounts receivable securitization facility ("the Receivable Securitization") with a three year term. Mallinckrodt Securitization may, from time to time, obtain up to $250.0 million in third-party borrowings secured by certain receivables. The borrowings under the Receivable Securitization are to be repaid as the secured receivables are collected. Loans under the Receivable Securitization will bear interest (including facility fees) at a rate equal to one month LIBOR rate plus a margin of 0.9% . Unused commitments on the Receivables Securitization are subject to an annual commitment fee of 0.4% . The Receivable Securitization agreements contain customary representations, warranties, and affirmative and negative covenants. The size of the securitization facility may be increased to $300.0 million upon approval of the third-party lenders. InfaCare Acquisition On August 3, 2017, the Company entered into an agreement to acquire InfaCare Pharmaceutical Corporation ("InfaCare") for an upfront payment of $80.0 million , with additional payments of up to $345.0 million dependent on regulatory and sales milestones. InfaCare is focused on development and commercialization of proprietary pharmaceuticals for neonatal and pediatric patient populations. InfaCare's developmental product stannsoporfin, a heme oxygenase inhibitor, is under investigation for its potential to reduce the production of bilirubin, the elevation of which can contribute to serious consequences in infants. This transaction is expected to close in the second half of 2017.

Discontinued Operations and D29

Discontinued Operations and Divestitures (Tables)	6 Months Ended
	Jun. 30, 2017
Disposal Groups, Including Discontinued Operations	The following table summarizes the assets and liabilities of the Nuclear Imaging business that are classified as held for sale on the unaudited condensed consolidated balance sheets: June 30, 2017 December 30, 2016 Carrying amounts of major classes of assets included as part of discontinued operations Accounts receivable $ — $ 49.6 Inventories — 20.0 Property, plant and equipment, net — 188.7 Other current and non-current assets — 52.6 Total assets classified as held for sale in the balance sheet $ — $ 310.9 Carrying amounts of major classes of liabilities included as part of discontinued operations Accounts payable $ — $ 19.7 Other current and non-current liabilities — 100.6 Total liabilities classified as held for sale in the balance sheet $ — $ 120.3
Schedule of Income (Loss) from Discontinued Operations	The following table summarizes the financial results of the Nuclear Imaging business presented in the unaudited condensed consolidated statements of income: Three Months Ended Six Months Ended Major line items constituting income from discontinued operations June 30, 2017 June 24, 2016 June 30, 2017 June 24, 2016 Net sales $ — $ 104.0 $ 31.6 $ 206.2 Cost of sales — 51.5 15.6 99.2 Selling, general and administrative expenses — 23.5 7.8 45.4 Restructuring charges, net — 0.1 — 0.4 Other — 1.1 (0.2 ) 1.4 Income from discontinued operations — 27.8 8.4 59.8 (Loss) gain on divestiture of discontinued operations (5.9 ) — 363.4 — (Loss) income from discontinued operations, before income taxes (5.9 ) 27.8 371.8 59.8 Income tax (benefit) expense (0.1 ) 8.8 5.3 19.0 (Loss) income from discontinued operations, net of income taxes $ (5.8 ) $ 19.0 $ 366.5 $ 40.8
Schedule of Significant Cash and Non-Cash Transactions	The following table summarizes significant cash and non-cash transactions of the Nuclear Imaging business that are included within the unaudited condensed consolidated statements of cash flows for the respective periods: Three Months Ended Six Months Ended June 30, 2017 June 24, 2016 June 30, 2017 June 24, 2016 Depreciation $ — $ 5.0 $ — $ 9.8 Capital expenditures — 1.2 0.3 3.8

Restructuring and Related Cha30

Restructuring and Related Charges (Tables)	6 Months Ended
	Jun. 30, 2017
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Charges by Segment	Net restructuring and related charges by segment are as follows: Three Months Ended Six Months Ended June 30, June 24, June 30, June 24, Specialty Brands $ 0.3 $ 8.8 $ 9.5 $ 16.8 Specialty Generics 0.5 1.0 7.9 1.6 Corporate 0.7 5.4 2.8 6.9 Restructuring and related charges, net 1.5 15.2 20.2 25.3 Less: accelerated depreciation (0.9 ) (1.2 ) (2.4 ) (2.9 ) Restructuring charges, net $ 0.6 $ 14.0 $ 17.8 $ 22.4
Schedule of Net Restructuring and Related Charges	Net restructuring and related charges by program are comprised of the following: Three Months Ended Six Months Ended June 30, June 24, June 30, June 24, 2016 Mallinckrodt Program $ 1.5 $ — $ 20.2 $ — 2013 Mallinckrodt Program — 14.3 — 22.4 Acquisitions — 0.9 — 2.9 Total 1.5 15.2 20.2 25.3 Less: non-cash charges, including accelerated share-based compensation expense (0.9 ) (1.2 ) (2.4 ) (2.9 ) Total charges expected to be settled in cash $ 0.6 $ 14.0 $ 17.8 $ 22.4
Schedule of Restructuring Reserves by Type of Cost	The following table summarizes cash activity for restructuring reserves, substantially all of which are related to employee severance and benefits: 2016 Mallinckrodt Program 2013 Mallinckrodt Program Acquisitions Total Balance at December 30, 2016 $ 9.5 $ 5.1 $ 0.2 $ 14.8 Charges 18.5 — — 18.5 Changes in estimate (0.7 ) — — (0.7 ) Cash payments (14.4 ) (3.6 ) (0.2 ) (18.2 ) Reclassifications (0.3 ) 0.3 — — Balance at June 30, 2017 $ 12.6 $ 1.8 $ — $ 14.4
Schedule of Restructuring Charges Incurred Cumulative to Date	Net restructuring and related charges, including associated asset impairments, incurred cumulative-to-date related to the 2016 Mallinckrodt Program was as follows: 2016 Mallinckrodt Program Specialty Brands $ 16.7 Specialty Generics 9.2 Corporate 7.8 $ 33.7

Earnings per Share (Tables)

Earnings per Share (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Schedule of Earnings per Share	The weighted-average number of shares outstanding used in the computations of basic and diluted earnings per share were as follows ( in millions ): Three Months Ended Six Months Ended June 30, 2017 June 24, 2016 June 30, 2017 June 24, 2016 Basic 98.5 108.6 100.9 109.9 Dilutive impact of restricted share units and share options 0.2 0.8 0.3 0.9 Diluted 98.7 109.4 101.2 110.8

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2017
Inventory, Net [Abstract]
Schedule of Inventories	Inventories were comprised of the following at the end of each period: June 30, December 30, Raw materials and supplies $ 72.5 $ 72.6 Work in process 170.6 178.4 Finished goods 96.3 99.7 $ 339.4 $ 350.7

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment
Property, Plant and Equipment	The gross carrying amount and accumulated depreciation of property, plant and equipment at the end of each period was as follows: June 30, December 30, 2016 Property, plant and equipment, gross $ 1,786.6 $ 1,679.4 Less: accumulated depreciation (845.9 ) (797.9 ) Property, plant and equipment, net $ 940.7 $ 881.5
Depreciation of Fixed Assets	Depreciation expense for property, plant and equipment was as follows: Three Months Ended Six Months Ended June 30, 2017 June 24, 2016 June 30, 2017 June 24, 2016 Depreciation expense $ 27.4 $ 28.3 $ 56.2 $ 60.3

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The gross carrying amount and accumulated impairment of goodwill by segment at the end of each period were as follows: June 30, 2017 December 30, 2016 Gross Carrying Amount Accumulated Impairment Gross Carrying Amount Accumulated Impairment Specialty Brands $ 3,446.2 $ — $ 3,498.1 $ — Specialty Generics 207.0 (207.0 ) 207.0 (207.0 ) Total $ 3,653.2 $ (207.0 ) $ 3,705.1 $ (207.0 )
Schedule of Intangible Assets	The gross carrying amount and accumulated amortization of intangible assets at the end of each period were as follows: June 30, 2017 December 30, 2016 Gross Carrying Amount Accumulated Impairment Gross Carrying Amount Accumulated Impairment Amortizable: Completed technology $ 9,955.6 $ 1,932.1 $ 10,028.7 $ 1,617.1 Licenses 177.1 118.4 177.1 112.7 Customer relationships 28.7 10.4 27.6 8.4 Trademarks 82.0 12.6 82.1 10.9 Other 8.6 7.9 6.7 6.7 Total $ 10,252.0 $ 2,081.4 $ 10,322.2 $ 1,755.8 Non-Amortizable: Trademarks $ 35.0 $ 35.0 In-process research and development 399.1 399.1 Total $ 434.1 $ 434.1
Schedule of Future Amortization Expense, Intangible Assets	The estimated aggregate amortization expense on intangible assets owned by the Company is expected to be as follows: Remainder of Fiscal 2017 $ 344.9 Fiscal 2018 686.5 Fiscal 2019 686.2 Fiscal 2020 685.9 Fiscal 2021 685.7
Intangible Asset Amortization Expense	Intangible asset amortization expense was as follows: Three Months Ended Six Months Ended June 30, 2017 June 24, 2016 June 30, 2017 June 24, 2016 Amortization expense $ 174.7 $ 175.8 $ 349.8 $ 350.8

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Schedule of Debt including Capital Lease Obligation	Debt was comprised of the following at the end of each period: June 30, 2017 December 30, 2016 Principal Unamortized Discount and Debt Issuance Costs Principal Unamortized Discount and Debt Issuance Costs Current maturities of long-term debt: Variable-rate receivable securitization $ 200.0 $ 0.1 $ 250.0 $ 0.3 3.50% notes due April 2018 300.0 0.5 — — Term loan due March 2021 — — 20.0 0.3 4.00% term loan due February 2022 1.1 — 1.0 — Term loan due September 2024 18.7 0.3 — — Capital lease obligation and vendor financing agreements 0.5 — 0.8 — Total current debt 520.3 0.9 271.8 0.6 Long-term debt: 3.50% notes due April 2018 — — 300.0 0.9 4.875% notes due April 2020 700.0 7.0 700.0 8.2 Term loan due March 2021 — — 1,928.5 33.4 4.00% term loan due February 2022 5.2 — 5.5 — 9.50% debentures due May 2022 10.4 — 10.4 — 5.75% notes due August 2022 884.0 10.5 884.0 11.6 8.00% debentures due March 2023 4.4 — 4.4 — 4.75% notes due April 2023 541.5 5.1 600.0 6.1 5.625% notes due October 2023 738.0 10.5 738.0 11.4 Term loan due September 2024 1,841.7 29.4 — — 5.50% notes due April 2025 692.1 9.6 695.0 10.2 Revolving credit facility — 6.7 100.0 3.2 Total long-term debt 5,417.3 78.8 5,965.8 85.0 Total debt $ 5,937.6 $ 79.7 $ 6,237.6 $ 85.6

Retirement Plans (Tables)

Retirement Plans (Tables)	6 Months Ended
	Jun. 30, 2017
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Schedule of Net Periodic Benefit Cost	The net periodic benefit cost for the Company's defined benefit pension plans was as follows: Three Months Ended Six Months Ended June 30, June 24, June 30, June 24, Service cost $ 0.2 $ 0.4 $ 1.5 $ 0.8 Interest cost 0.4 3.5 2.1 7.0 Expected return on plan assets — (4.2 ) (1.3 ) (8.4 ) Amortization of net actuarial loss 0.4 2.6 2.6 5.2 Amortization of prior service cost 0.1 — 0.2 — Plan settlements 0.5 3.3 69.7 7.0 Net periodic benefit cost $ 1.6 $ 5.6 $ 74.8 $ 11.6

Accumulated Other Comprehensi37

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income	Currency Translation Unrecognized Gain (Loss) on Derivatives Unrecognized Gain (Loss) on Benefit Plans Unrecognized Gain on Equity Securities Accumulated Other Comprehensive Income (Loss) Balance at December 25, 2015 $ (7.9 ) $ (6.3 ) $ (51.1 ) $ — $ (65.3 ) Other comprehensive income (loss) before reclassifications 8.3 — (15.5 ) — (7.2 ) Amounts reclassified from accumulated other comprehensive income (0.7 ) 0.4 7.1 — 6.8 Net current period other comprehensive income (loss) 7.6 0.4 (8.4 ) — (0.4 ) Balance at June 24, 2016 $ (0.3 ) $ (5.9 ) $ (59.5 ) $ — $ (65.7 ) The following summarizes the change in accumulated other comprehensive income for the six months ended June 30, 2017 and June 24, 2016: Currency Translation Unrecognized Gain (Loss) on Derivatives Unrecognized Gain (Loss) on Benefit Plans Unrecognized Gain on Equity Securities Accumulated Other Comprehensive Income (Loss) Balance at December 30, 2016 $ (19.5 ) $ (5.7 ) $ (47.3 ) $ — $ (72.5 ) Other comprehensive income before reclassifications 12.1 — 5.5 10.6 28.2 Amounts reclassified from accumulated other comprehensive income (4.7 ) 0.6 40.4 — 36.3 Net current period other comprehensive income 7.4 0.6 45.9 10.6 64.5 Balance at June 30, 2017 $ (12.1 ) $ (5.1 ) $ (1.4 ) $ 10.6 $ (8.0 )
Schedule of Reclassifications out of Accumulated Other Comprehensive Income	The following summarizes reclassifications from accumulated other comprehensive income for the six months ended June 30, 2017 and June 24, 2016: Amount Reclassified from Accumulated Other Comprehensive Income Six Months Ended June 30, June 24, Line Item in the Unaudited Condensed Consolidated Statement of Income Amortization and other of unrealized loss on derivatives $ 0.8 $ 0.4 Interest expense Income tax provision (0.2 ) — Income tax benefit Net of income taxes 0.6 0.4 Amortization of pension and post-retirement benefit plans: Net actuarial loss 2.6 5.3 (1) Prior service credit (1.1 ) (1.4 ) (1) Divestiture of discontinued operations (3.1 ) — Income from discontinued operations, net of income taxes Plan settlements 69.7 7.0 (1) Selling, general and administrative expenses Total before tax 68.1 10.9 Income tax provision (27.7 ) (3.8 ) Income tax benefit Net of income taxes 40.4 7.1 Currency translation (4.7 ) (0.7 ) Income from discontinued operations, net of income taxes Total reclassifications for the period $ 36.3 $ 6.8 (1) These accumulated other comprehensive income components are included in the computation of net periodic benefit cost. See Note 12 for additional details .

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2017
Schedule of Share Repurchases under the Repurchase Plan
Schedule of Share Repurchases under the Repurchase Plan	March 2017 Repurchase Program March 2016 Repurchase Program November 2015 Repurchase Program Number of Shares Amount Number of Shares Amount Number of Shares Amount Authorized repurchase amount $ 1,000.0 $ 350.0 $ 500.0 Repurchases: Fiscal 2016 (1) — — — — 6,510,824 425.6 Transition Period 2016 — — 1,501,676 84.0 1,063,337 74.4 Fiscal 2017 2,594,703 110.3 5,366,741 266.0 — — Remaining amount available $ 889.7 $ — $ — (1) Represents the Company's historical fiscal year ending on the last Friday in September.

Financial Instruments and Fai39

Financial Instruments and Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis	The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period: June 30, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Debt and equity securities held in rabbi trusts $ 32.6 $ 21.5 $ 11.1 $ — Equity securities 31.9 31.9 — — Foreign exchange forward and option contracts 0.6 0.6 — — $ 65.1 $ 54.0 $ 11.1 $ — Liabilities: Deferred compensation liabilities $ 35.1 $ — $ 35.1 $ — Contingent consideration and acquired contingent liabilities 228.4 — — 228.4 Foreign exchange forward and option contracts 0.3 0.3 — — $ 263.8 $ 0.3 $ 35.1 $ 228.4 December 30, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Debt and equity securities held in rabbi trusts $ 33.6 $ 22.8 $ 10.8 $ — Foreign exchange forward and option contracts 0.7 0.7 — — $ 34.3 $ 23.5 $ 10.8 $ — Liabilities: Deferred compensation liabilities $ 32.5 $ — $ 32.5 $ — Contingent consideration and acquired contingent liabilities 250.5 — — 250.5 Foreign exchange forward and option contracts 3.4 3.4 — — $ 286.4 $ 3.4 $ 32.5 $ 250.5
Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities	The following table provides a summary of the changes in the Company's contingent consideration and acquired contingent liabilities: Balance at December 30, 2016 $ 250.5 Payments (25.0 ) Accretion expense 2.7 Fair value adjustment 0.2 Balance at June 30, 2017 $ 228.4
Schedule of Carrying Amount and Fair Value of Long-term Debt	The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period: June 30, 2017 December 30, 2016 Carrying Value Fair Value Carrying Value Fair Value Variable-rate receivable securitization $ 200.0 $ 200.0 $ 250.0 $ 250.0 3.50% notes due April 2018 300.0 300.0 300.0 298.7 4.875% notes due April 2020 700.0 681.9 700.0 699.5 Term loans due March 2021 — — 1,948.5 1,953.2 4.00% term loan due February 2022 6.3 6.3 6.5 6.5 9.50% debentures due May 2022 10.4 11.5 10.4 12.0 5.75% notes due August 2022 884.0 830.8 884.0 850.3 8.00% debentures due March 2023 4.4 4.7 4.4 4.9 4.75% notes due April 2023 541.5 461.8 600.0 520.9 5.625% notes due October 2023 738.0 674.6 738.0 682.4 Term loan due September 2024 1,860.4 1,855.4 — — 5.50% notes due April 2025 692.1 604.0 695.0 615.7 Revolving credit facility — — 100.0 100.0
Schedules of Concentration of Risk	The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales: Three Months Ended Six Months Ended June 30, June 24, June 30, June 24, CuraScript, Inc. 43 % 38 % 39 % 36 % McKesson Corporation 8 % 7 % 9 % 10 % The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period: June 30, December 30, McKesson Corporation 26 % 28 % Amerisource Bergen Corporation 15 % 15 % CuraScript, Inc. 18 % 15 % Cardinal Health, Inc. 9 % 10 % The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales: Three Months Ended Six Months Ended June 30, June 24, June 30, June 24, Acthar 39 % 34 % 36 % 33 % Inomax 15 % 14 % 16 % 14 %

Segment Data (Tables)

Segment Data (Tables)	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Schedule of Segment Reporting Information by Reportable Segment	Selected information by reportable segment was as follows: Three Months Ended Six Months Ended June 30, June 24, June 30, June 24, Net sales: Specialty Brands $ 594.5 $ 589.3 $ 1,151.7 $ 1,124.3 Specialty Generics 216.0 263.4 454.6 527.8 Net sales of reportable segments 810.5 852.7 1,606.3 1,652.1 Other (1) 14.0 13.9 29.1 30.3 Net sales $ 824.5 $ 866.6 $ 1,635.4 $ 1,682.4 Operating income: Specialty Brands $ 274.1 $ 302.1 $ 549.1 $ 563.0 Specialty Generics 63.3 98.1 139.5 197.0 Segment operating income 337.4 400.2 688.6 760.0 Unallocated amounts: Corporate and unallocated expenses (2) (49.1 ) (34.1 ) (116.3 ) (59.5 ) Intangible asset amortization (174.7 ) (175.8 ) (349.8 ) (350.8 ) Restructuring and related charges, net (3) (1.5 ) (15.2 ) (20.2 ) (25.3 ) Non-restructuring impairment charges — — — (16.9 ) Operating income $ 112.1 $ 175.1 $ 202.3 $ 307.5 (1) Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business. (2) Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments. (3) Includes restructuring-related accelerated depreciation.
Schedule of Net Sales from External Customers by Products	Net sales by product family within the Company's reportable segments are as follows: Three Months Ended Six Months Ended June 30, June 24, June 30, June 24, Acthar $ 319.4 $ 298.3 $ 591.2 $ 546.7 Inomax 125.5 121.1 253.9 236.6 Ofirmev 75.7 70.7 149.1 141.8 Therakos immunotherapy 51.2 52.5 102.4 102.7 Hemostasis products 13.5 13.9 26.6 25.3 Other 9.2 32.8 28.5 71.2 Specialty Brands 594.5 589.3 1,151.7 1,124.3 Hydrocodone (API) and hydrocodone-containing tablets 23.0 38.2 53.3 79.0 Oxycodone (API) and oxycodone-containing tablets 25.1 30.6 47.2 68.5 Methylphenidate ER 20.2 24.3 43.9 48.9 Other controlled substances 107.7 124.7 215.1 246.6 Other products 40.0 45.6 95.1 84.8 Specialty Generics 216.0 263.4 454.6 527.8 Other (1) 14.0 13.9 29.1 30.3 Net sales $ 824.5 $ 866.6 $ 1,635.4 $ 1,682.4 (1) Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business.

Condensed Consolidating Finan41

Condensed Consolidating Financial Statements (Tables)	6 Months Ended
	Jun. 30, 2017
Condensed Consolidating Financial Statements [Abstract]
Schedule of Condensed Consolidating Balance Sheets	MALLINCKRODT PLC CONDENSED CONSOLIDATING BALANCE SHEET As of June 30, 2017 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Assets Current Assets: Cash and cash equivalents $ 0.9 $ 149.9 $ 179.4 $ — $ 330.2 Accounts receivable, net — — 482.1 — 482.1 Inventories — — 339.4 — 339.4 Prepaid expenses and other current assets 0.4 0.4 133.2 — 134.0 Notes receivable — — 154.0 — 154.0 Current assets held for sale — — — — — Intercompany receivables 95.7 19.7 1,135.7 (1,251.1 ) — Total current assets 97.0 170.0 2,423.8 (1,251.1 ) 1,439.7 Property, plant and equipment, net — — 940.7 — 940.7 Goodwill — — 3,446.2 — 3,446.2 Intangible assets, net — — 8,604.7 — 8,604.7 Investment in subsidiaries 4,846.2 21,498.0 10,484.6 (36,828.8 ) — Intercompany loans receivable 805.2 — 4,203.7 (5,008.9 ) — Other assets — — 189.9 — 189.9 Total Assets $ 5,748.4 $ 21,668.0 $ 30,293.6 $ (43,088.8 ) $ 14,621.2 Liabilities and Shareholders' Equity Current Liabilities: Current maturities of long-term debt $ — $ 317.8 $ 201.6 $ — $ 519.4 Accounts payable 0.1 0.9 112.9 — 113.9 Accrued payroll and payroll-related costs — — 92.8 — 92.8 Accrued interest — 53.0 1.1 — 54.1 Income taxes payable — — 122.0 — 122.0 Accrued and other current liabilities 0.5 0.4 459.3 — 460.2 Current liabilities held for sale — — — — — Intercompany payables 651.8 476.3 123.0 (1,251.1 ) — Total current liabilities 652.4 848.4 1,112.7 (1,251.1 ) 1,362.4 Long-term debt — 5,318.6 19.9 — 5,338.5 Pension and postretirement benefits — — 67.7 — 67.7 Environmental liabilities — — 73.6 — 73.6 Deferred income taxes — — 2,254.4 — 2,254.4 Other income tax liabilities — — 67.5 — 67.5 Intercompany loans payable — 5,008.9 — (5,008.9 ) — Other liabilities — 7.5 353.6 — 361.1 Total Liabilities 652.4 11,183.4 3,949.4 (6,260.0 ) 9,525.2 Shareholders' Equity 5,096.0 10,484.6 26,344.2 (36,828.8 ) 5,096.0 Total Liabilities and Shareholders' Equity $ 5,748.4 $ 21,668.0 $ 30,293.6 $ (43,088.8 ) $ 14,621.2 MALLINCKRODT PLC CONDENSED CONSOLIDATING BALANCE SHEET As of December 30, 2016 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Assets Current Assets: Cash and cash equivalents $ 0.5 $ 44.5 $ 297.0 $ — $ 342.0 Accounts receivable, net — — 431.0 — 431.0 Inventories — — 350.7 — 350.7 Prepaid expenses and other current assets 1.0 — 130.9 — 131.9 Notes receivable — — — — — Current assets held for sale — — 310.9 — 310.9 Intercompany receivables 59.7 65.1 1,081.3 (1,206.1 ) — Total current assets 61.2 109.6 2,601.8 (1,206.1 ) 1,566.5 Property, plant and equipment, net — — 881.5 — 881.5 Goodwill — — 3,498.1 — 3,498.1 Intangible assets, net — — 9,000.5 — 9,000.5 Investment in subsidiaries 5,534.1 20,624.1 10,988.5 (37,146.7 ) — Intercompany loans receivable 3.5 — 3,325.9 (3,329.4 ) — Other assets — — 259.7 — 259.7 Total Assets $ 5,598.8 $ 20,733.7 $ 30,556.0 $ (41,682.2 ) $ 15,206.3 Liabilities and Shareholders' Equity Current Liabilities: Current maturities of long-term debt $ — $ 19.7 $ 251.5 $ — $ 271.2 Accounts payable 0.1 0.1 111.9 — 112.1 Accrued payroll and payroll-related costs — — 76.1 — 76.1 Accrued interest — 53.9 14.8 — 68.7 Income taxes payable — — 101.7 — 101.7 Accrued and other current liabilities 1.9 7.5 547.7 — 557.1 Current liabilities held for sale — — 120.3 — 120.3 Intercompany payables 612.5 467.1 126.5 (1,206.1 ) — Total current liabilities 614.5 548.3 1,350.5 (1,206.1 ) 1,307.2 Long-term debt — 5,860.6 20.2 — 5,880.8 Pension and postretirement benefits — — 136.4 — 136.4 Environmental liabilities — — 73.0 — 73.0 Deferred income taxes — — 2,398.1 — 2,398.1 Other income tax liabilities — — 70.4 — 70.4 Intercompany loans payable — 3,329.4 — (3,329.4 ) — Other liabilities — 7.0 349.1 — 356.1 Total Liabilities 614.5 9,745.3 4,397.7 (4,535.5 ) 10,222.0 Shareholders' Equity 4,984.3 10,988.4 26,158.3 (37,146.7 ) 4,984.3 Total Liabilities and Shareholders' Equity $ 5,598.8 $ 20,733.7 $ 30,556.0 $ (41,682.2 ) $ 15,206.3
Schedule of Condensed Consolidating Statements of Comprehensive Income	MALLINCKRODT PLC CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME For the three months ended June 30, 2017 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Net sales $ — $ — $ 824.5 $ — $ 824.5 Cost of sales 0.9 — 407.5 — 408.4 Gross profit (0.9 ) — 417.0 — 416.1 Selling, general and administrative expenses 15.1 0.2 216.8 — 232.1 Research and development expenses 1.8 — 67.4 — 69.2 Restructuring charges, net — — 0.6 — 0.6 Non-restructuring impairment charges — — — — — Losses on divestiture and license — — 2.1 — 2.1 Operating income (17.8 ) (0.2 ) 130.1 — 112.1 Interest expense (3.4 ) (88.7 ) (18.7 ) 18.6 (92.2 ) Interest income 2.0 0.3 16.9 (18.6 ) 0.6 Other income, net 2.2 6.6 1.2 — 10.0 Intercompany fees (3.5 ) — 3.5 — — Equity in net income of subsidiaries 81.0 254.7 172.9 (508.6 ) — Income from continuing operations before income taxes 60.5 172.7 305.9 (508.6 ) 30.5 Income tax benefit (1.3 ) (0.2 ) (38.6 ) — (40.1 ) Income from continuing operations 61.8 172.9 344.5 (508.6 ) 70.6 Income (loss) from discontinued operations, net of income taxes 1.0 — (8.8 ) — (7.8 ) Net income 62.8 172.9 335.7 (508.6 ) 62.8 Other comprehensive income, net of tax 1.9 1.9 3.4 (5.3 ) 1.9 Comprehensive income $ 64.7 $ 174.8 $ 339.1 $ (513.9 ) $ 64.7 MALLINCKRODT PLC CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME For the three months ended June 24, 2016 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Net sales $ — $ — $ 866.6 $ — $ 866.6 Cost of sales — — 377.8 — 377.8 Gross profit — — 488.8 — 488.8 Selling, general and administrative expenses 12.3 0.2 212.4 — 224.9 Research and development expenses — — 74.8 — 74.8 Restructuring charges, net — — 14.0 — 14.0 Non-restructuring impairment charge — — — — — Losses on divestiture and license — — — — — Operating income (12.3 ) (0.2 ) 187.6 — 175.1 Interest expense (56.3 ) (81.6 ) (20.3 ) 62.6 (95.6 ) Interest income — 0.1 62.9 (62.6 ) 0.4 Other income (expense), net 2.6 0.1 (4.0 ) — (1.3 ) Intercompany fees (4.5 ) — 4.5 — — Equity in net income of subsidiaries 260.2 380.5 308.9 (949.6 ) — Income from continuing operations before income taxes 189.7 298.9 539.6 (949.6 ) 78.6 Income tax benefit (9.6 ) (10.2 ) (78.3 ) — (98.1 ) Income from continuing operations 199.3 309.1 617.9 (949.6 ) 176.7 (Loss) income from discontinued operations, net of income taxes — (0.2 ) 22.8 — 22.6 Net income 199.3 308.9 640.7 (949.6 ) 199.3 Other comprehensive loss, net of tax (0.6 ) (0.6 ) (1.4 ) 2.0 (0.6 ) Comprehensive income $ 198.7 $ 308.3 $ 639.3 $ (947.6 ) $ 198.7 MALLINCKRODT PLC CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME For the six months ended June 30, 2017 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Net sales $ — $ — $ 1,635.4 $ — $ 1,635.4 Cost of sales 0.9 — 799.8 — 800.7 Gross profit (0.9 ) — 835.6 — 834.7 Selling, general and administrative expenses 33.3 0.4 506.5 — 540.2 Research and development expenses 1.8 — 129.6 — 131.4 Restructuring charges, net — — 17.8 — 17.8 Non-restructuring impairment charge — — — — — Gains on divestiture and license — — (57.0 ) — (57.0 ) Operating income (36.0 ) (0.4 ) 238.7 — 202.3 Interest expense (6.7 ) (174.0 ) (38.9 ) 33.2 (186.4 ) Interest income 3.1 0.6 31.0 (33.2 ) 1.5 Other income (expense), net 17.6 (3.3 ) (11.8 ) — 2.5 Intercompany fees (9.0 ) — 9.0 — — Equity in net income of subsidiaries 489.7 851.7 673.4 (2,014.8 ) — Income from continuing operations before income taxes 458.7 674.6 901.4 (2,014.8 ) 19.9 Income tax benefit (3.3 ) (0.5 ) (75.8 ) — (79.6 ) Income from continuing operations 462.0 675.1 977.2 (2,014.8 ) 99.5 (Loss) income from discontinued operations, net of income taxes — (1.7 ) 364.2 — 362.5 Net income 462.0 673.4 1,341.4 (2,014.8 ) 462.0 Other comprehensive income, net of tax 64.5 64.5 128.4 (192.9 ) 64.5 Comprehensive income $ 526.5 $ 737.9 $ 1,469.8 $ (2,207.7 ) $ 526.5 MALLINCKRODT PLC CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME For the six months ended June 24, 2016 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Net sales $ — $ — $ 1,682.4 $ — $ 1,682.4 Cost of sales — — 768.5 — 768.5 Gross profit — — 913.9 — 913.9 Selling, general and administrative expenses 26.2 0.4 407.6 — 434.2 Research and development expenses — — 132.9 — 132.9 Restructuring charges, net — — 22.4 — 22.4 Non-restructuring impairment charge — — 16.9 — 16.9 Gains on divestiture and license — — — — — Operating income (26.2 ) (0.4 ) 334.1 — 307.5 Interest expense (126.2 ) (163.1 ) (42.0 ) 138.5 (192.8 ) Interest income — 0.3 138.8 (138.5 ) 0.6 Other income (expense), net 14.9 — (16.9 ) — (2.0 ) Intercompany fees (7.3 ) 0.1 7.2 — — Equity in net income of subsidiaries 452.7 712.5 561.7 (1,726.9 ) — Income from continuing operations before income taxes 307.9 549.4 982.9 (1,726.9 ) 113.3 Income tax benefit (9.7 ) (14.0 ) (138.2 ) — (161.9 ) Income from continuing operations 317.6 563.4 1,121.1 (1,726.9 ) 275.2 (Loss) income from discontinued operations, net of income taxes — (1.7 ) 44.1 — 42.4 Net income 317.6 561.7 1,165.2 (1,726.9 ) 317.6 Other comprehensive loss, net of tax (0.4 ) (0.4 ) (1.2 ) 1.6 (0.4 ) Comprehensive income $ 317.2 $ 561.3 $ 1,164.0 $ (1,725.3 ) $ 317.2
Schedule of Condensed Consolidating Statements of Cash Flows	MALLINCKRODT PLC CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the six months ended June 30, 2017 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Cash Flows From Operating Activities: Net cash from operating activities $ 1,177.0 $ 175.8 $ 1,487.0 $ (2,617.3 ) $ 222.5 Cash Flows From Investing Activities: Capital expenditures — — (101.6 ) — (101.6 ) Acquisitions and intangibles, net of cash acquired — — — — — Proceeds from divestiture of discontinued operations, net of cash — — 576.9 — 576.9 Intercompany loan investment, net (801.7 ) — (860.4 ) 1,662.1 — Investment in subsidiary — (307.9 ) — 307.9 — Other — — (9.9 ) — (9.9 ) Net cash from investing activities (801.7 ) (307.9 ) (395.0 ) 1,970.0 465.4 Cash Flows From Financing Activities: Issuance of external debt — — 40.0 — 40.0 Repayment of external debt and capital leases — (242.1 ) (90.7 ) — (332.8 ) Debt financing costs — (12.5 ) (0.5 ) — (13.0 ) Proceeds from exercise of share options 3.9 — — — 3.9 Repurchase of shares (380.8 ) — — — (380.8 ) Intercompany loan borrowings, net — 1,662.1 — (1,662.1 ) — Intercompany dividends — (1,170.0 ) (1,447.3 ) 2,617.3 — Capital contribution — — 307.9 (307.9 ) — Other 2.0 — (21.5 ) — (19.5 ) Net cash from financing activities (374.9 ) 237.5 (1,212.1 ) 647.3 (702.2 ) Effect of currency rate changes on cash — — 1.6 — 1.6 Net change in cash, cash equivalents and restricted cash 0.4 105.4 (118.5 ) — (12.7 ) Cash, cash equivalents and restricted cash at beginning of period 0.5 44.5 316.1 — 361.1 Cash, cash equivalents and restricted cash at end of period $ 0.9 $ 149.9 $ 197.6 $ — $ 348.4 Cash and cash equivalents at end of period $ 0.9 $ 149.9 $ 179.4 $ — $ 330.2 Restricted Cash, Current at end of period — — — — — Restricted Cash, Noncurrent at end of period — — 18.2 — 18.2 Cash, cash equivalents and restricted cash at end of period $ 0.9 $ 149.9 $ 197.6 $ — $ 348.4 MALLINCKRODT PLC CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS For the six months ended June 24, 2016 (unaudited, in millions) Mallinckrodt plc Mallinckrodt International Finance S.A. Other Subsidiaries Eliminations Consolidated Cash Flows From Operating Activities: Net cash from operating activities $ (4.3 ) $ (72.9 ) $ 760.2 $ — $ 683.0 Cash Flows From Investing Activities: Capital expenditures — — (84.5 ) — (84.5 ) Acquisitions and intangibles, net of cash acquired — — (169.5 ) — (169.5 ) Proceeds from divestiture of discontinued operations, net of cash — (1.4 ) 4.4 — 3.0 Intercompany loan investment, net — 105.8 (952.4 ) 846.6 — Investment in subsidiary — (461.7 ) — 461.7 — Other — — 4.6 — 4.6 Net cash from investing activities — (357.3 ) (1,197.4 ) 1,308.3 (246.4 ) Cash Flows From Financing Activities: Issuance of external debt — — 36.3 — 36.3 Repayment of external debt and capital leases — (160.3 ) (17.2 ) — (177.5 ) Debt financing costs — — — — — Proceeds from exercise of share options 4.9 — — — 4.9 Repurchase of shares (326.6 ) — — — (326.6 ) Intercompany loan borrowings, net 325.8 520.8 — (846.6 ) — Capital contribution — — 461.7 (461.7 ) — Other — — (23.0 ) — (23.0 ) Net cash from financing activities 4.1 360.5 457.8 (1,308.3 ) (485.9 ) Effect of currency rate changes on cash — — 2.1 — 2.1 Net change in cash, cash equivalents and restricted cash (0.2 ) (69.7 ) 22.7 — (47.2 ) Cash, cash equivalents and restricted cash at beginning of period 0.3 158.5 429.6 — 588.4 Cash, cash equivalents and restricted cash at end of period $ 0.1 $ 88.8 $ 452.3 $ — $ 541.2 Cash and cash equivalents at end of period $ 0.1 $ 88.8 $ 433.0 $ — $ 521.9 Restricted Cash, Current at end of period — — 0.3 — 0.3 Restricted Cash, Noncurrent at end of period — — 19.0 — 19.0 Cash, cash equivalents and restricted cash at end of period $ 0.1 $ 88.8 $ 452.3 $ — $ 541.2

Recently Issued Accounting St42

Recently Issued Accounting Standards (Details)	6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016
ASU 2016-16 | Retained Earnings
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted	75
ASU 2016-16 | Other Assets
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted	67.2
ASU 2016-16 | Prepaid Expenses and Other Current Assets
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted	7.8
ASU 2016-15
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted		47.2
ASU 2016-09 | Retained Earnings
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted	2.9

Discontinued Operations and D43

Discontinued Operations and Divestitures Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016	Jan. 30, 2017	Jan. 27, 2017	Nov. 27, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued operation, (loss) income from discontinued operations, net of tax	$ 7.8	$ (22.6)	$ (362.5)	$ (42.4)
Income from discontinued operations			8.4
Nuclear Imaging
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration						$ 690
Disposal Group, Including Discontinued Operation, Upfront Consideration						574
Disposal Group, Including Discontinued Operation, Contingent Consideration Maximum Amount						$ 77
(Loss) gain on divestiture of discontinued operations	(5.9)	0	363.4	0
Discontinued operation, income tax (benefit) expense	0.1	(8.8)	(5.3)	(19)
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation			4.3
Disposal Group, Including Discontinued Operations, Net Sales	0	104	31.6	206.2
Discontinued operation, (loss) income from discontinued operations, net of tax	5.8	(19)	(366.5)	(40.8)
Income from discontinued operations	0	27.8	8.4	59.8
Other Tax Expense (Benefit)			1
(Loss) income from discontinued operations, before income taxes	(5.9)	27.8	371.8	59.8
Contrast Media and Delivery Systems
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration							$ 270
(Loss) gain on divestiture of discontinued operations		1.7
Discontinued operation, income tax (benefit) expense		0		0.2
Disposal Group, Including Discontinued Operations, Net Sales		$ 0.7		1.8
Discontinued operation, (loss) income from discontinued operations, net of tax				$ 0
Intrathecal Therapy
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group, not discontinued operation, consideration					$ 203
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	$ (2.1)		57
Disposal group, not discontinued operation, upfront consideration					17
Disposal Group, not discontinued operation, Note Receivable Consideration					154
Disposal group, not discontinued operation, contingent consideration					32
Disposal group, not discontinued operation, fixed consideration					171
Disposal Group, Not Discontinued Operations, Other Commitment					$ 7.3
Other Intangible Assets | Intrathecal Therapy
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal			(48.7)
Goodwill | Intrathecal Therapy
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal			$ (49.8)

Discontinued Operations and D44

Discontinued Operations and Divestitures Discontinued Operations (Income) Loss from Discontinued Operations (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations			$ 8.4
(Loss) income from discontinued operations, net of income taxes	$ (7.8)	$ 22.6	362.5	$ 42.4
Nuclear Imaging
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operations, Net Sales	0	104	31.6	206.2
Discontinued operation, costs of goods sold	0	51.5	15.6	99.2
Discontinued operation, selling general and administrative expense	0	23.5	7.8	45.4
Disposal Group, Including Discontinued Operation, Restructuring Charges, Net	0	0.1	0	0.4
Disposal Group, Including Discontinued Operation, Other Expense			(0.2)
Discontinued operation, other income	0	1.1		1.4
Income from discontinued operations	0	27.8	8.4	59.8
(Loss) gain on divestiture of discontinued operations	(5.9)	0	363.4	0
(Loss) income from discontinued operations, before income taxes	(5.9)	27.8	371.8	59.8
Income tax (benefit) expense	(0.1)	8.8	5.3	19
(Loss) income from discontinued operations, net of income taxes	$ (5.8)	19	$ 366.5	40.8
Contrast Media and Delivery Systems
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operations, Net Sales		0.7		1.8
(Loss) gain on divestiture of discontinued operations		1.7
Income tax (benefit) expense		$ 0		(0.2)
(Loss) income from discontinued operations, net of income taxes				$ 0

Discontinued Operations and D45

Discontinued Operations and Divestitures Discontinued Operations (Assets and Liabilities Held-for-sale) (Details) - Nuclear Imaging - Discontinued Operations, Held-for-sale [Member] - USD ($) $ in Millions	Jun. 30, 2017	Dec. 30, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, held for sale	$ 0	$ 49.6
Inventories, held for sale	0	20
Property, plant and equipment, net, held for sale	0	188.7
Other current assets and non-current assets, held for sale	0	52.6
Total assets classified as held for sale in the balance sheet	0	310.9
Accounts payable, held for sale	0	19.7
Other current and non-current liabilities, held for sale	0	100.6
Total liabilities classified as held for sale in the balance sheet	$ 0	$ 120.3

Discontinued Operations and D46

Discontinued Operations and Divestitures Discontinued Operations (Significant Cash and Non-Cash Transactions) (Details) - Nuclear Imaging - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation, Discontinued Operations	$ 0	$ 5	$ 0	$ 9.8
Capital Expenditure, Discontinued Operations	$ 0	$ 1.2	$ 0.3	$ 3.8

Acquisitions, License Agreeme47

Acquisitions, License Agreements and Other Investments (Narrative) (Details) - USD ($) $ in Millions	Feb. 01, 2016	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Business Acquisition
Business Combination, Acquisition Related Costs		$ 1.1	$ 0.1	$ 1.1	$ 2
Mesoblast
Business Acquisition
Available-for-sale Securities, Current		19.7		19.7
Payments to Acquire Marketable Securities				21.5
Intangible Assets, Current		1.8		1.8
Hemostasis Products
Business Acquisition
Contingent consideration	$ 52
Fair value of contingent liability	10.6
Business Combination, Consideration Transferred, Other	173.5
Business Combination, Contingent Consideration Arrangements, Potential Payment	$ 395
Cost of Sales | Total Acquisitions
Business Acquisition
Amortization Of Inventory Step-Up To Cost Of Sales		$ 2.9	$ 2.6	$ 5.9	$ 4.7

Restructuring and Related Cha48

Restructuring and Related Charges (Narrative) (Details) - Restructuring Fiscal 2016 Plan $ in Millions	Jun. 30, 2017USD ($)
Minimum
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost	$ 100
Maximum
Restructuring Cost and Reserve
Restructuring and Related Cost, Expected Cost	$ 125

Restructuring and Related Cha49

Restructuring and Related Charges (Schedule of Restructuring and Related Charges by Segment) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Restructuring Cost and Reserve
Restructuring and related charges, net	$ 1.5	$ 15.2	$ 20.2	$ 25.3
Less: accelerated depreciation	(0.9)	(1.2)	(2.4)	(2.9)
Restructuring charges, net	0.6	14	17.8	22.4
Specialty Brands
Restructuring Cost and Reserve
Restructuring and related charges, net	0.3	8.8	9.5	16.8
Specialty Generics
Restructuring Cost and Reserve
Restructuring and related charges, net	0.5	1	7.9	1.6
Corporate
Restructuring Cost and Reserve
Restructuring and related charges, net	$ 0.7	$ 5.4	$ 2.8	$ 6.9

Restructuring and Related Cha50

Restructuring and Related Charges (Schedule of Net Restructuring and Related Charges) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Restructuring Cost and Reserve
Restructuring and related charges, net	$ 1.5	$ 15.2	$ 20.2	$ 25.3
Less: non-cash charges, including accelerated share-based compensation expense	(0.9)	(1.2)	(2.4)	(2.9)
Total charges expected to be settled in cash	0.6	14	17.8	22.4
Restructuring Fiscal 2016 Plan
Restructuring Cost and Reserve
Restructuring and related charges, net	1.5	0	20.2	0
2013 Mallinckrodt program
Restructuring Cost and Reserve
Restructuring and related charges, net	0	14.3	0	22.4
Acquisitions
Restructuring Cost and Reserve
Restructuring and related charges, net	$ 0	$ 0.9	$ 0	$ 2.9

Restructuring and Related Cha51

Restructuring and Related Charges (Schedule of Restructuring Reserves by Type of Cost) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2017USD ($)
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 14.8
Charges	18.5
Changes in estimate	(0.7)
Cash payments	(18.2)
Reclassification	0
Ending Balance	14.4
Restructuring Fiscal 2016 Plan
Restructuring Reserve [Roll Forward]
Beginning Balance	9.5
Charges	18.5
Changes in estimate	(0.7)
Cash payments	(14.4)
Reclassification	(0.3)
Ending Balance	12.6
2013 Mallinckrodt program
Restructuring Reserve [Roll Forward]
Beginning Balance	5.1
Charges	0
Changes in estimate	0
Cash payments	(3.6)
Reclassification	0.3
Ending Balance	1.8
Acquisitions
Restructuring Reserve [Roll Forward]
Beginning Balance	0.2
Charges	0
Changes in estimate	0
Cash payments	(0.2)
Reclassification	0
Ending Balance	$ 0

Restructuring and Related Cha52

Restructuring and Related Charges (Schedule of Restructuring Charges Incurred Cumulative to Date) (Details) - Restructuring Fiscal 2016 Plan $ in Millions	Jun. 30, 2017USD ($)
Restructuring Cost and Reserve
Restructuring costs incurred cumulative to date	$ 33.7
Specialty Brands
Restructuring Cost and Reserve
Restructuring costs incurred cumulative to date	16.7
Specialty Generics
Restructuring Cost and Reserve
Restructuring costs incurred cumulative to date	9.2
Corporate
Restructuring Cost and Reserve
Restructuring costs incurred cumulative to date	$ 7.8

Income Taxes (Details)

Income Taxes (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017USD ($)	Jun. 24, 2016USD ($)	Jun. 30, 2017USD ($)	Jun. 24, 2016USD ($)	Dec. 30, 2016USD ($)
Income Taxes [Line Items]
Deferred tax benefit, intangible assets			$ (187.4)
Deferred tax expense, Utilization of Tax Attributes			27.2
Income tax benefit	$ (40.1)	$ (98.1)	$ (79.6)	$ (161.9)
Increase (Decrease) Tax Expense (Benefit), Change in Operating Income, Percentage Point	(8.5)		(15.3)
Other increase, percentage point			32.2
Increase (Decrease) Tax Expense (Benefit) Due to Foreign Tax Credit, Percentage Point	34.9		24.2
Loss (income) from continuing operations before income taxes	$ 30.5	$ 78.6	$ 19.9	$ 113.3
Effective tax rate	(131.50%)	(124.80%)	(400.00%)	(142.90%)
Current Income Tax Expense (Benefit)	$ 44.7	$ 1.8	$ 80.6	$ 48
Deferred Income Tax Expense (Benefit)	$ (84.8)	(99.9)	$ (160.2)	(209.9)
Increase (Decrease) in Effective Tax Rate, Percentage Point	(6.7)		(257.1)
Effective Income Tax Rate Reconciliation, Other Adjustments, Percentage Point	(33.1)		(274)
Increase (Decrease) Effective Tax Rate, Divestitures, Percentage Point			8
Unrecognized tax benefits	$ 119.1		$ 119.1		$ 118.7
Unrecognized tax benefits, net increase			0.4
Unrecognized tax benefits, net decreases related to prior period tax positions			(2)
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations			(1.7)
Unrecognized tax benefits, additions related to current year tax positions			4.1
Unrecognized tax benefits, which if favorably settled would benefit the effective tax rate	117.3		117.3
Interest accrued on unrecognized tax benefits	5.9		5.9		7.1
Unrecognized tax benefits that would impact effective tax rate, upper bound of change	18.2		18.2
Income tax penalties and interest accrued that would impact effective tax rate, upper bound of change	3.8		3.8
Stratatech
Income Taxes [Line Items]
Increase (Decrease), Deferred Tax Liability, Net	22.1		22.1		$ 24.3
Nuclear Imaging
Income Taxes [Line Items]
Other Tax Expense (Benefit)			1
Income tax (benefit) expense	(0.1)	$ 8.8	5.3	$ 19
Intrathecal Therapy
Income Taxes [Line Items]
Increase (Decrease) in Deferred Tax Liability, Future Consideration			56.5
Increase (Decrease) Deferred Tax Asset, Net Operating Losses			(4.3)
Deferred tax benefit, intangible assets			(17.9)
Increase (Decrease) Deferred Tax Asset, Product Development	2.6
Increase (Decrease), Deferred Tax Liability, Net	$ 40.3		$ 40.3
Retained Earnings | ASU 2016-16
Income Taxes [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted			75
Retained Earnings | ASU 2016-09
Income Taxes [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted			2.9
Other Assets | ASU 2016-16
Income Taxes [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted			67.2
Prepaid Expenses and Other Current Assets | ASU 2016-16
Income Taxes [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Description of Prior-period Information Retrospectively Adjusted			7.8

Earnings per Share (Details)

Earnings per Share (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Earnings Per Share
Weighted-average shares outstanding - basic (in shares)	98.5	108.6	100.9	109.9
Dilutive impact of restricted share units and share options (in shares)	0.2	0.8	0.3	0.9
Weighted-average shares outstanding - diluted (in shares)	98.7	109.4	101.2	110.8

Earnings per Share Anti-Dilutiv

Earnings per Share Anti-Dilutive Shares (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4	1.5	3.6	1.4

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 30, 2016
Raw materials and supplies	$ 72.5	$ 72.6
Work in process	170.6	178.4
Finished goods	96.3	99.7
Inventories	$ 339.4	$ 350.7

Property, Plant and Equipment57

Property, Plant and Equipment (Schedule of Property, Plant and Equipment) (Details) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 30, 2016
Property, Plant and Equipment
Property, plant and equipment, gross	$ 1,786.6	$ 1,679.4
Less: accumulated depreciation	(845.9)	(797.9)
Property, plant and equipment, net	$ 940.7	$ 881.5

Property, Plant and Equipment D

Property, Plant and Equipment Depreciation (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Property, Plant and Equipment
Depreciation	$ 27.4	$ 28.3	$ 56.2	$ 60.3

Goodwill and Intangible Asset59

Goodwill and Intangible Assets (Schedule Of Goodwill) (Details) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 30, 2016
Goodwill
Gross Carrying Amount	$ 3,653.2	$ 3,705.1
Accumulated Impairment	(207)	(207)
Specialty Brands
Goodwill
Gross Carrying Amount	3,446.2	3,498.1
Accumulated Impairment	0	0
Specialty Generics
Goodwill
Gross Carrying Amount	207	207
Accumulated Impairment	$ (207)	$ (207)

Goodwill and Intangible Asset60

Goodwill and Intangible Assets (Schedule Of Intangible Assets) (Details) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 30, 2016
Schedule of Intangible Asset by Major Class [Line Items]
Amortizable intangible assets, gross	$ 10,252	$ 10,322.2
Accumulated amortization	2,081.4	1,755.8
Non-Amortizable intangible assets, gross	434.1	434.1
Trademarks
Schedule of Intangible Asset by Major Class [Line Items]
Non-Amortizable intangible assets, gross	35	35
In-process Research and Development
Schedule of Intangible Asset by Major Class [Line Items]
Non-Amortizable intangible assets, gross	399.1	399.1
Completed Technology
Schedule of Intangible Asset by Major Class [Line Items]
Amortizable intangible assets, gross	9,955.6	10,028.7
Accumulated amortization	1,932.1	1,617.1
Licenses
Schedule of Intangible Asset by Major Class [Line Items]
Amortizable intangible assets, gross	177.1	177.1
Accumulated amortization	118.4	112.7
Customer Relationships
Schedule of Intangible Asset by Major Class [Line Items]
Amortizable intangible assets, gross	28.7	27.6
Accumulated amortization	10.4	8.4
Trademarks
Schedule of Intangible Asset by Major Class [Line Items]
Amortizable intangible assets, gross	82	82.1
Accumulated amortization	12.6	10.9
Other
Schedule of Intangible Asset by Major Class [Line Items]
Amortizable intangible assets, gross	8.6	6.7
Accumulated amortization	$ 7.9	$ 6.7

Goodwill and Intangible Asset61

Goodwill and Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Goodwill
Non-restructuring impairment charges	$ 0	$ 0	$ 0	$ 16.9
Specialty Brands
Goodwill
Goodwill, Period Increase (Decrease)			51.9
Intrathecal Therapy
Goodwill
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	$ (2.1)		57
Intrathecal Therapy | Goodwill
Goodwill
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal			$ (49.8)

Goodwill and Intangible Asset62

Goodwill and Intangible Assets (Schedule of Intangible Asset Amortization Expense) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 174.7	$ 175.8	$ 349.8	$ 350.8

Goodwill and Intangible Asset63

Goodwill and Intangible Assets (Schedule of Future Amortization Expense, Intangible Assets) (Details) $ in Millions	Jun. 30, 2017USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of Fiscal 2017	$ 344.9
Fiscal 2,018	686.5
Fiscal 2,019	686.2
Fiscal 2,020	685.9
Fiscal 2,021	$ 685.7

Debt (Details)

Debt (Details) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 30, 2016
Current maturities of long-term debt
Debt Issuance Costs, Current, Net	$ 0.9	$ 0.6
Long-term Debt, Current Maturities	520.3	271.8
Long-term debt
Long-term Debt	5,417.3	5,965.8
Total Debt	5,937.6	6,237.6
Total Debt Issuance Costs	79.7	85.6
Long-term Debt
Long-term debt
Debt Issuance Costs	78.8	85
Receivable Securitization
Current maturities of long-term debt
Variable Rate Receivable Securitization	200	250
Debt Issuance Costs, Current, Net	0.1	0.3
Term Loan | Secured Debt
Current maturities of long-term debt
Debt Issuance Costs, Current, Net	0	0.3
Long-term Debt, Current Maturities	0	20
Long-term debt
Long-term Debt	0	1,928.5
Debt Issuance Costs	0	33.4
4.00% Term Loan | Secured Debt
Current maturities of long-term debt
Debt Issuance Costs, Current, Net	0	0
Long-term Debt, Current Maturities	1.1	1
Long-term debt
Long-term Debt	5.2	5.5
Debt Issuance Costs	0	0
New Term Loan | Secured Debt
Current maturities of long-term debt
Debt Issuance Costs, Current, Net	0.3	0
Long-term Debt, Current Maturities	18.7	0
Long-term debt
Long-term Debt	1,841.7	0
Debt Issuance Costs	29.4	0
Capital Lease Obligations and Vendor Financing
Current maturities of long-term debt
Debt Issuance Costs, Current, Net	0	0
Capital Lease Obligations, Current	0.5	0.8
3.50% Senior Notes | Unsecured Debt
Current maturities of long-term debt
Debt Issuance Costs, Current, Net	0.5	0
Long-term Debt, Current Maturities	300	0
Long-term debt
Long-term Debt	0	300
Debt Issuance Costs	0	0.9
4.88% Senior Notes | Unsecured Debt
Long-term debt
Long-term Debt	700	700
Debt Issuance Costs	7	8.2
9.50% Debenture | Debentures
Long-term debt
Long-term Debt	10.4	10.4
Debt Issuance Costs	0	0
5.75% Senior Notes | Unsecured Debt
Long-term debt
Long-term Debt	884	884
Debt Issuance Costs	10.5	11.6
8.00% Debenture | Debentures
Long-term debt
Long-term Debt	4.4	4.4
Debt Issuance Costs	0	0
4.75% Senior Notes | Unsecured Debt
Long-term debt
Long-term Debt	541.5	600
Debt Issuance Costs	5.1	6.1
5.625% Senior Notes | Unsecured Debt
Long-term debt
Long-term Debt	738	738
Debt Issuance Costs	10.5	11.4
5.50% Senior Notes | Unsecured Debt
Long-term debt
Long-term Debt	692.1	695
Debt Issuance Costs	9.6	10.2
2017 Revolving Credit Facility [Member] [Domain] | Secured Debt
Long-term debt
Long-term Debt	0
Debt Issuance Costs	$ 6.7
2015 Revolving Credit Facility | Secured Debt
Long-term debt
Long-term Debt		100
Debt Issuance Costs		$ 3.2

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Feb. 28, 2017	Dec. 30, 2016
Debt Instrument
Long-term Debt	$ 5,417.3	$ 5,417.3		$ 5,965.8
Total Debt	$ 5,937.6	$ 5,937.6		6,237.6
Secured Debt | Receivable Securitization
Debt Instrument
Interest rate	2.02%	2.02%
Long-term Line of Credit	$ 200	$ 200
Secured Debt | Term Loan and New Term Loan
Debt Instrument
Long-term Debt			$ 1,865
Debt Instrument, Basis Spread on Variable Rate	2.75%
Long-term Loans Payable, Periodic Amortization Payment, Percentage of Original Principal Amount	0.25%
Repayments of Debt		83.5
Write off of Deferred Debt Issuance Cost		$ 10
Long-term Debt, Weighted Average Interest Rate	4.05%	4.05%
Total Debt	$ 1,860.4	$ 1,860.4
Secured Debt | 2015 Revolving Credit Facility
Debt Instrument
Long-term Debt				100
Secured Debt | 2017 Revolving Credit Facility [Member] [Domain]
Debt Instrument
Long-term Debt	$ 0	$ 0
Revolving Credit Facility
Debt Instrument
Interest rate	3.55%	3.55%
Long-term Line of Credit	$ 0	$ 0
Unsecured Debt | 2015 Revolving Credit Facility
Debt Instrument
Line of Credit Facility, Maximum Borrowing Capacity				500
Unsecured Debt | 2017 Revolving Credit Facility [Member] [Domain]
Debt Instrument
Debt Instrument, Basis Spread on Variable Rate	2.25%
Line of Credit Facility, Maximum Borrowing Capacity	$ 900	$ 900
Debtor-in-Possession Financing, Fee on Unused Borrowings	0.275%	0.275%
Letter of Credit [Member] | 2015 Revolving Credit Facility
Debt Instrument
Line of Credit Facility, Maximum Borrowing Capacity				$ 150
Letter of Credit [Member] | 2017 Revolving Credit Facility [Member] [Domain]
Debt Instrument
Line of Credit Facility, Maximum Borrowing Capacity	$ 50	$ 50

Retirement Plans (Narrative) (D

Retirement Plans (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Postretirement Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net periodic benefit credit	$ 0	$ 0	$ 0	$ 0.1
Pension Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net periodic benefit credit	1.6	5.6	74.8	11.6
Defined Benefit Plan, Contributions by Employer			61.3
Plan settlements	$ 0.5	$ 3.3	$ 69.7	$ 7

Retirement Plans (Schedule of N

Retirement Plans (Schedule of Net Periodic Benefit Cost) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 0.2	$ 0.4	$ 1.5	$ 0.8
Interest cost	0.4	3.5	2.1	7
Expected return on plan assets	0	(4.2)	(1.3)	(8.4)
Amortization of net actuarial loss	0.4	2.6	2.6	5.2
Amortization of prior service cost	0.1	0	0.2	0
Plan settlements	0.5	3.3	69.7	7
Net periodic benefit cost	1.6	5.6	74.8	11.6
Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost	$ 0	$ 0	$ 0	$ 0.1

Accumulated Other Comprehensi68

Accumulated Other Comprehensive Income (Schedule of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	$ (72.5)	$ (65.3)
Other Comprehensive Income (Loss), before Reclassifications	28.2	(7.2)
Reclassification from Accumulated Other Comprehensive Income	36.3	6.8
Other Comprehensive Income (Loss)	64.5	(0.4)
Ending Balance	(8)	(65.7)
Accumulated Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	(19.5)	(7.9)
Other Comprehensive Income (Loss), before Reclassifications	12.1	8.3
Reclassification from Accumulated Other Comprehensive Income	(4.7)	(0.7)
Other Comprehensive Income (Loss)	7.4	7.6
Ending Balance	(12.1)	(0.3)
Accumulated Unrecognized Gain (Loss) on Derivatives
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	(5.7)	(6.3)
Other Comprehensive Income (Loss), before Reclassifications	0	0
Reclassification from Accumulated Other Comprehensive Income	0.6	0.4
Other Comprehensive Income (Loss)	0.6	0.4
Ending Balance	(5.1)	(5.9)
Accumulated Unrecognized Gain (Loss) on Benefit Plans
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	(47.3)	(51.1)
Other Comprehensive Income (Loss), before Reclassifications	5.5	(15.5)
Reclassification from Accumulated Other Comprehensive Income	40.4	7.1
Other Comprehensive Income (Loss)	45.9	(8.4)
Ending Balance	(1.4)	(59.5)
Accumulated Unrecognized Gain on Equity Securities
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning Balance	0	0
Other Comprehensive Income (Loss), before Reclassifications	10.6	0
Reclassification from Accumulated Other Comprehensive Income	0	0
Other Comprehensive Income (Loss)	10.6	0
Ending Balance	$ 10.6	$ 0

Accumulated Other Comprehensi69

Accumulated Other Comprehensive Income (Schedule of Reclassifications out of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total reclassifications for the period	$ 36.3	$ 6.8
Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Amortization of unrealized loss on derivatives, before tax	0.8	0.4
Amortization of unrealized loss on derivatives, tax	(0.2)	0
Amortization of unrealized loss on derivatives, net of tax	0.6	0.4
Amortization of pension and post-retirement plans, net actuarial loss	2.6	5.3
Amortization of pension and post-retirement plans, prior service credit	1.1	(1.4)
Divestiture of discontinued operations	(3.1)	0
Plan settlements	69.7	7
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, before Tax	68.1	10.9
Amortization of pension and post-retirement plans, tax	(27.7)	(3.8)
Amortization of pension and post-retirement plans, net of tax	40.4	7.1
Currency translation	$ (4.7)	$ (0.7)

Equity (Details)

Equity (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended	6 Months Ended	12 Months Ended
	Dec. 30, 2016	Jun. 30, 2017	Sep. 30, 2016	[1]	Mar. 01, 2017	Mar. 16, 2016	Nov. 19, 2015
November 2015 Share Repurchase Program
Equity, Class of Treasury Stock
Stock Repurchase Program, Authorized Amount							$ 500
Stock Repurchased During Period, Number of Shares	1,063,337	0	6,510,824
Stock Repurchased During Period, Amount	$ 74.4	$ 0	$ 425.6
Stock Repurchase Program, Remaining Amount Available		$ 0
March 2016 Repurchase Program
Equity, Class of Treasury Stock
Stock Repurchase Program, Authorized Amount						$ 350
Stock Repurchased During Period, Number of Shares	1,501,676	5,366,741	0
Stock Repurchased During Period, Amount	$ 84	$ 266	$ 0
Stock Repurchase Program, Remaining Amount Available		$ 0
March 2017 Repurchase Program
Equity, Class of Treasury Stock
Stock Repurchase Program, Authorized Amount					$ 1,000
Stock Repurchased During Period, Number of Shares	0	2,594,703	0
Stock Repurchased During Period, Amount	$ 0	$ 110.3	$ 0
Stock Repurchase Program, Remaining Amount Available		$ 889.7
[1]	(1)Represents the Company's historical fiscal year ending on the last Friday in September.

Guarantees (Details)

Guarantees (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2017	Dec. 30, 2016
Others
Guarantor Obligations [Line Items]
Maximum future payments	$ 28.7
Mallinckrodt Baker | Indemnification Agreement
Guarantor Obligations [Line Items]
Guarantor obligations, obligation term	17 years
Maximum future payments	$ 70.2
Escrow Deposit	30
Mallinckrodt Baker | Indemnification Agreement | Other Liabilities
Guarantor Obligations [Line Items]
Guarantors obligation	15	$ 15.1
Mallinckrodt Baker | Indemnification Agreement | Other Assets
Guarantor Obligations [Line Items]
Escrow Deposit	18.2	19
Mallinckrodt Baker | Environmental, Health and Safety Matters | Indemnification Agreement | Other Liabilities
Guarantor Obligations [Line Items]
Guarantors obligation	$ 12.3	$ 12.4

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details) $ in Millions

Apr. 01, 2014USD ($)Defendent

Sep. 26, 2012action

Aug. 31, 2012principal

Sep. 29, 2017USD ($)

Jun. 30, 2017USD ($)Case

Jun. 24, 2016USD ($)

Jun. 30, 2017USD ($)DefendentCaseorder

Jun. 24, 2016USD ($)

Jun. 26, 2015USD ($)

Sep. 25, 2015USD ($)

Dec. 30, 2016USD ($)

Mar. 27, 2015USD ($)

Mar. 28, 2014USD ($)

Aug. 31, 2013Case

Loss Contingencies [Line Items]

Environmental liabilities

$ 75.9

$ 75.9

Deferred tax liabilities related to installment sales

1,781.7

1,781.7

Section 453(a) interest

17.8

$ 18.6

36.2

$ 37.7

Interest Payable, Installment Sales

38.8

$ 38.8

$ 30.3

Lower Passaic River, New Jersey

Loss Contingencies [Line Items]

Number of defendants | Defendent

70

98

Environmental liabilities

$ 13.3

$ 23.1

Remedial cost, estimate

$ 1,700

$ 1,380

$ 1,380

Asbestos Matters

Loss Contingencies [Line Items]

Pending claims | Case

11,600

11,600

Estimation of liability, historical term

5 years

Estimation of liability, expected future term of claims

7 years

Accrued and other current liabilities

Loss Contingencies [Line Items]

Environmental liabilities, current

$ 2.3

$ 2.3

Questcor Acquisition of Synacthen [Member]

Loss Contingencies [Line Items]

Litigation Settlement, Expense

$ 102

Retrophin Litigation [Member]

Loss Contingencies [Line Items]

Litigation Settlement, Expense

$ 15.5

Glenridge Litigation

Loss Contingencies [Line Items]

Number of defendants | principal

3

Pending claims | Case

1

Questcor Securities Litigation

Loss Contingencies [Line Items]

Subsequent actions consolidated into lawsuit | action

4

Litigation Settlement, Amount

$ 38

Loss Contingency Accrual

$ 38

Mallinckrodt Veterinary, Inc., Millsboro, Delaware [Member]

Loss Contingencies [Line Items]

Number of Administrative Orders of Consent Entered Into | order

2

Industrial Revenue Bonds

Loss Contingencies [Line Items]

Plant assets exchanged for IRBs

$ 16

Minimum | Environmental Remediation

Loss Contingencies [Line Items]

Remedial cost, estimate

38

38

Minimum | Lower Passaic River, New Jersey

Loss Contingencies [Line Items]

Remedial cost, estimate

365

483.4

483.4

Maximum | Environmental Remediation

Loss Contingencies [Line Items]

Remedial cost, estimate

116.1

116.1

Maximum | Lower Passaic River, New Jersey

Loss Contingencies [Line Items]

Remedial cost, estimate

$ 3,200

$ 2,700

$ 2,700

Subsequent Event [Member]

Loss Contingencies [Line Items]

Payments for Legal Settlements

$ 35

Financial Instruments and Fai73

Financial Instruments and Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Dec. 30, 2016	Feb. 01, 2016	Apr. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements		$ 25
Notes receivable	$ 154	154	$ 0
Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent consideration				$ 52
Fair value of contingent liability				$ 10.6
Senior Notes | 3.50% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage					3.50%
Senior Notes | 4.75% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage					4.75%
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	32.6	32.6	$ 33.6
Level 3 | Secured Debt | 4.00% Term Loan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			4.00%
Level 3 | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Cash surrender value of life insurance	66.9	66.9	$ 67.6
Level 3 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	0	0	0
Level 3 | Recurring | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent liability	103.2	103.2	124.7
Level 3 | Recurring | Stratatech
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent liability	53.3	53.3	55.7
Level 3 | Raplixa | Recurring | Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent consideration	60.5	60.5	58.9
Level 3 | PreveLeak | Recurring | Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent liability	11.4	11.4	$ 11.2
Level 2 | Debentures | 8.00% Debenture
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Level 2 | Debentures | 9.50% Debenture
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			9.50%
Level 2 | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	5	5	$ 11.1
Level 2 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	11.1	11.1	$ 10.8
Level 1 | Senior Notes | 3.50% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			3.50%
Level 1 | Senior Notes | 4.75% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			4.75%
Level 1 | Senior Notes | 5.75% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			5.75%
Level 1 | Senior Notes | 4.88% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			4.875%
Level 1 | Senior Notes | 5.50% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			5.50%
Level 1 | Unsecured Debt | 5.625% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage			5.625%
Level 1 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	21.5	21.5	$ 22.8
Maximum | Synacthen | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Milestone Payment	140
Indemnification Agreement | Mallinckrodt Baker | Level 1 | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Restricted Cash and Cash Equivalents	$ 18.2	$ 18.2	$ 19.1

Financial Instruments and Fai74

Financial Instruments and Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - Recurring - USD ($) $ in Millions	Jun. 30, 2017	Dec. 30, 2016
Assets:
Rabbi Trust Investments, Fair Value Disclosure	$ 32.6	$ 33.6
Equity Securities, Fair Value Disclosure	31.9
Foreign exchange forward and option contracts	0.6	0.7
Total assets at fair value	65.1	34.3
Liabilities:
Deferred Compensation Liability, Fair Value	35.1	32.5
Contingent consideration and acquired contingent liabilities	228.4	250.5
Foreign exchange forward and option contracts	0.3	3.4
Total liabilities at fair value	263.8	286.4
Level 1
Assets:
Rabbi Trust Investments, Fair Value Disclosure	21.5	22.8
Equity Securities, Fair Value Disclosure	31.9
Foreign exchange forward and option contracts	0.6	0.7
Total assets at fair value	54	23.5
Liabilities:
Deferred Compensation Liability, Fair Value	0	0
Contingent consideration and acquired contingent liabilities	0	0
Foreign exchange forward and option contracts	0.3	3.4
Total liabilities at fair value	0.3	3.4
Level 2
Assets:
Rabbi Trust Investments, Fair Value Disclosure	11.1	10.8
Equity Securities, Fair Value Disclosure	0
Foreign exchange forward and option contracts	0	0
Total assets at fair value	11.1	10.8
Liabilities:
Deferred Compensation Liability, Fair Value	35.1	32.5
Contingent consideration and acquired contingent liabilities	0	0
Foreign exchange forward and option contracts	0	0
Total liabilities at fair value	35.1	32.5
Level 3
Assets:
Rabbi Trust Investments, Fair Value Disclosure	0	0
Equity Securities, Fair Value Disclosure	0
Foreign exchange forward and option contracts	0	0
Total assets at fair value	0	0
Liabilities:
Deferred Compensation Liability, Fair Value	0	0
Contingent consideration and acquired contingent liabilities	228.4	250.5
Foreign exchange forward and option contracts	0	0
Total liabilities at fair value	$ 228.4	$ 250.5

Financial Instruments and Fai75

Financial Instruments and Fair Value Measurements (Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2017USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Period Increase (Decrease)	$ (25)
Level 3 | Recurring | Contingent Liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	250.5
Accretion expense	2.7
Fair value adjustment	0.2
Ending balance	$ 228.4

Financial Instruments and Fai76

Financial Instruments and Fair Value Measurements (Schedule of Carrying Amount and Fair Value of Long-term Debt) (Details) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 30, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Variable Rate Receivable Securitization, Fair Value	$ 200	$ 250
Long-term Debt, Current Maturities	520.3	271.8
Long-term Debt	5,417.3	5,965.8
Receivable Securitization
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Variable Rate Receivable Securitization	200	250
4.00% Term Loan
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Loans Payable	6.3	6.5
Loans Payable, Fair Value Disclosure	6.3	6.5
Secured Debt | Term Loan
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt, Current Maturities	0	20
Loans Payable	0	1,948.5
Long-term Debt	0	1,928.5
Loans Payable, Fair Value Disclosure	0	1,953.2
Secured Debt | 4.00% Term Loan
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt, Current Maturities	1.1	1
Long-term Debt	5.2	5.5
Secured Debt | New Term Loan
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt, Current Maturities	18.7	0
Loans Payable	1,860.4	0
Long-term Debt	1,841.7	0
Loans Payable, Fair Value Disclosure	1,855.4	0
Secured Debt | 2017 Revolving Credit Facility [Member] [Domain]
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	0
Long-term Debt	0
Secured Debt | 2015 Revolving Credit Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt		100
Senior Notes | 3.50% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	300	298.7
Senior Notes | 5.75% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	830.8	850.3
Senior Notes | 4.75% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	461.8	520.9
Unsecured Debt | 3.50% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt, Current Maturities	300	0
Long-term Debt	0	300
Unsecured Debt | 4.88% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	681.9	699.5
Long-term Debt	700	700
Unsecured Debt | 5.75% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt	884	884
Unsecured Debt | 4.75% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long-term Debt	541.5	600
Unsecured Debt | 5.625% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	674.6	682.4
Long-term Debt	738	738
Unsecured Debt | 5.50% Senior Notes
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	604	615.7
Long-term Debt	692.1	695
Unsecured Debt | 2015 Revolving Credit Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value		100
Debentures | 9.50% Debenture
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	11.5	12
Long-term Debt	10.4	10.4
Debentures | 8.00% Debenture
Fair Value, Balance Sheet Grouping, Financial Statement Captions
Long term debt, fair value	4.7	4.9
Long-term Debt	$ 4.4	$ 4.4

Financial Instruments and Fai77

Financial Instruments and Fair Value Measurements (Schedules of Concentration of Risk) (Details)	3 Months Ended			6 Months Ended
	Jun. 30, 2017	Dec. 30, 2016	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Distributor Concentration Risk | Net Sales Attributable to Distributors | McKesson Corporation
Concentration Risk
Concentration Risk, Percentage	8.00%		7.00%	9.00%	10.00%
Distributor Concentration Risk | Net Sales Attributable to Distributors | CuraScript, Inc
Concentration Risk
Concentration Risk, Percentage	43.00%		38.00%	39.00%	36.00%
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | McKesson Corporation
Concentration Risk
Concentration Risk, Percentage	26.00%	28.00%
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | Amerisource Bergen Corporation
Concentration Risk
Concentration Risk, Percentage	15.00%	15.00%
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | CuraScript, Inc
Concentration Risk
Concentration Risk, Percentage	18.00%	15.00%
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | Cardinal Health, Inc.
Concentration Risk
Concentration Risk, Percentage	9.00%	10.00%
Product Concentration Risk | Net Sales Attributable to Products | Acthar
Concentration Risk
Concentration Risk, Percentage	39.00%		34.00%	36.00%	33.00%
Product Concentration Risk | Net Sales Attributable to Products | Inomax
Concentration Risk
Concentration Risk, Percentage	15.00%		14.00%	16.00%	14.00%

Segment Data (Schedule of Segme

Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Net sales		$ 824.5	$ 866.6	$ 1,635.4	$ 1,682.4
Operating income		112.1	175.1	202.3	307.5
Intangible asset amortization		(174.7)	(175.8)	(349.8)	(350.8)
Restructuring and related charges, net		(1.5)	(15.2)	(20.2)	(25.3)
Non-restructuring impairment charges		0	0	0	16.9
Specialty Brands
Restructuring and related charges, net		(0.3)	(8.8)	(9.5)	(16.8)
Specialty Generics
Restructuring and related charges, net		(0.5)	(1)	(7.9)	(1.6)
Operating Segments
Net sales		810.5	852.7	1,606.3	1,652.1
Operating income		337.4	400.2	688.6	760
Operating Segments | Specialty Brands
Net sales		594.5	589.3	1,151.7	1,124.3
Operating income		274.1	302.1	549.1	563
Operating Segments | Specialty Generics
Net sales		216	263.4	454.6	527.8
Operating income		63.3	98.1	139.5	197
Corporate, Non-Segment
Net sales	[1]	14	13.9	29.1	30.3
Corporate and unallocated expenses	[2]	(49.1)	(34.1)	(116.3)	(59.5)
Intangible asset amortization		(174.7)	(175.8)	(349.8)	(350.8)
Restructuring and related charges, net	[3]	(1.5)	(15.2)	(20.2)	(25.3)
Non-restructuring impairment charges		$ 0	$ 0	$ 0	$ (16.9)
[1]	Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business.
[2]	Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.
[3]	Includes restructuring-related accelerated depreciation.

Segment Data (Schedule of Net S

Segment Data (Schedule of Net Sales from External Customers by Products) (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Segment Reporting Information
Net sales		$ 824.5	$ 866.6	$ 1,635.4	$ 1,682.4
Operating Segments
Segment Reporting Information
Net sales		810.5	852.7	1,606.3	1,652.1
Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		594.5	589.3	1,151.7	1,124.3
Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		216	263.4	454.6	527.8
Corporate, Non-Segment
Segment Reporting Information
Net sales	[1]	14	13.9	29.1	30.3
Acthar | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		319.4	298.3	591.2	546.7
Inomax | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		125.5	121.1	253.9	236.6
Ofirmev | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		75.7	70.7	149.1	141.8
Therakos immunotherapy | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		51.2	52.5	102.4	102.7
Hemostasis Products | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		13.5	13.9	26.6	25.3
Other | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		9.2	32.8	28.5	71.2
Other | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		40	45.6	95.1	84.8
Hydrocodone (API) and hydrocodone-containing tablets | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		23	38.2	53.3	79
Oxycodone (API) and oxycodone-containing tablets | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		25.1	30.6	47.2	68.5
Methylphenidate ER | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		20.2	24.3	43.9	48.9
Other Controlled Substances | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		$ 107.7	$ 124.7	$ 215.1	$ 246.6
[1]	Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business.

Condensed Consolidating Finan80

Condensed Consolidating Financial Statements (Narrative) (Details)	Jun. 30, 2017	Apr. 30, 2013
Condensed Consolidating Financial Statements
Percentage of ownership in MIFSA	100.00%
Senior Notes | 3.50% Senior Notes
Condensed Consolidating Financial Statements
Stated interest rate		3.50%
Senior Notes | 4.75% Senior Notes
Condensed Consolidating Financial Statements
Stated interest rate		4.75%

Condensed Consolidating Finan81

Condensed Consolidating Financial Statements (Schedule of Condensed Consolidating Balance Sheets) (Details) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 30, 2016	Jun. 24, 2016
Current Assets:
Cash and cash equivalents	$ 330.2	$ 342	$ 521.9
Accounts receivable, net	482.1	431
Inventories	339.4	350.7
Prepaid expenses and other current assets	134	131.9
Notes receivable	154	0
Current assets held for sale	0	310.9
Intercompany receivables	0	0
Total current assets	1,439.7	1,566.5
Property, plant and equipment, net	940.7	881.5
Goodwill	3,446.2	3,498.1
Intangible assets, net	8,604.7	9,000.5
Investment in subsidiaries	0	0
Intercompany loans receivable	0	0
Other assets	189.9	259.7
Total Assets	14,621.2	15,206.3
Current Liabilities:
Current maturities of long-term debt	519.4	271.2
Accounts payable	113.9	112.1
Accrued payroll and payroll-related costs	92.8	76.1
Accrued interest	54.1	68.7
Income taxes payable	122	101.7
Accrued and other current liabilities	460.2	557.1
Current liabilities held for sale	0	120.3
Intercompany payables	0	0
Total current liabilities	1,362.4	1,307.2
Long-term debt	5,338.5	5,880.8
Pension and postretirement benefits	67.7	136.4
Environmental liabilities	73.6	73
Deferred income taxes	2,254.4	2,398.1
Other income tax liabilities	67.5	70.4
Intercompany loans payable	0	0
Other liabilities	361.1	356.1
Total Liabilities	9,525.2	10,222
Shareholders' Equity	5,096	4,984.3
Total Liabilities and Shareholders' Equity	14,621.2	15,206.3
Mallinckrodt plc
Current Assets:
Cash and cash equivalents	0.9	0.5	0.1
Accounts receivable, net	0	0
Inventories	0	0
Prepaid expenses and other current assets	0.4	1
Notes receivable	0	0
Current assets held for sale	0	0
Intercompany receivables	95.7	59.7
Total current assets	97	61.2
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Investment in subsidiaries	4,846.2	5,534.1
Intercompany loans receivable	805.2	3.5
Other assets	0	0
Total Assets	5,748.4	5,598.8
Current Liabilities:
Current maturities of long-term debt	0	0
Accounts payable	0.1	0.1
Accrued payroll and payroll-related costs	0	0
Accrued interest	0	0
Income taxes payable	0	0
Accrued and other current liabilities	0.5	1.9
Current liabilities held for sale	0	0
Intercompany payables	651.8	612.5
Total current liabilities	652.4	614.5
Long-term debt	0	0
Pension and postretirement benefits	0	0
Environmental liabilities	0	0
Deferred income taxes	0	0
Other income tax liabilities	0	0
Intercompany loans payable	0	0
Other liabilities	0	0
Total Liabilities	652.4	614.5
Shareholders' Equity	5,096	4,984.3
Total Liabilities and Shareholders' Equity	5,748.4	5,598.8
Mallinckrodt International Finance S.A.
Current Assets:
Cash and cash equivalents	149.9	44.5	88.8
Accounts receivable, net	0	0
Inventories	0	0
Prepaid expenses and other current assets	0.4	0
Notes receivable	0	0
Current assets held for sale	0	0
Intercompany receivables	19.7	65.1
Total current assets	170	109.6
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Investment in subsidiaries	21,498	20,624.1
Intercompany loans receivable	0	0
Other assets	0	0
Total Assets	21,668	20,733.7
Current Liabilities:
Current maturities of long-term debt	317.8	19.7
Accounts payable	0.9	0.1
Accrued payroll and payroll-related costs	0	0
Accrued interest	53	53.9
Income taxes payable	0	0
Accrued and other current liabilities	0.4	7.5
Current liabilities held for sale	0	0
Intercompany payables	476.3	467.1
Total current liabilities	848.4	548.3
Long-term debt	5,318.6	5,860.6
Pension and postretirement benefits	0	0
Environmental liabilities	0	0
Deferred income taxes	0	0
Other income tax liabilities	0	0
Intercompany loans payable	5,008.9	3,329.4
Other liabilities	7.5	7
Total Liabilities	11,183.4	9,745.3
Shareholders' Equity	10,484.6	10,988.4
Total Liabilities and Shareholders' Equity	21,668	20,733.7
Other Subsidiaries
Current Assets:
Cash and cash equivalents	179.4	297	433
Accounts receivable, net	482.1	431
Inventories	339.4	350.7
Prepaid expenses and other current assets	133.2	130.9
Notes receivable	154	0
Current assets held for sale	0	310.9
Intercompany receivables	1,135.7	1,081.3
Total current assets	2,423.8	2,601.8
Property, plant and equipment, net	940.7	881.5
Goodwill	3,446.2	3,498.1
Intangible assets, net	8,604.7	9,000.5
Investment in subsidiaries	10,484.6	10,988.5
Intercompany loans receivable	4,203.7	3,325.9
Other assets	189.9	259.7
Total Assets	30,293.6	30,556
Current Liabilities:
Current maturities of long-term debt	201.6	251.5
Accounts payable	112.9	111.9
Accrued payroll and payroll-related costs	92.8	76.1
Accrued interest	1.1	14.8
Income taxes payable	122	101.7
Accrued and other current liabilities	459.3	547.7
Current liabilities held for sale	0	120.3
Intercompany payables	123	126.5
Total current liabilities	1,112.7	1,350.5
Long-term debt	19.9	20.2
Pension and postretirement benefits	67.7	136.4
Environmental liabilities	73.6	73
Deferred income taxes	2,254.4	2,398.1
Other income tax liabilities	67.5	70.4
Intercompany loans payable	0	0
Other liabilities	353.6	349.1
Total Liabilities	3,949.4	4,397.7
Shareholders' Equity	26,344.2	26,158.3
Total Liabilities and Shareholders' Equity	30,293.6	30,556
Eliminations
Current Assets:
Cash and cash equivalents	0	0	$ 0
Accounts receivable, net	0	0
Inventories	0	0
Prepaid expenses and other current assets	0	0
Notes receivable	0	0
Current assets held for sale	0	0
Intercompany receivables	(1,251.1)	(1,206.1)
Total current assets	(1,251.1)	(1,206.1)
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Investment in subsidiaries	(36,828.8)	(37,146.7)
Intercompany loans receivable	(5,008.9)	(3,329.4)
Other assets	0	0
Total Assets	(43,088.8)	(41,682.2)
Current Liabilities:
Current maturities of long-term debt	0	0
Accounts payable	0	0
Accrued payroll and payroll-related costs	0	0
Accrued interest	0	0
Income taxes payable	0	0
Accrued and other current liabilities	0	0
Current liabilities held for sale	0	0
Intercompany payables	(1,251.1)	(1,206.1)
Total current liabilities	(1,251.1)	(1,206.1)
Long-term debt	0	0
Pension and postretirement benefits	0	0
Environmental liabilities	0	0
Deferred income taxes	0	0
Other income tax liabilities	0	0
Intercompany loans payable	(5,008.9)	(3,329.4)
Other liabilities	0	0
Total Liabilities	(6,260)	(4,535.5)
Shareholders' Equity	(36,828.8)	(37,146.7)
Total Liabilities and Shareholders' Equity	(43,088.8)	(41,682.2)
Ordinary A
Condensed Consolidating Financial Statements
Ordinary A shares	$ 0	$ 0

Condensed Consolidating Finan82

Condensed Consolidating Financial Statements (Schedule of Condensed Consolidating Statements of Comprehensive Income) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Condensed Consolidating Financial Statements
Net sales	$ 824.5	$ 866.6	$ 1,635.4	$ 1,682.4
Cost of sales	408.4	377.8	800.7	768.5
Gross profit	416.1	488.8	834.7	913.9
Selling, general and administrative expenses	232.1	224.9	540.2	434.2
Research and development expenses	69.2	74.8	131.4	132.9
Restructuring charges, net	0.6	14	17.8	22.4
Non-restructuring impairment charges	0	0	0	16.9
Losses (gains) on divestiture and license	2.1	0	(57)	0
Operating income	112.1	175.1	202.3	307.5
Interest expense	(92.2)	(95.6)	(186.4)	(192.8)
Interest income	0.6	0.4	1.5	0.6
Other income (expense), net	10	(1.3)	2.5	(2)
Intercompany Interest And Fees	0	0	0	0
Income (Loss) from Equity Method Investments	0	0	0	0
Income from continuing operations before income taxes	30.5	78.6	19.9	113.3
Income tax benefit	(40.1)	(98.1)	(79.6)	(161.9)
Income (Loss) from Continuing Operations	70.6	176.7	99.5	275.2
(Loss) income from discontinued operations, net of income taxes	(7.8)	22.6	362.5	42.4
Net Income (Loss)	62.8	199.3	462	317.6
Other Comprehensive Income (Loss), Net of Tax	1.9	(0.6)	64.5	(0.4)
Comprehensive Income (Loss)	64.7	198.7	526.5	317.2
Mallinckrodt plc
Condensed Consolidating Financial Statements
Net sales	0	0	0	0
Cost of sales	0.9	0	0.9	0
Gross profit	(0.9)	0	(0.9)	0
Selling, general and administrative expenses	15.1	12.3	33.3	26.2
Research and development expenses	1.8	0	1.8	0
Restructuring charges, net	0	0	0	0
Non-restructuring impairment charges	0	0	0	0
Losses (gains) on divestiture and license	0	0	0	0
Operating income	(17.8)	(12.3)	(36)	(26.2)
Interest expense	(3.4)	(56.3)	(6.7)	(126.2)
Interest income	2	0	3.1	0
Other income (expense), net	2.2	2.6	17.6	14.9
Intercompany Interest And Fees	(3.5)	(4.5)	(9)	(7.3)
Income (Loss) from Equity Method Investments	81	260.2	489.7	452.7
Income from continuing operations before income taxes	60.5	189.7	458.7	307.9
Income tax benefit	(1.3)	(9.6)	(3.3)	(9.7)
Income (Loss) from Continuing Operations	61.8	199.3	462	317.6
(Loss) income from discontinued operations, net of income taxes	1	0	0	0
Net Income (Loss)	62.8	199.3	462	317.6
Other Comprehensive Income (Loss), Net of Tax	1.9	(0.6)	64.5	(0.4)
Comprehensive Income (Loss)	64.7	198.7	526.5	317.2
Mallinckrodt International Finance S.A.
Condensed Consolidating Financial Statements
Net sales	0	0	0	0
Cost of sales	0	0	0	0
Gross profit	0	0	0	0
Selling, general and administrative expenses	0.2	0.2	0.4	0.4
Research and development expenses	0	0	0	0
Restructuring charges, net	0	0	0	0
Non-restructuring impairment charges	0	0	0	0
Losses (gains) on divestiture and license	0	0	0	0
Operating income	(0.2)	(0.2)	(0.4)	(0.4)
Interest expense	(88.7)	(81.6)	(174)	(163.1)
Interest income	0.3	0.1	0.6	0.3
Other income (expense), net	6.6	0.1	(3.3)	0
Intercompany Interest And Fees	0	0	0	0.1
Income (Loss) from Equity Method Investments	254.7	380.5	851.7	712.5
Income from continuing operations before income taxes	172.7	298.9	674.6	549.4
Income tax benefit	(0.2)	(10.2)	(0.5)	(14)
Income (Loss) from Continuing Operations	172.9	309.1	675.1	563.4
(Loss) income from discontinued operations, net of income taxes	0	(0.2)	(1.7)	(1.7)
Net Income (Loss)	172.9	308.9	673.4	561.7
Other Comprehensive Income (Loss), Net of Tax	1.9	(0.6)	64.5	(0.4)
Comprehensive Income (Loss)	174.8	308.3	737.9	561.3
Other Subsidiaries
Condensed Consolidating Financial Statements
Net sales	824.5	866.6	1,635.4	1,682.4
Cost of sales	407.5	377.8	799.8	768.5
Gross profit	417	488.8	835.6	913.9
Selling, general and administrative expenses	216.8	212.4	506.5	407.6
Research and development expenses	67.4	74.8	129.6	132.9
Restructuring charges, net	0.6	14	17.8	22.4
Non-restructuring impairment charges	0	0	0	16.9
Losses (gains) on divestiture and license	2.1	0	(57)	0
Operating income	130.1	187.6	238.7	334.1
Interest expense	(18.7)	(20.3)	(38.9)	(42)
Interest income	16.9	62.9	31	138.8
Other income (expense), net	1.2	(4)	(11.8)	(16.9)
Intercompany Interest And Fees	3.5	4.5	9	7.2
Income (Loss) from Equity Method Investments	172.9	308.9	673.4	561.7
Income from continuing operations before income taxes	305.9	539.6	901.4	982.9
Income tax benefit	(38.6)	(78.3)	(75.8)	(138.2)
Income (Loss) from Continuing Operations	344.5	617.9	977.2	1,121.1
(Loss) income from discontinued operations, net of income taxes	(8.8)	22.8	364.2	44.1
Net Income (Loss)	335.7	640.7	1,341.4	1,165.2
Other Comprehensive Income (Loss), Net of Tax	3.4	(1.4)	128.4	(1.2)
Comprehensive Income (Loss)	339.1	639.3	1,469.8	1,164
Eliminations
Condensed Consolidating Financial Statements
Net sales	0	0	0	0
Cost of sales	0	0	0	0
Gross profit	0	0	0	0
Selling, general and administrative expenses	0	0	0	0
Research and development expenses	0	0	0	0
Restructuring charges, net	0	0	0	0
Non-restructuring impairment charges	0	0	0	0
Losses (gains) on divestiture and license	0	0	0	0
Operating income	0	0	0	0
Interest expense	18.6	62.6	33.2	138.5
Interest income	(18.6)	(62.6)	(33.2)	(138.5)
Other income (expense), net	0	0	0	0
Intercompany Interest And Fees	0	0	0	0
Income (Loss) from Equity Method Investments	(508.6)	(949.6)	(2,014.8)	(1,726.9)
Income from continuing operations before income taxes	(508.6)	(949.6)	(2,014.8)	(1,726.9)
Income tax benefit	0	0	0	0
Income (Loss) from Continuing Operations	(508.6)	(949.6)	(2,014.8)	(1,726.9)
(Loss) income from discontinued operations, net of income taxes	0	0	0	0
Net Income (Loss)	(508.6)	(949.6)	(2,014.8)	(1,726.9)
Other Comprehensive Income (Loss), Net of Tax	(5.3)	2	(192.9)	1.6
Comprehensive Income (Loss)	$ (513.9)	$ (947.6)	$ (2,207.7)	$ (1,725.3)

Condensed Consolidating Finan83

Condensed Consolidating Financial Statements (Schedule of Condensed Consolidating Statements of Cash Flows) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Dec. 30, 2016	Dec. 25, 2015
Condensed Consolidating Financial Statements
Cash and Cash Equivalents and Restricted Cash		$ 541.2	$ 348.4	$ 361.1	$ 588.4
Restricted Cash and Investments, Current		0.3	0
Cash Flows From Operating Activities:
Net cash from operating activities	$ 222.5	683
Cash Flows From Investing Activities:
Capital expenditures	(101.6)	(84.5)
Acquisitions and intangibles, net of cash acquired	0	(169.5)
Proceeds from divestitures, net of cash	576.9	3
Cash paid with acquisition	0
Intercompany loan investment, net	0	0
Investment in subsidiary	0	0
Other	(9.9)	4.6
Net cash from investing activities	465.4	(246.4)
Cash Flows From Financing Activities:
Issuance of external debt	40	36.3
Repayment of external debt and capital leases	(332.8)	(177.5)
Debt financing costs	(13)	0
Proceeds from exercise of share options	3.9	4.9
Repurchase of shares	(380.8)	(326.6)
Intercompany loan borrowings, net	0	0
Payment of Subsidiary Dividend	0
Capital contribution	0	0
Other	(19.5)	(23)
Net cash from financing activities	(702.2)	(485.9)
Effect of currency rate changes on cash	1.6	2.1
Net change in cash, cash equivalents and restricted cash	(12.7)	(47.2)
Cash, cash equivalents and restricted cash at beginning of period	342
Cash and cash equivalents	342	521.9	330.2	342
Restricted Cash and Investments, Noncurrent		19	18.2
Mallinckrodt plc
Condensed Consolidating Financial Statements
Cash and Cash Equivalents and Restricted Cash		0.1	0.9	0.5	0.3
Restricted Cash and Investments, Current		0	0
Cash Flows From Operating Activities:
Net cash from operating activities	1,177	(4.3)
Cash Flows From Investing Activities:
Capital expenditures	0	0
Acquisitions and intangibles, net of cash acquired		0
Proceeds from divestitures, net of cash	0	0
Cash paid with acquisition	0
Intercompany loan investment, net	(801.7)	0
Investment in subsidiary	0	0
Other	0	0
Net cash from investing activities	(801.7)	0
Cash Flows From Financing Activities:
Issuance of external debt	0	0
Repayment of external debt and capital leases	0	0
Debt financing costs	0	0
Proceeds from exercise of share options	3.9	4.9
Repurchase of shares	(380.8)	(326.6)
Intercompany loan borrowings, net	0	325.8
Payment of Subsidiary Dividend	0
Capital contribution	0	0
Other	2	0
Net cash from financing activities	(374.9)	4.1
Effect of currency rate changes on cash	0	0
Net change in cash, cash equivalents and restricted cash	0.4	(0.2)
Cash, cash equivalents and restricted cash at beginning of period	0.5
Cash and cash equivalents	0.5	0.1	0.9	0.5
Restricted Cash and Investments, Noncurrent		0	0
Mallinckrodt International Finance S.A.
Condensed Consolidating Financial Statements
Cash and Cash Equivalents and Restricted Cash		88.8	149.9	44.5	158.5
Restricted Cash and Investments, Current		0	0
Cash Flows From Operating Activities:
Net cash from operating activities	175.8	(72.9)
Cash Flows From Investing Activities:
Capital expenditures	0	0
Acquisitions and intangibles, net of cash acquired		0
Proceeds from divestitures, net of cash	0	(1.4)
Cash paid with acquisition	0
Intercompany loan investment, net	0	105.8
Investment in subsidiary	(307.9)	(461.7)
Other	0	0
Net cash from investing activities	(307.9)	(357.3)
Cash Flows From Financing Activities:
Issuance of external debt	0	0
Repayment of external debt and capital leases	(242.1)	(160.3)
Debt financing costs	(12.5)	0
Proceeds from exercise of share options	0	0
Repurchase of shares	0	0
Intercompany loan borrowings, net	1,662.1	520.8
Payment of Subsidiary Dividend	(1,170)
Capital contribution	0	0
Other	0	0
Net cash from financing activities	237.5	360.5
Effect of currency rate changes on cash	0	0
Net change in cash, cash equivalents and restricted cash	105.4	(69.7)
Cash, cash equivalents and restricted cash at beginning of period	44.5
Cash and cash equivalents	44.5	88.8	149.9	44.5
Restricted Cash and Investments, Noncurrent		0	0
Other Subsidiaries
Condensed Consolidating Financial Statements
Cash and Cash Equivalents and Restricted Cash		452.3	197.6	316.1	429.6
Restricted Cash and Investments, Current		0.3	0
Cash Flows From Operating Activities:
Net cash from operating activities	1,487	760.2
Cash Flows From Investing Activities:
Capital expenditures	(101.6)	(84.5)
Acquisitions and intangibles, net of cash acquired		(169.5)
Proceeds from divestitures, net of cash	576.9	4.4
Cash paid with acquisition	0
Intercompany loan investment, net	(860.4)	(952.4)
Investment in subsidiary	0	0
Other	(9.9)	4.6
Net cash from investing activities	(395)	(1,197.4)
Cash Flows From Financing Activities:
Issuance of external debt	40	36.3
Repayment of external debt and capital leases	(90.7)	(17.2)
Debt financing costs	(0.5)	0
Proceeds from exercise of share options	0	0
Repurchase of shares	0	0
Intercompany loan borrowings, net	0	0
Payment of Subsidiary Dividend	(1,447.3)
Capital contribution	307.9	461.7
Other	(21.5)	(23)
Net cash from financing activities	(1,212.1)	457.8
Effect of currency rate changes on cash	1.6	2.1
Net change in cash, cash equivalents and restricted cash	(118.5)	22.7
Cash, cash equivalents and restricted cash at beginning of period	297
Cash and cash equivalents	297	433	179.4	297
Restricted Cash and Investments, Noncurrent		19	18.2
Eliminations
Condensed Consolidating Financial Statements
Cash and Cash Equivalents and Restricted Cash		0	0	0	$ 0
Restricted Cash and Investments, Current		0	0
Cash Flows From Operating Activities:
Net cash from operating activities	(2,617.3)	0
Cash Flows From Investing Activities:
Capital expenditures	0	0
Acquisitions and intangibles, net of cash acquired		0
Proceeds from divestitures, net of cash	0	0
Cash paid with acquisition	0
Intercompany loan investment, net	1,662.1	846.6
Investment in subsidiary	307.9	461.7
Other	0	0
Net cash from investing activities	1,970	1,308.3
Cash Flows From Financing Activities:
Issuance of external debt	0	0
Repayment of external debt and capital leases	0	0
Debt financing costs	0	0
Proceeds from exercise of share options	0	0
Repurchase of shares	0	0
Intercompany loan borrowings, net	(1,662.1)	(846.6)
Payment of Subsidiary Dividend	2,617.3
Capital contribution	(307.9)	(461.7)
Other	0	0
Net cash from financing activities	647.3	(1,308.3)
Effect of currency rate changes on cash	0	0
Net change in cash, cash equivalents and restricted cash	0	0
Cash, cash equivalents and restricted cash at beginning of period	0
Cash and cash equivalents	$ 0	0	0	$ 0
Restricted Cash and Investments, Noncurrent		$ 0	$ 0

Subsequent Events Subsequent Ev

Subsequent Events Subsequent Events (Details) - Subsequent Event [Member] - USD ($) $ in Millions	Aug. 03, 2017	Jul. 28, 2017	Sep. 29, 2017
Subsequent Event [Line Items]
Payments for Legal Settlements			$ 35
InfaCare
Subsequent Event [Line Items]
Business Combination, Consideration Transferred, Other	$ 80
Business Combination, Contingent Consideration Arrangements, Potential Payment	$ 345
Secured Debt | Receivable securitization, Maturity Date of July 2020
Subsequent Event [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 250
Debt Instrument, Basis Spread on Variable Rate		0.90%
Line of Credit Facility, Commitment Fee Percentage		0.40%
Line of Credit Facility, Contingent Maximum Borrowing Capacity		$ 300